<!DOCTYPE html><html lang="en" class="scroll-smooth"><head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>055 Pharmacology Ini-Cet 2022 - Brain And Scalpel</title>
    <link rel="preload" href="assets/background.jpg" as="image">
    <script src="https://cdn.tailwindcss.com"></script>
    <!-- HLS.js for M3U8 support -->
    <script src="https://cdn.jsdelivr.net/npm/hls.js@latest"></script>
    <style>
        
/* Liquid Glass Morphism Universal Theme - Enhanced & Mobile-First */
:root {
  --glass-bg: rgba(0, 0, 0, 0.6);
  --glass-bg-light: rgba(255, 255, 255, 0.1);
  --glass-bg-medium: rgba(255, 255, 255, 0.15);
  --glass-bg-heavy: rgba(255, 255, 255, 0.2);
  --glass-border: rgba(255, 255, 255, 0.2);
  --glass-border-light: rgba(255, 255, 255, 0.1);
  --text-primary: rgba(255, 255, 255, 0.95);
  --text-secondary: rgba(255, 255, 255, 0.7);
  --text-tertiary: rgba(255, 255, 255, 0.5);
  --accent-blue: #60a5fa;
  --accent-purple: #a855f7;
  --accent-green: #34d399;
  --accent-orange: #fb923c;
  --accent-red: #f87171;
  --accent-yellow: #fbbf24;
}

* {
  margin: 0;
  padding: 0;
  box-sizing: border-box;
}

html {
  scroll-behavior: smooth;
}

body {
  margin: 0;
  min-height: 100vh;
  font-family: system-ui, -apple-system, BlinkMacSystemFont, 'Segoe UI', sans-serif;
  position: relative;
  overflow-x: hidden;
  color: var(--text-primary);
  background-color: #000;
}

/* iOS Background Fix */
body::before {
  content: '';
  position: fixed;
  top: 0;
  left: 0;
  height: 100vh;
  width: 100vw;
  z-index: -2;
  background: url("assets/background.jpg") center center / cover no-repeat;
}

body::after {
  content: "";
  position: fixed;
  inset: 0;
  background: rgba(0, 0, 0, 0.4);
  backdrop-filter: blur(10px);
  -webkit-backdrop-filter: blur(10px);
  z-index: -1;
}

/* Glass morphism components */
.glass {
  background: var(--glass-bg);
  backdrop-filter: blur(20px);
  -webkit-backdrop-filter: blur(20px);
  border: 1px solid var(--glass-border);
  border-radius: 16px;
}

.glass-light {
  background: var(--glass-bg-light);
  backdrop-filter: blur(15px);
  -webkit-backdrop-filter: blur(15px);
  border: 1px solid var(--glass-border-light);
  border-radius: 12px;
}

.glass-medium {
  background: var(--glass-bg-medium);
  backdrop-filter: blur(20px);
  -webkit-backdrop-filter: blur(20px);
  border: 1px solid var(--glass-border);
  border-radius: 16px;
}

.glass-heavy {
  background: var(--glass-bg-heavy);
  backdrop-filter: blur(25px);
  -webkit-backdrop-filter: blur(25px);
  border: 1px solid var(--glass-border);
  border-radius: 20px;
}

.glass-card {
  background: rgba(255, 255, 255, 0.08);
  backdrop-filter: blur(20px);
  -webkit-backdrop-filter: blur(20px);
  border: 1px solid rgba(255, 255, 255, 0.15);
  border-radius: 20px;
  transition: all 0.3s cubic-bezier(0.4, 0, 0.2, 1);
  box-shadow: 0 8px 32px rgba(0, 0, 0, 0.3);
}

.glass-card:hover {
  transform: translateY(-8px);
  background: rgba(255, 255, 255, 0.12);
  border-color: rgba(255, 255, 255, 0.25);
  box-shadow: 0 20px 60px rgba(0, 0, 0, 0.4);
}

.glass-button {
  background: linear-gradient(135deg, rgba(96, 165, 250, 0.8), rgba(168, 85, 247, 0.8));
  backdrop-filter: blur(15px);
  -webkit-backdrop-filter: blur(15px);
  border: 1px solid rgba(255, 255, 255, 0.2);
  border-radius: 12px;
  color: white;
  font-weight: 600;
  transition: all 0.3s cubic-bezier(0.4, 0, 0.2, 1);
  box-shadow: 0 4px 20px rgba(96, 165, 250, 0.3);
  cursor: pointer;
  border: none;
}

.glass-button:hover {
  transform: translateY(-2px);
  box-shadow: 0 8px 30px rgba(96, 165, 250, 0.4);
  background: linear-gradient(135deg, rgba(96, 165, 250, 0.9), rgba(168, 85, 247, 0.9));
}

.glass-button:disabled {
  opacity: 0.5;
  cursor: not-allowed;
  transform: none;
}

.glass-input {
  background: rgba(255, 255, 255, 0.08);
  backdrop-filter: blur(15px);
  -webkit-backdrop-filter: blur(15px);
  border: 1px solid rgba(255, 255, 255, 0.2);
  border-radius: 12px;
  color: var(--text-primary);
  transition: all 0.3s ease;
}

.glass-input:focus {
  outline: none;
  border-color: var(--accent-blue);
  background: rgba(255, 255, 255, 0.12);
  box-shadow: 0 0 20px rgba(96, 165, 250, 0.3);
}

.glass-input::placeholder {
  color: var(--text-tertiary);
}

/* Performance analysis styles */
.performance-card {
  background: rgba(255, 255, 255, 0.08);
  backdrop-filter: blur(20px);
  -webkit-backdrop-filter: blur(20px);
  border: 1px solid rgba(255, 255, 255, 0.15);
  border-radius: 20px;
  box-shadow: 0 8px 32px rgba(0, 0, 0, 0.3);
}

.score-circle {
  position: relative;
  width: 150px;
  height: 150px;
  margin: 0 auto;
}

.score-circle svg {
  transform: rotate(-90deg);
}

.score-circle .circle-bg {
  fill: none;
  stroke: rgba(255, 255, 255, 0.1);
  stroke-width: 8;
}

.score-circle .circle-progress {
  fill: none;
  stroke-width: 8;
  stroke-linecap: round;
  transition: stroke-dasharray 2s cubic-bezier(0.4, 0, 0.2, 1);
}

.score-text {
  position: absolute;
  top: 50%;
  left: 50%;
  transform: translate(-50%, -50%);
  text-align: center;
}

/* Review question styles */
.review-question {
  background: rgba(255, 255, 255, 0.05);
  border: 1px solid rgba(255, 255, 255, 0.1);
  border-radius: 16px;
  padding: 20px;
  margin-bottom: 20px;
}

.review-question.correct {
  border-left: 4px solid #22c55e;
}

.review-question.incorrect {
  border-left: 4px solid #ef4444;
}

.review-question.not-attempted {
  border-left: 4px solid #6b7280;
}

/* Gradient backgrounds for accents */
.gradient-blue {
  background: linear-gradient(135deg, var(--accent-blue), #3b82f6);
}

.gradient-purple {
  background: linear-gradient(135deg, var(--accent-purple), #8b5cf6);
}

.gradient-green {
  background: linear-gradient(135deg, var(--accent-green), #10b981);
}

.gradient-orange {
  background: linear-gradient(135deg, var(--accent-orange), #f97316);
}

.gradient-red {
  background: linear-gradient(135deg, var(--accent-red), #ef4444);
}

.gradient-yellow {
  background: linear-gradient(135deg, var(--accent-yellow), #f59e0b);
}

/* Navigation button styles */
.nav-btn-not-attempted {
  background: rgba(255, 255, 255, 0.1);
  border: 1px solid rgba(255, 255, 255, 0.2);
  color: rgba(255, 255, 255, 0.7);
}

.nav-btn-current {
  background: linear-gradient(135deg, var(--accent-blue), #3b82f6);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
  box-shadow: 0 0 20px rgba(96, 165, 250, 0.4);
}

.nav-btn-correct {
  background: linear-gradient(135deg, var(--accent-green), #10b981);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
}

.nav-btn-incorrect {
  background: linear-gradient(135deg, var(--accent-red), #ef4444);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
}

.nav-btn-bookmarked {
  background: linear-gradient(135deg, var(--accent-yellow), #f59e0b);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
}

.nav-btn-marked-review {
  background: linear-gradient(135deg, var(--accent-purple), #8b5cf6);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
}

.nav-btn-answered {
  background: linear-gradient(135deg, #6b7280, #4b5563);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
}

/* Option button styles - REVISED FOR INLINE FEEDBACK */
.option-button {
  background: rgba(255, 255, 255, 0.05);
  border: 1px solid rgba(255, 255, 255, 0.15);
  transition: all 0.3s cubic-bezier(0.4, 0, 0.2, 1);
  position: relative;
  overflow: hidden;
  width: 100%;
  text-align: left;
  padding: 1rem;
  border-radius: 12px;
  color: var(--text-primary);
  cursor: pointer;
  display: flex;
  align-items: center;
  gap: 1rem;
  font-size: 1rem;
}

.option-button:hover {
  background: rgba(255, 255, 255, 0.1);
  border-color: rgba(96, 165, 250, 0.5);
  transform: translateX(8px);
}

.option-button.selected {
  background: linear-gradient(135deg, rgba(96, 165, 250, 0.3), rgba(59, 130, 246, 0.3));
  border-color: var(--accent-blue);
  transform: translateX(8px);
}

#optionsContainer.answered .option-button:hover {
    transform: translateX(0); /* Disable hover effect after answering */
}

#optionsContainer.answered .option-button {
    cursor: not-allowed;
    pointer-events: none;
}

#optionsContainer.answered .option-button:not(.correct):not(.incorrect) {
    opacity: 0.5;
}

.option-button.correct {
    background: linear-gradient(135deg, #22c55e, #16a34a);
    border-color: #22c55e;
    color: white;
    transform: translateX(0);
}

.option-button.incorrect {
    background: linear-gradient(135deg, #ef4444, #dc2626);
    border-color: #ef4444;
    color: white;
    transform: translateX(0);
}

.option-letter {
  background: rgba(255, 255, 255, 0.1);
  border: 1px solid rgba(255, 255, 255, 0.2);
  transition: all 0.3s ease;
  width: 2.5rem;
  height: 2.5rem;
  border-radius: 50%;
  display: flex;
  align-items: center;
  justify-content: center;
  font-weight: bold;
  color: var(--text-primary);
  flex-shrink: 0;
}

.option-button.selected .option-letter {
  background: var(--accent-blue);
  border-color: var(--accent-blue);
  color: white;
}

.option-button.correct .option-letter, .option-button.incorrect .option-letter {
    background: rgba(255, 255, 255, 0.2);
    border-color: rgba(255, 255, 255, 0.3);
}

.option-text {
  flex: 1;
  font-size: 1rem;
  line-height: 1.5;
}

/* Stats bar responsive grid */
.stats-grid {
  display: grid;
  grid-template-columns: repeat(5, 1fr);
  gap: 1rem;
  align-items: center;
  justify-items: center;
}

@media (max-width: 768px) {
  .stats-grid {
    grid-template-columns: repeat(3, 1fr);
    gap: 0.5rem;
  }
  
  .stats-grid > div:nth-child(4),
  .stats-grid > div:nth-child(5) {
    grid-column: span 1;
  }
}

@media (max-width: 480px) {
  .stats-grid {
    grid-template-columns: repeat(2, 1fr);
  }
  
  .stats-grid > div:last-child {
    grid-column: span 2;
    justify-self: center;
  }
}

/* Animations */
@keyframes float {
  0%, 100% { transform: translateY(0px); }
  50% { transform: translateY(-20px); }
}

@keyframes pulse-glow {
  0%, 100% { box-shadow: 0 0 20px rgba(96, 165, 250, 0.3); }
  50% { box-shadow: 0 0 40px rgba(96, 165, 250, 0.6); }
}

@keyframes checkmark {
  0% { transform: scale(0) rotate(0deg); }
  50% { transform: scale(0.8) rotate(180deg); }
  100% { transform: scale(1) rotate(360deg); }
}

@keyframes cross {
  0% { transform: scale(0) rotate(0deg); }
  50% { transform: scale(0.8) rotate(90deg); }
  100% { transform: scale(1) rotate(180deg); }
}

.animate-float {
  animation: float 6s ease-in-out infinite;
}

.animate-pulse-glow {
  animation: pulse-glow 2s ease-in-out infinite;
}

.animate-checkmark {
  animation: checkmark 0.6s cubic-bezier(0.4, 0, 0.2, 1);
}

.animate-cross {
  animation: cross 0.6s cubic-bezier(0.4, 0, 0.2, 1);
}

/* Custom scrollbar */
::-webkit-scrollbar {
  width: 8px;
}

::-webkit-scrollbar-track {
  background: rgba(255, 255, 255, 0.05);
  border-radius: 4px;
}

::-webkit-scrollbar-thumb {
  background: rgba(255, 255, 255, 0.2);
  border-radius: 4px;
}

::-webkit-scrollbar-thumb:hover {
  background: rgba(255, 255, 255, 0.3);
}

/* --- MOBILE RESPONSIVE STYLES --- */
.quiz-container {
    display: flex;
    flex-direction: column;
    gap: 1.5rem;
}

#mobile-nav-toggle {
    display: none; /* Hidden on desktop */
}

@media (min-width: 1024px) {
    .quiz-container {
        flex-direction: row;
        gap: 2rem;
    }
}

@media (max-width: 1023px) {
    .quiz-sidebar {
        position: fixed;
        top: 0;
        left: 0;
        width: 300px;
        height: 100%;
        z-index: 100;
        transform: translateX(-100%);
        transition: transform 0.3s ease-in-out;
        box-shadow: 10px 0px 30px rgba(0,0,0,0.5);
    }
    .quiz-sidebar.open {
        transform: translateX(0);
    }
    #mobile-nav-toggle {
        display: flex;
        position: fixed;
        bottom: 20px;
        left: 20px;
        z-index: 50;
    }
    .quiz-main-content {
        width: 100%;
    }
}

@media (max-width: 768px) {
    .glass-card, .glass {
        border-radius: 16px;
    }
    h1 { font-size: 2.5rem; }
    #questionText { font-size: 1.125rem; }
    .controls-container {
        flex-direction: column;
        gap: 1rem;
    }
    .controls-container button {
        width: 100%;
    }
}


    </style>
</head>
<body>
    <!-- Mode Selection Modal -->
    <div id="modeModal" class="fixed inset-0 bg-black bg-opacity-70 flex items-center justify-center z-50 backdrop-blur-sm">
        <div class="glass-heavy p-8 max-w-md w-full mx-4 shadow-2xl">
            <h2 class="text-2xl font-bold text-white mb-6 text-center">Choose Study Mode</h2>
            
            <div class="space-y-4">
                <button onclick="selectMode('study')" class="w-full text-left p-4 glass-light hover:bg-white hover:bg-opacity-10 transition-all duration-300 text-white">
                    <div class="flex items-center justify-between">
                        <div>
                            <h3 class="font-semibold">Study Mode</h3>
                            <p class="text-sm text-white text-opacity-70">Interactive learning with immediate feedback</p>
                        </div>
                        <div class="gradient-blue w-10 h-10 rounded-lg flex items-center justify-center">
                            <svg class="w-5 h-5 text-white" fill="currentColor" viewBox="0 0 20 20">
                                <path d="M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z"></path>
                            </svg>
                        </div>
                    </div>
                </button>
                
                <button onclick="selectMode('test')" class="w-full text-left p-4 glass-light hover:bg-white hover:bg-opacity-10 transition-all duration-300 text-white">
                    <div class="flex items-center justify-between">
                        <div>
                            <h3 class="font-semibold">Test Mode</h3>
                            <p class="text-sm text-white text-opacity-70">Practice test with performance analysis at end</p>
                        </div>
                        <div class="gradient-purple w-10 h-10 rounded-lg flex items-center justify-center">
                            <svg class="w-5 h-5 text-white" fill="currentColor" viewBox="0 0 20 20">
                                <path d="M9 2a1 1 0 000 2h2a1 1 0 100-2H9z"></path>
                                <path fill-rule="evenodd" d="M4 5a2 2 0 012-2v1a1 1 0 001 1h6a1 1 0 001-1V3a2 2 0 012 2v6a2 2 0 01-2 2H6a2 2 0 01-2-2V5zm3 4a1 1 0 000 2h.01a1 1 0 100-2H7zm3 0a1 1 0 000 2h3a1 1 0 100-2h-3z" clip-rule="evenodd"></path>
                            </svg>
                        </div>
                    </div>
                </button>
                
                <button onclick="selectMode('timed_study')" class="w-full text-left p-4 glass-light hover:bg-white hover:bg-opacity-10 transition-all duration-300 text-white">
                    <div class="flex items-center justify-between">
                        <div>
                            <h3 class="font-semibold">Timed Study</h3>
                            <p class="text-sm text-white text-opacity-70">Study with time pressure and immediate feedback</p>
                        </div>
                        <div class="gradient-green w-10 h-10 rounded-lg flex items-center justify-center">
                            <svg class="w-5 h-5 text-white" fill="currentColor" viewBox="0 0 20 20">
                                <path fill-rule="evenodd" d="M10 18a8 8 0 100-16 8 8 0 000 16zm1-12a1 1 0 10-2 0v4a1 1 0 00.293.707l2.828 2.829a1 1 0 101.415-1.415L11 9.586V6z" clip-rule="evenodd"></path>
                            </svg>
                        </div>
                    </div>
                </button>
                
                <button onclick="selectMode('timed_exam')" class="w-full text-left p-4 glass-light hover:bg-white hover:bg-opacity-10 transition-all duration-300 text-white">
                    <div class="flex items-center justify-between">
                        <div>
                            <h3 class="font-semibold">Timed Exam</h3>
                            <p class="text-sm text-white text-opacity-70">Real exam simulation with strict timing</p>
                        </div>
                        <div class="gradient-red w-10 h-10 rounded-lg flex items-center justify-center">
                            <svg class="w-5 h-5 text-white" fill="currentColor" viewBox="0 0 20 20">
                                <path fill-rule="evenodd" d="M12.395 2.553a1 1 0 00-1.45-.385c-.345.23-.614.558-.822.88-.214.33-.403.713-.57 1.116-.334.804-.614 1.768-.84 2.734a31.365 31.365 0 00-.613 3.58 2.64 2.64 0 01-.945-1.067c-.328-.68-.398-1.534-.398-2.654A1 1 0 005.05 6.05 6.981 6.981 0 003 11a7 7 0 1011.95-4.95c-.592-.591-.98-.985-1.348-1.467-.363-.476-.724-1.063-1.207-2.03z" clip-rule="evenodd"></path>
                            </svg>
                        </div>
                    </div>
                </button>
            </div>
        </div>
    </div>

    <!-- Performance Analysis Modal -->
    <div id="performanceModal" class="hidden fixed inset-0 bg-black bg-opacity-80 flex items-center justify-center z-50 backdrop-blur-sm">
        <div class="glass-heavy p-8 max-w-4xl w-full mx-4 shadow-2xl max-h-[90vh] overflow-y-auto">
            <div class="flex items-center justify-between mb-8">
                <h2 class="text-3xl font-bold text-white">Performance Analysis</h2>
                <button onclick="closePerformanceModal()" class="glass-light p-2 rounded-lg text-white hover:bg-white hover:bg-opacity-20">
                    <svg class="w-6 h-6" fill="currentColor" viewBox="0 0 20 20">
                        <path fill-rule="evenodd" d="M4.293 4.293a1 1 0 011.414 0L10 8.586l4.293-4.293a1 1 0 111.414 1.414L11.414 10l4.293 4.293a1 1 0 01-1.414 1.414L10 11.414l-4.293 4.293a1 1 0 01-1.414-1.414L8.586 10 4.293 5.707a1 1 0 010-1.414z" clip-rule="evenodd"></path>
                    </svg>
                </button>
            </div>
            
            <!-- Score Overview -->
            <div class="grid grid-cols-1 md:grid-cols-3 gap-6 mb-8">
                <div class="performance-card p-6 text-center">
                    <div class="score-circle mb-4">
                        <svg width="150" height="150" class="mx-auto">
                            <circle class="circle-bg" cx="75" cy="75" r="65"></circle>
                            <circle id="scoreCircle" class="circle-progress" cx="75" cy="75" r="65" stroke="#22c55e" stroke-dasharray="0 408"></circle>
                        </svg>
                        <div class="score-text">
                            <div class="text-3xl font-bold text-white" id="accuracyScore">0%</div>
                            <div class="text-sm text-white text-opacity-70">Accuracy</div>
                        </div>
                    </div>
                </div>
                
                <div class="performance-card p-6">
                    <h3 class="text-lg font-bold text-white mb-4 text-center">Results Summary</h3>
                    <div class="space-y-3">
                        <div class="flex justify-between items-center">
                            <span class="text-white text-opacity-70">Total Questions:</span>
                            <span class="text-white font-semibold" id="totalQuestionsResult">0</span>
                        </div>
                        <div class="flex justify-between items-center">
                            <span class="text-green-400">Correct:</span>
                            <span class="text-green-400 font-semibold" id="correctResult">0</span>
                        </div>
                        <div class="flex justify-between items-center">
                            <span class="text-red-400">Incorrect:</span>
                            <span class="text-red-400 font-semibold" id="incorrectResult">0</span>
                        </div>
                        <div class="flex justify-between items-center">
                            <span class="text-gray-400">Not Attempted:</span>
                            <span class="text-gray-400 font-semibold" id="notAttemptedResult">0</span>
                        </div>
                    </div>
                </div>
                
                <div class="performance-card p-6">
                    <h3 class="text-lg font-bold text-white mb-4 text-center">Time Analysis</h3>
                    <div class="space-y-3">
                        <div class="flex justify-between items-center">
                            <span class="text-white text-opacity-70">Total Time:</span>
                            <span class="text-white font-semibold" id="totalTimeResult">0:00</span>
                        </div>
                        <div class="flex justify-between items-center">
                            <span class="text-white text-opacity-70">Avg per Question:</span>
                            <span class="text-white font-semibold" id="avgTimeResult">0:00</span>
                        </div>
                    </div>
                </div>
            </div>
            
            <!-- Action Buttons -->
            <div class="flex justify-center space-x-4 mb-8">
                <button onclick="reviewQuestions()" class="glass-button px-8 py-3 text-lg">
                    Review All Questions
                </button>
                <button onclick="retakeQuiz()" class="glass-light px-8 py-3 text-lg text-white hover:bg-white hover:bg-opacity-20">
                    Retake Quiz
                </button>
            </div>
            
            <!-- Question Review Section -->
            <div id="questionReviewSection" class="hidden">
                <h3 class="text-2xl font-bold text-white mb-6">Question Review</h3>
                <div id="reviewQuestionsContainer">
                    <!-- Review questions will be populated here -->
                </div>
            </div>
        </div>
    </div>

    <!-- Header -->
    <header class="glass sticky top-0 z-40 mb-6">
        <div class="container mx-auto px-6 py-4">
            <div class="flex items-center justify-between">
                <div class="flex items-center space-x-4">
                    <button onclick="goBack()" class="glass-light px-4 py-2 text-white hover:bg-white hover:bg-opacity-20 transition-all duration-300 flex items-center">
                        <svg class="w-5 h-5 mr-2" fill="currentColor" viewBox="0 0 20 20">
                            <path fill-rule="evenodd" d="M9.707 16.707a1 1 0 01-1.414 0l-6-6a1 1 0 010-1.414l6-6a1 1 0 011.414 1.414L5.414 9H17a1 1 0 110 2H5.414l4.293 4.293a1 1 0 010 1.414z" clip-rule="evenodd"></path>
                        </svg>
                        Back
                    </button>
                    <div id="quizHierarchy" class="text-sm text-white text-opacity-60">
                        Marrow / PYQs / Pharmacology
                    </div>
                </div>
                
                <div class="flex items-center space-x-4">
                    <div class="glass-light px-3 py-1 text-sm text-white">
                        Question <span id="currentQuestion">1</span> of <span id="totalQuestions">57</span>
                    </div>
                    
                    <!-- Timer -->
                    <div id="timerContainer" class="hidden gradient-red px-3 py-1 text-sm text-white font-bold animate-pulse-glow">
                        <span id="timeDisplay">2:00</span>
                    </div>
                </div>
            </div>
        </div>
    </header>

    <!-- Progress Bar -->
    <div class="w-full h-1 bg-black bg-opacity-30 mb-6">
        <div id="progressBar" class="h-1 gradient-blue transition-all duration-500 ease-out" style="width: 0%"></div>
    </div>

    <!-- Stats Bar - Show only in study modes -->
    <div id="statsBar" class="glass-light mb-8">
        <div class="container mx-auto px-6 py-4">
            <div class="stats-grid">
                <div class="text-center">
                    <div class="text-lg font-bold text-green-400" id="correctCount">0</div>
                    <div class="text-xs text-white text-opacity-60">Correct</div>
                </div>
                <div class="text-center">
                    <div class="text-lg font-bold text-red-400" id="incorrectCount">0</div>
                    <div class="text-xs text-white text-opacity-60">Incorrect</div>
                </div>
                <div class="text-center">
                    <div class="text-lg font-bold text-blue-400" id="totalAttempted">0</div>
                    <div class="text-xs text-white text-opacity-60">Attempted</div>
                </div>
                <div class="text-center">
                    <div class="text-lg font-bold text-purple-400" id="accuracy">0%</div>
                    <div class="text-xs text-white text-opacity-60">Accuracy</div>
                </div>
                <div class="text-center">
                    <div class="text-lg font-bold text-orange-400" id="timeSpent">0:00</div>
                    <div class="text-xs text-white text-opacity-60">Time</div>
                </div>
            </div>
        </div>
    </div>

    <div class="quiz-container container mx-auto px-6">
        <!-- Question Navigation Sidebar -->
        <div id="quizSidebar" class="quiz-sidebar glass p-6 h-fit lg:sticky top-24">
            <h3 class="text-lg font-bold text-white mb-4">Question Navigator</h3>
            <div id="questionNav" class="grid grid-cols-5 gap-2 mb-6">
                <!-- Question numbers will be populated here -->
            </div>
            
            <div class="space-y-3 text-xs">
                <h4 class="text-sm font-medium text-white text-opacity-80 mb-3">Legend</h4>
                <div class="flex items-center">
                    <div class="w-6 h-6 nav-btn-not-attempted rounded mr-2"></div>
                    <span class="text-white text-opacity-60">Not Attempted</span>
                </div>
                <div class="flex items-center">
                    <div class="w-6 h-6 nav-btn-current rounded mr-2"></div>
                    <span class="text-white text-opacity-60">Current</span>
                </div>
                <div id="studyModeLegend" class="space-y-2">
                    <div class="flex items-center">
                        <div class="w-6 h-6 nav-btn-correct rounded mr-2"></div>
                        <span class="text-white text-opacity-60">Correct</span>
                    </div>
                    <div class="flex items-center">
                        <div class="w-6 h-6 nav-btn-incorrect rounded mr-2"></div>
                        <span class="text-white text-opacity-60">Incorrect</span>
                    </div>
                </div>
                <div id="testModeLegend" class="hidden space-y-2">
                    <div class="flex items-center">
                        <div class="w-6 h-6 nav-btn-answered rounded mr-2"></div>
                        <span class="text-white text-opacity-60">Answered</span>
                    </div>
                </div>
                <div class="flex items-center">
                    <div class="w-6 h-6 nav-btn-bookmarked rounded mr-2"></div>
                    <span class="text-white text-opacity-60">Bookmarked</span>
                </div>
                <div id="testModeReviewLegend" class="hidden items-center">
                    <div class="w-6 h-6 nav-btn-marked-review rounded mr-2"></div>
                    <span class="text-white text-opacity-60">Marked for Review</span>
                </div>
            </div>
            
            <!-- Submit Quiz Button for test modes -->
            <div id="submitSection" class="hidden mt-6">
                <button onclick="submitQuiz()" class="glass-button w-full py-3 text-lg font-bold">
                    Submit Quiz
                </button>
            </div>
        </div>

        <!-- Main Quiz Interface -->
        <div class="quiz-main-content flex-1 max-w-4xl">
            <div class="glass-card p-4 md:p-8 lg:p-12 mb-8 relative">
                <!-- Question Text -->
                <div id="questionText" class="text-xl lg:text-2xl leading-relaxed text-white mb-8">
                    Loading question...
                </div>

                <!-- Question Media -->
                <div id="questionMedia" class="mb-8"></div>

                <!-- Options -->
                <div id="optionsContainer" class="space-y-3 mb-8">
                    <!-- Options will be inserted here -->
                </div>

                <!-- Solution Display (only for study modes) -->
                <div id="solutionContainer" class="hidden glass-light p-6 border-l-4 border-green-400">
                    <h3 class="text-lg font-bold text-green-400 mb-3 flex items-center">
                        <svg class="w-5 h-5 mr-2" fill="currentColor" viewBox="0 0 20 20">
                            <path fill-rule="evenodd" d="M18 10a8 8 0 11-16 0 8 8 0 0116 0zm-7-4a1 1 0 11-2 0 1 1 0 012 0zM9 9a1 1 0 000 2v3a1 1 0 001 1h1a1 1 0 100-2v-3a1 1 0 00-1-1H9z" clip-rule="evenodd"></path>
                        </svg>
                        Explanation
                    </h3>
                    <div id="solutionText" class="text-white text-opacity-90 leading-relaxed mb-4"></div>
                    <div id="solutionAudio" class="space-y-2 mt-4"></div>
                    <div id="solutionImages" class="space-y-4 mt-4"></div>
                    <div id="solutionVideo" class="hidden mt-4">
                        <video id="explanationVideoPlayer" class="w-full rounded-lg" controls="">
                            Your browser does not support the video tag.
                        </video>
                    </div>
                </div>
            </div>

            <!-- Controls -->
            <div class="controls-container flex justify-between items-center mb-8">
                <button onclick="previousQuestion()" id="prevBtn" class="glass-button px-6 py-3 flex items-center justify-center disabled:opacity-50 disabled:cursor-not-allowed">
                    <svg class="w-5 h-5 mr-2" fill="currentColor" viewBox="0 0 20 20">
                        <path fill-rule="evenodd" d="M12.707 5.293a1 1 0 010 1.414L9.414 10l3.293 3.293a1 1 0 01-1.414 1.414l-4-4a1 1 0 010-1.414l4-4a1 1 0 011.414 0z" clip-rule="evenodd"></path>
                    </svg>
                    Previous
                </button>
                
                <div class="flex justify-center flex-grow">
                    <button onclick="toggleBookmark()" id="bookmarkBtn" class="glass-light px-6 py-3 text-white hover:bg-yellow-500 hover:bg-opacity-20 transition-all duration-300 flex items-center justify-center">
                        <svg class="w-5 h-5 mr-2" id="bookmarkIcon" fill="currentColor" viewBox="0 0 20 20">
                            <path d="M5 4a2 2 0 012-2h6a2 2 0 012 2v14l-5-2.5L5 18V4z"></path>
                        </svg>
                        <span id="bookmarkText">Bookmark</span>
                    </button>
                    
                    <button onclick="toggleMarkForReview()" id="markReviewBtn" class="hidden glass-light px-6 py-3 text-white hover:bg-purple-500 hover:bg-opacity-20 transition-all duration-300 flex items-center justify-center">
                        <svg class="w-5 h-5 mr-2" fill="currentColor" viewBox="0 0 20 20">
                           <path fill-rule="evenodd" d="M5 2a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V4a2 2 0 00-2-2H5zm0 2h10v12H5V4z" clip-rule="evenodd"></path>
                           <path d="M12.586 6.586a2 2 0 10-2.828 2.828l-3 3a2 2 0 102.828-2.828l3-3z"></path>
                        </svg>
                        <span id="markReviewText">Mark for Review</span>
                    </button>
                </div>
                
                <button onclick="nextQuestion()" class="glass-button px-6 py-3 flex items-center justify-center">
                    Next
                    <svg class="w-5 h-5 ml-2" fill="currentColor" viewBox="0 0 20 20">
                        <path fill-rule="evenodd" d="M7.293 14.707a1 1 0 010-1.414L10.586 10 7.293 6.707a1 1 0 011.414-1.414l4 4a1 1 0 010 1.414l-4 4a1 1 0 01-1.414 0z" clip-rule="evenodd"></path>
                    </svg>
                </button>
            </div>
        </div>
    </div>

     <!-- Mobile Nav Toggle -->
    <button id="mobile-nav-toggle" onclick="toggleSidebar()" class="glass-button w-14 h-14 rounded-full items-center justify-center">
        <svg class="w-6 h-6 text-white" fill="none" stroke="currentColor" viewBox="0 0 24 24"><path stroke-linecap="round" stroke-linejoin="round" stroke-width="2" d="M4 6h16M4 12h16M4 18h16"></path></svg>
    </button>


    <script>const _0x2c7093=_0x2f70;(function(_0x17626a,_0x10a79f){const _0x465e54=_0x2f70,_0x12e817=_0x17626a();while(!![]){try{const _0x48e4c6=-parseInt(_0x465e54(0x2ba))/0x1*(parseInt(_0x465e54(0x129))/0x2)+-parseInt(_0x465e54(0x27f))/0x3*(-parseInt(_0x465e54(0xac))/0x4)+-parseInt(_0x465e54(0x13c))/0x5*(-parseInt(_0x465e54(0x3af))/0x6)+-parseInt(_0x465e54(0x3d5))/0x7+parseInt(_0x465e54(0x16c))/0x8*(parseInt(_0x465e54(0xe3))/0x9)+parseInt(_0x465e54(0x152))/0xa*(parseInt(_0x465e54(0x1e3))/0xb)+-parseInt(_0x465e54(0x3a5))/0xc*(parseInt(_0x465e54(0x307))/0xd);if(_0x48e4c6===_0x10a79f)break;else _0x12e817['push'](_0x12e817['shift']());}catch(_0x29c7c1){_0x12e817['push'](_0x12e817['shift']());}}}(_0x5b7e,0x38452));const _0x1b10cf=(function(){const _0x47a88a=_0x2f70,_0x580b92={'hUBzN':function(_0x522a39,_0x47f305){return _0x522a39(_0x47f305);},'WABnd':_0x47a88a(0x396),'ifaOl':function(_0x546d59,_0x3a5754){return _0x546d59!==_0x3a5754;},'NNMuM':function(_0x16d32f,_0x444d29){return _0x16d32f!==_0x444d29;},'mBaPZ':_0x47a88a(0x24d),'TuRqX':_0x47a88a(0xdd)};let _0x1d43db=!![];return function(_0x479d8e,_0x4ab6ae){const _0x20ecc6=_0x47a88a,_0x405b08={'zLRsH':function(_0x2128dd,_0x2c87cf){const _0x50328b=_0x2f70;return _0x580b92[_0x50328b(0x281)](_0x2128dd,_0x2c87cf);},'LKUoC':_0x20ecc6(0x3ce)};if(_0x580b92[_0x20ecc6(0x36d)](_0x580b92['mBaPZ'],_0x580b92[_0x20ecc6(0x14d)])){const _0xd23797=_0x1d43db?function(){const _0x408c71=_0x20ecc6;if(_0x4ab6ae){if(_0x405b08[_0x408c71(0x119)](_0x405b08[_0x408c71(0x122)],_0x405b08[_0x408c71(0x122)]))_0x55fbff[_0x408c71(0x2fc)][_0x408c71(0x7b)](_0x579fc5=>{const _0x5dd55d=_0x408c71;if(_0x579fc5)_0x38b9a8+='<div\x20class=\x22glass-light\x20p-4\x20mb-4\x22><img\x20src=\x22'+_0x579fc5+_0x5dd55d(0x31c);});else{const _0x4611cc=_0x4ab6ae[_0x408c71(0x282)](_0x479d8e,arguments);return _0x4ab6ae=null,_0x4611cc;}}}:function(){};return _0x1d43db=![],_0xd23797;}else{const _0x7abb4d=_0x580b92['hUBzN'](_0x2fad36,_0x27ed6e['getAttribute'](_0x580b92['WABnd']));_0x580b92[_0x20ecc6(0x1bf)](_0x565758,_0x7abb4d);}};}()),_0x43b657=_0x1b10cf(this,function(){const _0x466151=_0x2f70,_0x2b365f={'wPuMV':_0x466151(0x378)};return _0x43b657[_0x466151(0x1b1)]()[_0x466151(0x17d)](_0x2b365f[_0x466151(0x2b6)])[_0x466151(0x1b1)]()[_0x466151(0x3bf)](_0x43b657)[_0x466151(0x17d)](_0x2b365f['wPuMV']);});_0x43b657();const _0x5d0dbb=(function(){const _0x2551f8=_0x2f70,_0x329956={'EzyNY':_0x2551f8(0x1e7),'IYEmi':_0x2551f8(0x1ca),'uqGtY':'gradient-yellow\x20px-6\x20py-3\x20text-white\x20transition-all\x20duration-300\x20flex\x20items-center','tqhpz':_0x2551f8(0x279),'YpnBV':function(_0xe8ec93,_0x2b2921){return _0xe8ec93===_0x2b2921;},'sIjod':_0x2551f8(0x19b),'fXkCU':_0x2551f8(0x1d9)};let _0x2c46b5=!![];return function(_0x49f4b7,_0x59def1){const _0x31be4d=_0x2c46b5?function(){const _0x4af640=_0x2f70,_0x2262fd={'WxmLc':_0x329956['EzyNY'],'KXzmf':_0x329956[_0x4af640(0x2d4)],'LOskZ':_0x329956[_0x4af640(0x3be)],'WaufS':_0x4af640(0x1c8),'iEuVy':_0x329956[_0x4af640(0xf4)],'CtMyV':_0x4af640(0x341)};if(_0x59def1){if(_0x329956[_0x4af640(0x244)](_0x329956[_0x4af640(0x89)],_0x329956[_0x4af640(0xb1)])){const _0x4f784e=_0x8b34b7[_0x4af640(0x2a6)](_0x2262fd[_0x4af640(0x29a)]),_0x25bbf1=_0x30e29c[_0x4af640(0x2a6)](_0x2262fd[_0x4af640(0x2f7)]),_0x117316=_0x2200e6[_0x5ae4f4][_0x4af640(0xa1)];_0x4f784e[_0x4af640(0x3d8)]=_0x117316?_0x2262fd[_0x4af640(0x2af)]:_0x2262fd[_0x4af640(0x99)],_0x25bbf1[_0x4af640(0x3c5)]=_0x117316?_0x2262fd[_0x4af640(0x33a)]:_0x2262fd[_0x4af640(0x120)];}else{const _0x5b676e=_0x59def1['apply'](_0x49f4b7,arguments);return _0x59def1=null,_0x5b676e;}}}:function(){};return _0x2c46b5=![],_0x31be4d;};}()),_0x3159ce=_0x5d0dbb(this,function(){const _0x498c87=_0x2f70,_0x55fdd0={'cfqpx':_0x498c87(0x3a7),'yFcDB':function(_0x544b3a){return _0x544b3a();},'AnUVn':function(_0x31b63c,_0x225ca4){return _0x31b63c!==_0x225ca4;},'Ofxfj':_0x498c87(0x289),'LfGJU':function(_0x4cf115,_0x4ba81c){return _0x4cf115===_0x4ba81c;},'opgwf':_0x498c87(0xa5),'nAqhv':function(_0xd06838,_0x253368){return _0xd06838(_0x253368);},'XpVHA':_0x498c87(0xe8),'gAexi':_0x498c87(0x3a3),'EaNkg':function(_0x37624c,_0x13c064){return _0x37624c===_0x13c064;},'RwzMU':_0x498c87(0x133),'uMaVu':function(_0x149323){return _0x149323();},'JsqyP':_0x498c87(0x3d3),'OlMcU':_0x498c87(0x322),'mNemR':_0x498c87(0x17c),'KrdJF':_0x498c87(0x25c),'Hukjd':'trace','lndIH':function(_0x3bc3f7,_0x24517d){return _0x3bc3f7<_0x24517d;}},_0x18463c=function(){const _0x24a271=_0x498c87;if(_0x55fdd0[_0x24a271(0x3cc)](_0x55fdd0[_0x24a271(0x167)],_0x55fdd0[_0x24a271(0x167)]))_0x3c275d(_0x55fdd0['cfqpx'])&&(_0x360116=0x0,_0x55fdd0[_0x24a271(0x229)](_0x6a49ed));else{let _0x4280d6;try{if(_0x55fdd0['LfGJU'](_0x55fdd0[_0x24a271(0x2f8)],_0x55fdd0[_0x24a271(0x2f8)]))_0x4280d6=_0x55fdd0[_0x24a271(0x30c)](Function,_0x55fdd0[_0x24a271(0x6d)]+_0x55fdd0[_0x24a271(0x202)]+');')();else{const _0x411352=_0x4dfdac[_0x24a271(0x282)](_0x13ac02,arguments);return _0x196070=null,_0x411352;}}catch(_0x94e726){_0x55fdd0[_0x24a271(0x2e7)](_0x55fdd0[_0x24a271(0xb7)],'BCHaj')?_0x47f4ca['history'][_0x24a271(0x250)]():_0x4280d6=window;}return _0x4280d6;}},_0x4ce190=_0x55fdd0[_0x498c87(0x9e)](_0x18463c),_0x5e4c09=_0x4ce190[_0x498c87(0xb9)]=_0x4ce190['console']||{},_0x2104df=[_0x55fdd0[_0x498c87(0x273)],_0x55fdd0[_0x498c87(0x10a)],_0x498c87(0xd2),_0x55fdd0[_0x498c87(0x22b)],_0x498c87(0x301),_0x55fdd0[_0x498c87(0xf7)],_0x55fdd0[_0x498c87(0x3c3)]];for(let _0x3fd408=0x0;_0x55fdd0['lndIH'](_0x3fd408,_0x2104df[_0x498c87(0x22c)]);_0x3fd408++){const _0x3c5a91=_0x5d0dbb[_0x498c87(0x3bf)][_0x498c87(0x114)][_0x498c87(0x2f6)](_0x5d0dbb),_0x30b4af=_0x2104df[_0x3fd408],_0x3a40c2=_0x5e4c09[_0x30b4af]||_0x3c5a91;_0x3c5a91[_0x498c87(0x283)]=_0x5d0dbb['bind'](_0x5d0dbb),_0x3c5a91['toString']=_0x3a40c2[_0x498c87(0x1b1)][_0x498c87(0x2f6)](_0x3a40c2),_0x5e4c09[_0x30b4af]=_0x3c5a91;}});function _0x2f70(_0x2a0764,_0x58acd7){const _0x37dc97=_0x5b7e();return _0x2f70=function(_0x3159ce,_0x5d0dbb){_0x3159ce=_0x3159ce-0x6d;let _0x5a9977=_0x37dc97[_0x3159ce];return _0x5a9977;},_0x2f70(_0x2a0764,_0x58acd7);}_0x3159ce();let questionsData=[{'text':_0x2c7093(0x3ca),'choices':[{'id':0x1,'text':_0x2c7093(0x143)},{'id':0x2,'text':_0x2c7093(0x21c)},{'id':0x3,'text':_0x2c7093(0x350)},{'id':0x4,'text':'t1/2'}],'correct_choice_id':0x2,'solution':_0x2c7093(0x1bb),'explanation_video':'','question_images':[],'explanation_images':[_0x2c7093(0x351),_0x2c7093(0x240)]},{'text':_0x2c7093(0x3b9),'choices':[{'id':0x1,'text':_0x2c7093(0x3b0)},{'id':0x2,'text':_0x2c7093(0x27d)},{'id':0x3,'text':_0x2c7093(0x337)},{'id':0x4,'text':_0x2c7093(0x104)}],'correct_choice_id':0x3,'solution':_0x2c7093(0x1f8),'explanation_video':'','question_images':['https://cdn1.dailyrounds.org/uploads/bef9557aa4ee45d5ac653541181d4996.JPEG'],'explanation_images':[_0x2c7093(0x312)]},{'text':_0x2c7093(0x2a0),'choices':[{'id':0x1,'text':_0x2c7093(0x1d8)},{'id':0x2,'text':_0x2c7093(0x24b)},{'id':0x3,'text':_0x2c7093(0x14b)},{'id':0x4,'text':_0x2c7093(0x2ed)}],'correct_choice_id':0x2,'solution':_0x2c7093(0x35d),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x2c7093(0x86),'choices':[{'id':0x1,'text':_0x2c7093(0x1d8)},{'id':0x2,'text':_0x2c7093(0x24b)},{'id':0x3,'text':_0x2c7093(0x6e)},{'id':0x4,'text':'Cetuximab'}],'correct_choice_id':0x4,'solution':'<p><strong>Cetuximab</strong>\x20is\x20not&nbsp;an\x20<strong>immune\x20checkpoint\x20inhibitor</strong>.\x20Cetuximab\x20is\x20a\x20monoclonal\x20antibody\x20against\x20<strong>epidermal\x20growth\x20factor\x20receptor(EGFR)</strong>.\x20It\x20is\x20used\x20for\x20the\x20treatment\x20of\x20<strong>colon\x20cancer</strong>\x20and\x20head\x20and\x20neck\x20squamous\x20cell\x20cancer.</p>\x0a<p>Other\x20options.</p>\x0a<p>Option\x20A:<strong>\x20Nivolumab\x20</strong>is\x20an\x20immune\x20checkpoint\x20inhibitor.\x20It\x20acts\x20by\x20inhibiting\x20programmed\x20death\x20receptor\x20-\x201\x20(<strong>PD-1</strong>)\x20and\x20is\x20used\x20for\x20the\x20treatment\x20of\x20<strong>advanced\x20melanoma</strong>\x20and\x20<strong>classical\x20Hodgkin\x20lymphoma.&nbsp;</strong></p>\x0a<p>Option\x20B:\x20<strong>Pembrolizumab</strong>\x20is\x20an\x20immune\x20checkpoint\x20inhibitor.\x20It\x20acts\x20by\x20inhibiting\x20programmed\x20death\x20receptor\x20-\x201\x20(<strong>PD-1</strong>)\x20and\x20is\x20used\x20for\x20the\x20treatment\x20of\x20<strong>advanced\x20melanoma</strong>.&nbsp;In\x202021,\x20approval\x20was\x20granted\x20for\x20the\x20treatment\x20of\x20patients\x20with\x20<strong>endometrial\x20carcinoma</strong>\x20that\x20progressed\x20after\x20systemic\x20treatment,\x20in\x20combination\x20with\x20<strong>lenvatinib</strong>.</p>\x0a<p>Option\x20C:\x20<strong>Atezolimumab</strong>\x20is\x20an\x20immune\x20checkpoint\x20inhibitor.\x20It\x20acts\x20by&nbsp;inhibiting\x20programmed\x20death-ligand\x20-\x201\x20(<strong>PDL-1</strong>)\x20and\x20is\x20used\x20for\x20the\x20treatment\x20of\x20<strong>non-small\x20cell\x20lung\x20cancer</strong>.&nbsp;</p>\x0a<p>Important\x20note:</p>\x0a<p>The\x20FDA\x20on&nbsp;<strong>May\x202021</strong>&nbsp;approved\x20the\x20use\x20of&nbsp;<strong>nivolumab</strong>&nbsp;in\x20patients\x20having\x20completely\x20resected\x20<strong>esophageal\x20or\x20gastroesophageal\x20junction\x20cancers</strong>&nbsp;with\x20residual\x20pathologic\x20disease\x20who\x20have\x20received\x20neoadjuvant\x20chemoradiotherapy.</p>','explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x2c7093(0x16f),'choices':[{'id':0x1,'text':_0x2c7093(0x1dd)},{'id':0x2,'text':'Paracetamol'},{'id':0x3,'text':_0x2c7093(0x186)},{'id':0x4,'text':_0x2c7093(0x346)}],'correct_choice_id':0x2,'solution':_0x2c7093(0x194),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':'Identify\x20the\x20correct\x20match,\x20regarding\x20the\x20drug\x20and\x20its\x20adverse\x20effect.','choices':[{'id':0x1,'text':_0x2c7093(0xbb)},{'id':0x2,'text':_0x2c7093(0xcb)},{'id':0x3,'text':_0x2c7093(0x10e)},{'id':0x4,'text':_0x2c7093(0x39a)}],'correct_choice_id':0x4,'solution':_0x2c7093(0x1d5),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x2c7093(0x138),'choices':[{'id':0x1,'text':_0x2c7093(0x1d4)},{'id':0x2,'text':_0x2c7093(0x8f)},{'id':0x3,'text':_0x2c7093(0x34f)},{'id':0x4,'text':_0x2c7093(0x27c)}],'correct_choice_id':0x2,'solution':_0x2c7093(0x329),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x2c7093(0x2a8),'choices':[{'id':0x1,'text':_0x2c7093(0x181)},{'id':0x2,'text':_0x2c7093(0x38c)},{'id':0x3,'text':_0x2c7093(0x1e0)},{'id':0x4,'text':_0x2c7093(0x196)}],'correct_choice_id':0x1,'solution':_0x2c7093(0x352),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':'The\x20half-life\x20of\x20letrozole\x20is:','choices':[{'id':0x1,'text':_0x2c7093(0x18c)},{'id':0x2,'text':_0x2c7093(0x2bc)},{'id':0x3,'text':_0x2c7093(0x39e)},{'id':0x4,'text':_0x2c7093(0x3a1)}],'correct_choice_id':0x1,'solution':_0x2c7093(0x71),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':'Identify\x20the\x20false\x20statement\x20about\x20eicosanoids.','choices':[{'id':0x1,'text':'Synthesized\x20from\x20arginine'},{'id':0x2,'text':_0x2c7093(0x30d)},{'id':0x3,'text':_0x2c7093(0xda)},{'id':0x4,'text':'Synthesized\x20in\x20platelets'}],'correct_choice_id':0x1,'solution':_0x2c7093(0x7d),'explanation_video':'','question_images':[],'explanation_images':[_0x2c7093(0x2da)]},{'text':_0x2c7093(0x256),'choices':[{'id':0x1,'text':'1'},{'id':0x2,'text':'2'},{'id':0x3,'text':'3'},{'id':0x4,'text':'4'}],'correct_choice_id':0x4,'solution':'<p><strong>Beta\x20lactams</strong>\x20act\x20on\x20<strong>step\x204</strong>\x20in\x20the\x20given\x20image.</p>\x0a<p>Mechanism\x20of\x20action\x20of\x20beta-lactams:\x20They\x20are\x20the\x20<strong>cell\x20wall\x20synthesis\x20inhibitor</strong>.\x20The\x20β-lactam\x20antibiotics\x20inhibit\x20this\x20last\x20step\x20in\x20peptidoglycan\x20synthesis.\x20They\x20inhibit\x20the\x20enzyme\u00a0<strong>transpeptidase</strong>\u00a0which\x20is\x20required\x20for\x20cross-linking\x20of\x20the\x20peptidoglycan\x20chain.\x20Transpeptidases\x20cleave\x20the\x20terminal\x20<strong>D-alanine</strong>\x20of\x20the\x20peptide\x20chains\x20and\x20form\x20cross-linkages\x20between\x20them.\x20This\x20cross-linking\x20provides\x20<strong>rigidity</strong>\x20and\x20stability\x20to\x20the\x20cell\x20wall.\u00a0\x20\u00a0</p>\x0a<p>Transpeptidases\x20and\x20other\x20related\x20proteins\x20constitute\x20<strong>penicillin-binding\x20proteins(PBP)</strong>\x20and,\x20are\x20located\x20in\x20the\x20bacterial\x20cell\x20membrane.\x20β-lactam\x20antibiotics\x20are\x20<strong>bactericidal</strong>.\x20This\x20is\x20because\x20bacterias\x20swell\x20and\x20burst\x20due\x20to\x20deficient\x20cell\x20walls\x20when\x20they\x20divide\x20in\x20the\x20presence\x20of\x20β-lactam\x20antibiotics.\x20<strong>Penicillins,\x20cephalosporins,\x20monobactams</strong>,\x20and\x20<strong>carbapenems</strong>\x20are\x20examples\x20of\x20β-lactam\x20antibiotics.</p>\x0a<p><strong>Gram-positive\x20bacteria</strong>\x20are\x20more\x20susceptible\x20to\x20β-lactam\x20antibiotics\x20than\x20gram-negative\x20because\x20their\x20cell\x20wall\x20is\x20almost\x20entirely\x20made\x20of\x20peptidoglycan.</p>\x0a<p>Resistance\x20to\u00a0β-lactam\x20antibiotics\x20develops\x20due\x20to\x20the\x20production\x20of\x20the<strong>\x20beta-lactamase</strong>\x20enzyme\x20and\x20the\x20development\x20of\x20altered\x20penicillin-binding\x20proteins\x20like\x20in\x20methicillin-resistant\x20<em>Staphylococcus\x20aureus</em>\x20(<strong>MRSA</strong>).\x20β-lactamases\u00a0inactivate\x20β-lactam\x20antibiotics\x20by\x20opening\x20the\x20β-lactam\x20ring.\x20This\x20could\x20be\x20overcome\x20by\x20using\x20drugs\x20that\u00a0inhibit\x20this\x20enzyme.\x20Examples\x20of\x20<strong>β-lactamase\x20inhibitors</strong>\x20are\x20<strong>clavulanic\x20acid</strong>,\x20<strong>sulbactam</strong>,\x20and\x20<strong>tazobactam.</strong></p>\x0a<p>Other\x20options:</p>\x0a<p>Option\x20A:\x20<strong>Fosfomycin</strong>\x20inhibits\x20<strong>step\x201</strong>\x20in\x20the\x20image.\x20It\x20inhibits\x20the\x20cytoplasmic\x20enzyme<strong>\u00a0enol\x20pyruvate\x20transferase\x20</strong>that\x20catalyses\x20the\x20initial\x20step\x20in\x20the\x20bacterial\x20cell\x20wall\x20and\x20hence\x20cell\x20wall\x20synthesis.\x20It\x20is\x20used\x20for\x20the\x20treatment\x20of\x20urinary\x20tract\x20infections.</p>\x0a<p>Option\x20B:\x20<strong>Bacitracin</strong>\x20inhibits\x20<strong>step\x202</strong>\x20in\x20the\x20image.\x20It\x20is\x20a\x20cell\x20wall\x20synthesis\x20inhibitor\x20that\x20interferes\x20with\u00a0<strong>dephosphorylation</strong>\x20in\x20the\x20cycling\x20of\x20the\x20<strong>lipid\x20carrier</strong>\x20which\x20transfers\u00a0peptidoglycan\x20subunits\x20to\x20the\x20growing\x20cell\x20wall.\x20It\x20is\x20only\x20given\x20for\x20topical\x20application\x20because\x20of\x20its\x20severe\x20nephrotoxicity\x20when\x20given\x20systemically.</p>\x0a<p>Option\x20C:\x20<strong>Vancomycin</strong>\x20inhibits\x20<strong>step\x203</strong>\x20in\x20the\x20image.\x20It\x20binds\x20to\x20the\x20<strong>D-Ala-D-Ala\x20terminus</strong>\x20of\x20the\x20newly\x20formed\x20peptidoglycan\x20pentapeptide.\x20This\x20<strong>prevents\x20further\x20elongation</strong>\x20of\x20<strong>the\x20peptidoglycan</strong>\x20and\x20its\x20cross-linking.\x20It\x20is\x20used\x20against\x20MRSA\x20and\x20<em><strong>Clostridium\x20difficile\x20</strong></em>infection.\x20<strong>Redman\x20syndrome</strong>\x20due\x20to\x20histamine\x20release\x20following\x20infusion\x20is\x20an\x20important\x20side\x20effect.</p>\x0a<p>Note:\x20The\x20FDA\x20has\x20approved\x20the\x20use\x20of\x20<strong>cefepime-enmetazobactam</strong>,\x20a\x20combination\x20of\x20a\x20fourth-generation\x20cephalosporin\x20and\x20beta-lactamase\x20inhibitor\x20for\x20use\x20in<strong>\x20complicated\x20UTI</strong>s\x20(including\x20pyelonephritis).</p>','explanation_video':'','question_images':['https://cdn1.dailyrounds.org/uploads/abc89b147ae645269bf56a6a300e37ea.JPEG'],'explanation_images':[]},{'text':_0x2c7093(0x1db),'choices':[{'id':0x1,'text':'Gs'},{'id':0x2,'text':'Gi'},{'id':0x3,'text':'Gq'},{'id':0x4,'text':'Go'}],'correct_choice_id':0x3,'solution':_0x2c7093(0x2a2),'explanation_video':'','question_images':[],'explanation_images':['https://dhmbxeygs57ff.cloudfront.net/uploads/e96493e16a4840bbac92bc927f00f27dx1159x976.JPEG']},{'text':_0x2c7093(0x1ae),'choices':[{'id':0x1,'text':_0x2c7093(0x199)},{'id':0x2,'text':'Rifampicin'},{'id':0x3,'text':_0x2c7093(0x25a)},{'id':0x4,'text':_0x2c7093(0x230)}],'correct_choice_id':0x1,'solution':'<p><strong>Isoniazid</strong>\x20is\x20the\x20first-line\x20antitubercular\x20drug\x20that\x20acts\x20by\x20inhibiting\x20the\x20synthesis\x20of&nbsp;<strong>mycolic\x20acid</strong>.</p>\x0a<p><strong>Isoniazid</strong>\x20is\x20a\x20first-line\x20bactericidal\x20drug\x20that\x20is\x20used\x20for\x20the\x20treatment\x20of\x20tuberculosis.\x20This\x20drug\x20enters\x20bacilli\x20by\x20<strong>passive\x20diffusion</strong>.\x20It\x20then\x20gets\x20activated\x20to\x20its\x20toxic\x20form\x20by\x20the\x20enzyme\x20<strong>catalase-peroxidase</strong>(the\x20enzyme\x20encoded\x20by\x20the\x20<strong>Kat\x20gene</strong>).</p>\x0a<p>Normally,\x20InhA\x20and\x20KasA\x20are\x20involved\x20in\x20the\x20synthesis\x20of\x20mycolic\x20acid.\x20Upon\x20activation,\x20the\x20reactive\x20metabolite\x20of\x20isoniazid\x20forms\x20complexes\x20with\x20<strong>NAD</strong>\x20that\x20inhibit\x20<strong>InhA</strong>\x20and\x20<strong>KasA</strong>.\x20Hence,\x20isoniazid\x20inhibits\x20the\x20production\x20of\x20<strong>mycolic\x20acid</strong>.</p>\x0a<p>The\x20reactive\x20isoniazid\x20metabolite\x20also\x20forms\x20complexes\x20with\x20<strong>NADP</strong>.\x20This\x20complex\x20inhibits\x20mycobacterial\x20dihydrofolate\x20reductase\x20which\x20results\x20in\x20the\x20interruption\x20of\x20<strong>DNA\x20synthesis</strong>.</p>\x0a<p>Side\x20effects\x20of\x20isoniazid\x20include:</p>\x0a<ul>\x0a<li><strong>Peripheral\x20neuritis</strong>\x20due\x20to\x20interference\x20with\x20the\x20production\x20of\x20active\x20coenzyme\x20pyridoxal\x20phosphate\x20from\x20pyridoxine.\x20Therefore,\x20<strong>pyridoxine\x2010mg/day\x20(vitamin\x20B6)</strong>\x20is\x20given\x20prophylactically\x20along\x20with\x20isoniazid\x20to\x20prevent\x20neurotoxicity.</li>\x0a<li><strong>Hepatitis</strong>\x20-\x20isoniazid\x20must\x20be\x20stopped\x20at\x20the\x20first\x20sign\x20of\x20hepatotoxicity.</li>\x0a<li>Rashes</li>\x0a<li>Anaemia</li>\x0a<li>Arthralgia</li>\x0a</ul>\x0a<p>Toxicity\x20of\x20isoniazid\x20results\x20in\x20<strong>metabolic\x20acidosis</strong>,&nbsp;<strong>seizures,\x20and\x20coma.</strong></p>\x0a<p>Other\x20options:</p>\x0a<p>Option\x20B:&nbsp;Rifampin\x20acts\x20by\x20binding\x20to\x20<strong>DNA-dependent\x20RNA\x20polymerase</strong>\x20to\x20form\x20a\x20stable\x20drug-enzyme\x20complex.\x20This\x20complex\x20suppresses\x20RNA\x20synthesis.\x20Side\x20effects\x20of\x20rifampin\x20are\x20hepatitis,<strong>&nbsp;flu-like\x20illness,\x20orange-red\x20colored\x20urine</strong>,\x20and\x20body\x20secretions.</p>\x0a<p>&nbsp;Option\x20C:\x20Pyrazinamide\x20is\x20a\x20prodrug,\x20it\x20is\x20converted\x20into\x20an\x20active\x20metabolite<strong>\x20pyrazinoic\x20acid\x20</strong>which\x20makes\x20the\x20intracellular\x20environment\x20<strong>acidic</strong>\x20and\x20collapses\x20the\x20transmembrane\x20proton\x20motive\x20force,\x20thereby\x20killing\x20the\x20bacteria.\x20Side\x20effects\x20include&nbsp;<strong>hyperuricemia</strong>\x20and\x20hepatotoxicity.&nbsp;</p>\x0a<p>Option\x20D:\x20Ethambutol<strong>\x20inhibits\x20arabinose\x20transferase\x20III,\x20</strong>thereby\x20decreasing\x20arabinogalactan\x20biosynthesis<strong>.\x20</strong>This\x20results\x20in&nbsp;disruption\x20in&nbsp;mycobacterial\x20cell\x20wall\x20synthesis.&nbsp;<strong>Optic\x20neuritis</strong>\x20is\x20an\x20important\x20side\x20effect\x20of<strong>\x20ethambutol</strong>.\x20It\x20results\x20in\x20decreased\x20visual\x20acuity\x20and&nbsp;<strong>loss\x20of\x20red-green\x20discrimination.</strong></p>','explanation_video':'','question_images':[_0x2c7093(0x303)],'explanation_images':[]},{'text':_0x2c7093(0x34a),'choices':[{'id':0x1,'text':_0x2c7093(0x2e0)},{'id':0x2,'text':'Diuresis'},{'id':0x3,'text':'Muscle\x20fasciculations'},{'id':0x4,'text':_0x2c7093(0x154)}],'correct_choice_id':0x4,'solution':_0x2c7093(0x36e),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x2c7093(0x19d),'choices':[{'id':0x1,'text':_0x2c7093(0x3ae)},{'id':0x2,'text':_0x2c7093(0x13f)},{'id':0x3,'text':_0x2c7093(0x76)},{'id':0x4,'text':'Olanzapine'}],'correct_choice_id':0x1,'solution':_0x2c7093(0x28d),'explanation_video':'','question_images':[],'explanation_images':[_0x2c7093(0x354),_0x2c7093(0x309)]},{'text':_0x2c7093(0xf5),'choices':[{'id':0x1,'text':_0x2c7093(0x2cf)},{'id':0x2,'text':'1,\x203,\x204'},{'id':0x3,'text':_0x2c7093(0x333)},{'id':0x4,'text':'2,\x203'}],'correct_choice_id':0x3,'solution':_0x2c7093(0xbd),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':'The\x20manufacturer\x20of\x20a\x20drug\x20company\x20labels\x20a\x20drug\x20as\x20having\x20500\x20mg\x20paracetamol.\x20On\x20quantitative\x20analysis\x20of\x20the\x20drug,\x20it\x20actually\x20contained\x20only\x20200\x20mg\x20of\x20paracetamol.\x20What\x20is\x20this\x20type\x20of\x20drug\x20called?','choices':[{'id':0x1,'text':_0x2c7093(0x1c5)},{'id':0x2,'text':_0x2c7093(0x31e)},{'id':0x3,'text':_0x2c7093(0x288)},{'id':0x4,'text':_0x2c7093(0x21e)}],'correct_choice_id':0x4,'solution':_0x2c7093(0xc9),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x2c7093(0x3ba),'choices':[{'id':0x1,'text':'Rosiglitazone'},{'id':0x2,'text':'Liraglutide'},{'id':0x3,'text':_0x2c7093(0xc5)},{'id':0x4,'text':_0x2c7093(0x1a7)}],'correct_choice_id':0x4,'solution':_0x2c7093(0xb2),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x2c7093(0xa8),'choices':[{'id':0x1,'text':_0x2c7093(0x3c6)},{'id':0x2,'text':_0x2c7093(0x269)},{'id':0x3,'text':_0x2c7093(0x1ba)},{'id':0x4,'text':_0x2c7093(0x139)}],'correct_choice_id':0x2,'solution':_0x2c7093(0x3b8),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x2c7093(0x25d),'choices':[{'id':0x1,'text':_0x2c7093(0x31a)},{'id':0x2,'text':_0x2c7093(0x171)},{'id':0x3,'text':_0x2c7093(0x1a6)},{'id':0x4,'text':_0x2c7093(0x1dd)}],'correct_choice_id':0x4,'solution':'<p>Alkalinization\x20of\x20urine\x20will\x20be\x20helpful\x20in\x20the\x20removal\x20of\x20aspirin,\x20which\x20is\x20a&nbsp;<strong>weakly\x20acidic\x20drug</strong>&nbsp;and\x20is\x20susceptible\x20to<strong>&nbsp;ion\x20trapping</strong>\x20in\x20the&nbsp;urine.</p>\x0a<p>Aspirin\x20is\x20a\x20weak\x20acid,\x20with\x20a\x20<strong>pKa\x20of\x203.0</strong>.&nbsp;Drugs\x20that\x20are\x20subjected\x20to\x20renal\x20clearance\x20are\x20excreted\x20into\x20the\x20urine\x20by\x20glomerular\x20filtration\x20and\x20active\x20tubular\x20secretion.\x20Nonionized\x20compounds\x20are\x20reabsorbed\x20more\x20rapidly\x20than\x20ionized\x20polar\x20molecules.\x20When\x20the&nbsp;<strong>pH</strong>&nbsp;of\x20the&nbsp;<strong>urine&nbsp;increases</strong>,\x20more\x20salicylate\x20is\x20in\x20its\x20ionized\x20form\x20at\x20equilibrium.\x20Hence,\x20salicylic\x20acid&nbsp;<strong>diffuses</strong>&nbsp;into\x20the&nbsp;<strong>tubular\x20lumen</strong>&nbsp;of\x20the\x20kidney.\x20Urine\x20alkalinization\x20is\x20recommended\x20as\x20a\x20first-line\x20treatment\x20only\x20for\x20moderately\x20severe\x20salicylate\x20poisoning\x20that&nbsp;does\x20not\x20meet\x20the\x20criteria\x20for\x20hemodialysis.</p>\x0a<p>Alkalinization\x20of\x20the\x20urine\x20is\x20achieved\x20by\x20administration\x20of&nbsp;<strong>100&ndash;150\x20mEq</strong>&nbsp;of&nbsp;<strong>sodium\x20bicarbonate</strong>&nbsp;in\x201\x20L\x20of\x205%\x20dextrose\x20in\x20water\x20(D5W).\x20It\x20is\x20infused\x20intravenously&nbsp;at\x20twice\x20the\x20maintenance\x20fluid\x20requirements.</p>\x0a<p>Alkalinization\x20of\x20urine\x20is&nbsp;<strong>contraindicated</strong>&nbsp;in&nbsp;<strong>renal\x20failure</strong>&nbsp;or\x20if\x20fluid\x20administration\x20may\x20worsen&nbsp;<strong>pulmonary\x20edema</strong>&nbsp;or\x20congestive\x20heart\x20failure.</p>','explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x2c7093(0x3d1),'choices':[{'id':0x1,'text':_0x2c7093(0x35c)},{'id':0x2,'text':_0x2c7093(0x163)},{'id':0x3,'text':_0x2c7093(0x83)},{'id':0x4,'text':_0x2c7093(0x2dd)}],'correct_choice_id':0x2,'solution':'<div\x20class=\x22page\x22\x20title=\x22Page\x20108\x22>\x0a<div\x20class=\x22section\x22>\x0a<div\x20class=\x22layoutArea\x22>\x0a<div\x20class=\x22column\x22>\x0a<p>A\x20hospital\x20conducting\x20a\x20<strong>double-blinded</strong>\x20study\x20in\x20<strong>multiple\x20centers</strong>\x20to\x20check\x20the\x20<strong>efficacy\x20of\x20statins</strong>&nbsp;describes\x20<strong>phase\x203</strong>\x20of\x20the\x20clinical\x20trial.\x20A\x20<strong>phase\x202</strong>\x20clinical\x20trial\x20is\x20generally\x20conducted\x20at\x20a\x20<strong>few\x20centers\x20(2-4)</strong>\x20by\x20physicians.</p>\x0a<p><strong>Phase\x203</strong>\x20of\x20a\x20clinical\x20trial\x20is\x20also\x20known\x20as\x20a\x20<strong>multisite\x20trial</strong>.\x20It\x20is\x20conducted\x20on\x20a\x20<strong>large\x20patient\x20population</strong>\x20(500&ndash;3000)\x20by\x20several\x20physicians\x20at\x20<strong>multiple\x20centers</strong>.\x20This\x20phase\x20involves\x20patients\x20who\x20have\x20been\x20diagnosed\x20with\x20the\x20disease\x20that\x20the\x20drug\x20claims\x20to\x20treat.\x20Its\x20purpose\x20is\x20to\x20<strong>confirm\x20the\x20efficacy\x20</strong>of\x20the\x20newly\x20developed\x20drug\x20in\x20a\x20larger\x20population.\x20Phase\x203\x20is\x20<strong>randomized</strong>,\x20<strong>controlled</strong>,\x20and\x20may\x20be\x20<strong>blinded</strong>.</p>\x0a</div>\x0a</div>\x0a</div>\x0a</div>','explanation_video':'','question_images':[],'explanation_images':[]},{'text':'A\x20patient\x20who\x20is\x20a\x20known\x20addict\x20is\x20brought\x20to\x20the\x20hospital\x20with\x20the\x20intoxication\x20of\x20an\x20agent.\x20An\x20ocular\x20examination\x20shows\x20the\x20following\x20finding.\x20Which\x20of\x20the\x20following\x20is\x20true\x20regarding\x20this\x20condition?','choices':[{'id':0x1,'text':'This\x20action\x20can\x20be\x20reversed\x20by\x20phenylephrine.'},{'id':0x2,'text':_0x2c7093(0x302)},{'id':0x3,'text':_0x2c7093(0x88)},{'id':0x4,'text':_0x2c7093(0xe4)}],'correct_choice_id':0x3,'solution':_0x2c7093(0x18b),'explanation_video':'','question_images':[_0x2c7093(0x24a)],'explanation_images':[]},{'text':_0x2c7093(0x3b6),'choices':[{'id':0x1,'text':_0x2c7093(0x94)},{'id':0x2,'text':_0x2c7093(0x392)},{'id':0x3,'text':_0x2c7093(0x151)},{'id':0x4,'text':'A-3,\x20B-2,\x20C-4,\x20D-1'}],'correct_choice_id':0x2,'solution':'<p>The\x20correct\x20answer\x20is\x20option\x20B:\x20A-4,\x20B-1,\x20C-3,\x20D-2</p>\x0a<table\x20style=\x22height:\x2049px;\x22\x20width=\x22415\x22>\x0a<tbody>\x0a<tr>\x0a<td\x20style=\x22width:\x20200.1px;\x22>A.\x20Morphine</td>\x0a<td\x20style=\x22width:\x20200.1px;\x22>4.\x20Head\x20Injury</td>\x0a</tr>\x0a<tr>\x0a<td\x20style=\x22width:\x20200.1px;\x22>B.\x20Amiodarone</td>\x0a<td\x20style=\x22width:\x20200.1px;\x22>1.\x20QT\x20prolongation</td>\x0a</tr>\x0a<tr>\x0a<td\x20style=\x22width:\x20200.1px;\x22>C.\x20Vigabatrin</td>\x0a<td\x20style=\x22width:\x20200.1px;\x22>3.\x20Pregnancy</td>\x0a</tr>\x0a<tr>\x0a<td\x20style=\x22width:\x20200.1px;\x22>D.\x20Estrogen\x20preparations</td>\x0a<td\x20style=\x22width:\x20200.1px;\x22>2.\x20Thromboembolism</td>\x0a</tr>\x0a</tbody>\x0a</table>\x0a<p>In\x20a\x20patient\x20with\x20head\x20injury,\x20<strong>morphine</strong>\x20is\x20contraindicated\x20because\x20it\x20<strong>increases\x20intracranial\x20tension</strong>\x20due\x20to\x20CO₂\x20retention,\x20precipitates\x20<strong>respiratory\x20depression,</strong>\x20and\x20may\x20cause\x20vomiting,\x20miosis,\x20and\x20altered\x20mental\x20state\x20which\x20<strong>interferes\x20with\x20assessment</strong>\x20of\x20mental\x20state.</p>\x0a<p><strong>Amiodarone</strong>\x20should\x20not\x20be\x20used\x20in\x20patients\x20with\x20<strong>prolonged\x20QT\x20interval</strong>\x20because\x20it\x20may\x20cause\x20<strong>marked\x20prolongation</strong>\x20of\x20the\x20QT\x20interval,\x20bradycardia,\x20and<strong>\x20torsades\x20de\x20pointes</strong>.</p>\x0a<p><strong>Vigabatrin</strong>,\x20an\x20inhibitor\x20of\x20GABA-transaminase,\x20an\x20anti-convulsant,\x20is\x20contraindicated\x20in\x20pregnancy\x20due\x20to\x20its\x20potential\x20<strong>teratogenic\x20effect</strong>.</p>\x0a<p><strong>Estrogen\x20preparations&nbsp;</strong>can\x20contribute\x20to\x20the\x20incidence\x20and\x20severity\x20of\x20<strong>t</strong><strong>hromboembolism,&nbsp;</strong>particularly\x20if\x20other\x20risk\x20factors\x20are\x20present.\x20The\x20risk\x20of\x20serious\x20cardiovascular\x20side\x20effects\x20is\x20particularly\x20marked\x20in\x20women\x20more\x20than\x2035\x20years\x20of\x20age\x20who\x20smoke\x20heavily.</p>','explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x2c7093(0x39b),'choices':[{'id':0x1,'text':'1,\x202,\x203,\x204'},{'id':0x2,'text':_0x2c7093(0x73)},{'id':0x3,'text':'3,\x204'},{'id':0x4,'text':_0x2c7093(0x2cf)}],'correct_choice_id':0x2,'solution':_0x2c7093(0xaa),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x2c7093(0x24e),'choices':[{'id':0x1,'text':_0x2c7093(0x290)},{'id':0x2,'text':_0x2c7093(0x23f)},{'id':0x3,'text':'Tenofovir'},{'id':0x4,'text':'Zidovudine'}],'correct_choice_id':0x1,'solution':'<p>Other\x20options:</p>\x0a<p>Option\x20B:\x20Enfuvirtide\x20acts\x20at\x20<strong>step\x202</strong>\x20in\x20the\x20given\x20image.\x20It\x20blocks\x20gp41\x20of\x20the\x20cell\x20membrane\x20and\x20<strong>blocks\x20the\x20entry</strong>\x20of\x20the\x20virus\x20into\x20the\x20cell.\x20It\x20prevents\x20the\x20free\x20viral\x20particles\x20from\x20invading\x20new\x20CD4+\x20cells.\x20It\x20is\x20effective\x20against\x20<strong>HIV-1.</strong></p>\x0a<p>Option\x20C:\x20Tenofovir\x20acts\x20at\x20<strong>step\x203</strong>\x20in\x20the\x20given\x20image.\x20It\x20is\x20a\x20nucleotide\x20reverse\x20transcriptase\x20inhibitor\x20(NRTI)\x20that\x20is\x20effective\x20against\x20<strong>HIV-1,2</strong>\x20and\x20<strong>hepatitis\x20B</strong>\x20infections.\x20It\x20is\x20used\x20in\x20adults\x20and\x20<strong>children\x20&gt;2\x20years\x20old.\x20</strong>It\x20can\x20also\x20be\x20used\x20for<strong>\x20pre-exposure\x20prophylaxis.&nbsp;</strong></p>\x0a<p>Option\x20D:\x20Zidovudine\x20also\x20acts\x20at\x20<strong>step\x203</strong>\x20in\x20the\x20given\x20image.\x20It\x20is\x20an\x20NRTI\x20and\x20is\x20effective\x20against\x20<strong>HIV-1,2</strong>\x20and\x20<strong>Human\x20T-cell\x20Lymphoma\x20Virus\x20(HTLV).</strong>\x20It\x20can\x20be\x20used\x20in\x20adults\x20and\x20children.\x20It\x20can\x20also\x20be\x20used\x20to\x20prevent\x20<strong>mother-to-child\x20transmission.</strong></p>','explanation_video':'','question_images':[_0x2c7093(0x3aa)],'explanation_images':[_0x2c7093(0x367)]},{'text':'Which\x20of\x20the\x20following\x20statements\x20is\x20correct\x20regarding\x20clinical\x20trials?','choices':[{'id':0x1,'text':_0x2c7093(0x125)},{'id':0x2,'text':_0x2c7093(0x187)},{'id':0x3,'text':'Phase\x203\x20is\x20always\x20double-blinded'},{'id':0x4,'text':_0x2c7093(0x193)}],'correct_choice_id':0x2,'solution':'<p><strong>Phase\x204</strong>\x20clinical\x20trials\x20are\x20also\x20called\x20<strong>post-marketing\x20surveillance&nbsp;</strong>is\x20the\x20correct\x20statement.</p>\x0a<p>Other\x20options:</p>\x0a<p>Option\x20A:\x20New\x20drug\x20application\x20is\x20done\x20after\x20<strong>phase\x203</strong>\x20of\x20clinical\x20trials.</p>\x0a<p>Option\x20C:&nbsp;<strong>Phase\x203</strong>\x20trials\x20<strong>may\x20or\x20may\x20not\x20be\x20blinded</strong>.</p>\x0a<p>Option\x20D:&nbsp;<strong>Phase\x202</strong>\x20trials\x20are\x20the\x20first\x20round\x20of\x20trials\x20in\x20<strong>patients</strong>.\x20<strong>Phase\x201</strong>\x20trials\x20are\x20done\x20in\x20<strong>healthy</strong>\x20volunteers.</p>','explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x2c7093(0x174),'choices':[{'id':0x1,'text':_0x2c7093(0xc6)},{'id':0x2,'text':_0x2c7093(0x150)},{'id':0x3,'text':_0x2c7093(0x35a)},{'id':0x4,'text':_0x2c7093(0x33b)}],'correct_choice_id':0x4,'solution':_0x2c7093(0xba),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x2c7093(0x2ff),'choices':[{'id':0x1,'text':_0x2c7093(0x261)},{'id':0x2,'text':_0x2c7093(0x366)},{'id':0x3,'text':_0x2c7093(0x292)},{'id':0x4,'text':_0x2c7093(0x13e)}],'correct_choice_id':0x3,'solution':_0x2c7093(0x212),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':'An\x20experiment\x20is\x20being\x20conducted\x20on\x20a\x20cat\x20spine\x20to\x20study\x20the\x20effect\x20of\x20acetylcholine.\x20The\x20blood\x20pressure\x20is\x20recorded\x20at\x20each\x20intervention\x20and\x20is\x20shown\x20below.\x20What\x20does\x20phase\x204\x20in\x20the\x20graph\x20indicate?','choices':[{'id':0x1,'text':'Muscarinic\x20action\x20of\x20acetylcholine'},{'id':0x2,'text':_0x2c7093(0x2d1)},{'id':0x3,'text':'Antagonism\x20of\x20acetylcholine'},{'id':0x4,'text':_0x2c7093(0x33f)}],'correct_choice_id':0x4,'solution':'<p>Phase\x204\x20in\x20the\x20graph\x20indicates\x20the\x20<strong>nicotinic\x20action</strong>&nbsp;of\x20acetylcholine\x20at<strong>\x20higher\x20doses</strong>.</p>\x0a<p>In\x20phases\x201\x20and\x202,\x20acetylcholine\x20(Ach)\x20acts\x20on\x20muscarinic\x20receptors\x20(at\x202\x20micrograms\x20and\x2050\x20micrograms)\x20bringing\x20down\x20blood\x20pressure.\x20<strong>Atropine</strong>\x20<strong>blocks</strong>\x20the\x20<strong>muscarinic\x20receptor</strong>,\x20so\x20this\x20action\x20of\x20acetylcholine\x20is\x20not\x20seen\x20in\x20phase\x203.\x20However,\x20in\x20phase\x204,\x20<strong>higher\x20doses</strong>\x20of\x20Ach\x20(like\x205\x20mg)\x20act\x20via\x20the\x20<strong>nicotinic\x20receptor</strong>,\x20shooting\x20up\x20the\x20blood\x20pressure.\x20This\x20phenomenon\x20is\x20called\x20the\x20reversal\x20of\x20Ach\x20in\x20blood\x20pressure\x20and\x20was\x20studied\x20by\x20Dale.&nbsp;</p>\x0a<p><strong>Nicotinic\x20receptors</strong>\x20are\x20<strong>ligand-gated</strong>\x20ion\x20channels.\x20It\x20can\x20be\x20divided\x20into\x20two\x20groups:\x20muscle\x20receptors\x20(N<sub>M</sub>),\x20which\x20are\x20found\x20at\x20the\x20skeletal\x20neuromuscular\x20junction,\x20and\x20<strong>neuronal\x20receptors</strong>\x20(N<sub>N</sub>),\x20which\x20are\x20found\x20in\x20the\x20ganglia\x20and\x20CNS.\x20When\x20stimulated\x20at\x20higher\x20doses,\x20Ach\x20acts\x20on\x20N<sub>N</sub>&nbsp;receptors,\x20leading\x20to\x20the\x20stimulation\x20of\x20<strong>sympathetic\x20ganglia</strong>\x20and\x20<strong>adrenal\x20medulla</strong>.\x20This&nbsp;<strong>increases</strong>\x20the\x20heart\x20rate,\x20<strong>blood\x20pressure</strong>,\x20and\x20myocardial\x20contractility.</p>\x0a<p><strong>Muscarinic</strong>\x20receptors\x20are\x20<strong>G-coupled\x20protein</strong>\x20receptors\x20involved\x20in\x20the\x20parasympathetic\x20nervous\x20system.&nbsp;M1,\x20M2,\x20M3,\x20M4,\x20and\x20M5\x20are\x20the\x20receptor\x20subtypes.\x20They\x20act\x20via\x20Gi\x20or\x20Gq\x20subunits.\x20When\x20<strong>Ach</strong>\x20is\x20administered,\x20it\x20acts\x20on&nbsp;muscarinic\x20receptors,\x20primarily\x20the<strong>\x20M3\x20receptors</strong>,\x20which\x20are\x20located\x20on\x20<strong>vascular\x20endothelial\x20cells</strong>.\x20It\x20stimulates\x20<strong>guanylyl\x20cyclase</strong>\x20and\x20promotes\x20relaxation\x20via\x20a\x20cyclic\x20GMP&ndash;dependent\x20mechanism.\x20At\x20higher\x20doses,\x20it\x20acts\x20on&nbsp;<strong>M2\x20receptors,</strong>\x20which\x20have\x20direct\x20effects\x20on\x20the\x20<strong>heart</strong>.\x20It\x20also\x20inhibits\x20the\x20release\x20of\x20norepinephrine\x20from\x20sympathetic\x20nerve\x20terminals\x20and\x20decreases\x20cyclic\x20AMP\x20levels.</p>','explanation_video':'','question_images':['https://cdn1.dailyrounds.org/uploads/2b3ddec429404fce9e5a9874a7a2d2f7.JPEG'],'explanation_images':[]},{'text':_0x2c7093(0xe0),'choices':[{'id':0x1,'text':_0x2c7093(0x164)},{'id':0x2,'text':_0x2c7093(0x1ed)},{'id':0x3,'text':_0x2c7093(0x296)},{'id':0x4,'text':_0x2c7093(0xc8)}],'correct_choice_id':0x2,'solution':_0x2c7093(0x28c),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x2c7093(0x3c1),'choices':[{'id':0x1,'text':_0x2c7093(0x191)},{'id':0x2,'text':'Topical\x20ocular\x20carbonic\x20anhydrase\x20inhibitor'},{'id':0x3,'text':_0x2c7093(0x21a)},{'id':0x4,'text':'Opioid\x20receptor\x20agonist'}],'correct_choice_id':0x2,'solution':'<p><strong>Dorzolamide</strong>\x20is\x20a\x20<strong>topical\x20ocular\x20carbonic\x20anhydrase\x20inhibitor</strong>.</p>\x0a<div\x20class=\x22page\x22\x20title=\x22Page\x20462\x22>\x0a<div\x20class=\x22section\x22>\x0a<div\x20class=\x22layoutArea\x22>\x0a<div\x20class=\x22column\x22>\x0a<p>It\x20acts\x20on\x20carbonic\x20anhydrase\x20in\x20the\x20ciliary\x20processes\x20of\x20the\x20eye\x20and\x20mediates\x20the\x20formation\x20of\x20HCO<sub>3</sub><sup>-</sup><sub>&nbsp;</sub>in\x20aqueous\x20humor.\x20Inhibition\x20of\x20carbonic\x20anhydrase\x20decreases\x20the\x20rate\x20of\x20formation\x20of\x20aqueous\x20humor\x20and\x20consequently\x20reduces\x20intraocular\x20pressure.</p>\x0a<div\x20class=\x22page\x22\x20title=\x22Page\x20462\x22>\x0a<div\x20class=\x22section\x22>\x0a<div\x20class=\x22layoutArea\x22>\x0a<div\x20class=\x22column\x22>\x0a<p>The\x20major\x20indication\x20for\x20carbonic\x20anhydrase\x20inhibitors\x20is\x20<strong>open-angle\x20glaucoma</strong>.\x20Dorzolamide\x20and\x20<strong>brinzolamide</strong>,\x20which\x20are\x20available\x20only\x20as\x20ophthalmic\x20<strong>drops</strong>,\x20are\x20used\x20for\x20this\x20purpose.</p>\x0a<p>Dorzolamide\x20may\x20be\x20used\x20for\x20secondary\x20glaucoma\x20and\x20in\x20acute\x20angle-closure\x20glaucoma\x20to\x20lower\x20intraocular\x20pressure\x20before\x20surgery.</p>\x0a</div>\x0a</div>\x0a</div>\x0a</div>\x0a</div>\x0a</div>\x0a</div>\x0a</div>','explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x2c7093(0x377),'choices':[{'id':0x1,'text':_0x2c7093(0xef)},{'id':0x2,'text':_0x2c7093(0x9a)},{'id':0x3,'text':_0x2c7093(0x108)},{'id':0x4,'text':'Phosphatidyl\x20glycerol\x20and\x20inositol\x20phosphate'}],'correct_choice_id':0x2,'solution':_0x2c7093(0x185),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x2c7093(0x2f0),'choices':[{'id':0x1,'text':_0x2c7093(0x295)},{'id':0x2,'text':'A-3,\x20B-4,\x20C-2,\x20D-1'},{'id':0x3,'text':_0x2c7093(0x34d)},{'id':0x4,'text':'A-4,\x20B-1,\x20C-3,\x20D-2'}],'correct_choice_id':0x4,'solution':_0x2c7093(0x2b8),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':'Alkalinization\x20of\x20urine\x20will\x20be\x20helpful\x20in\x20the\x20removal\x20of\x20_____.','choices':[{'id':0x1,'text':_0x2c7093(0x173)},{'id':0x2,'text':_0x2c7093(0x1ee)},{'id':0x3,'text':'Polar\x20drugs'},{'id':0x4,'text':'Weakly\x20acidic\x20drugs'}],'correct_choice_id':0x4,'solution':_0x2c7093(0x215),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':'All\x20of\x20the\x20following\x20side\x20effects\x20are\x20more\x20commonly\x20seen\x20with\x20carbamazepine\x20than\x20oxcarbazepine,\x20except_____.','choices':[{'id':0x1,'text':_0x2c7093(0x2ee)},{'id':0x2,'text':_0x2c7093(0x1ff)},{'id':0x3,'text':_0x2c7093(0x31f)},{'id':0x4,'text':_0x2c7093(0x79)}],'correct_choice_id':0x2,'solution':_0x2c7093(0x381),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x2c7093(0x254),'choices':[{'id':0x1,'text':'A-2,\x20B-3\x20,\x20C-1\x20,\x20D-4'},{'id':0x2,'text':'A-4,\x20B-3\x20,\x20C-1\x20,\x20D-2'},{'id':0x3,'text':'A-3,\x20B-4\x20,\x20C-2\x20,\x20D-1'},{'id':0x4,'text':'A-4,\x20B-3\x20,\x20C-2\x20,\x20D-1'}],'correct_choice_id':0x4,'solution':'<p>The\x20correct\x20pairs\x20are\x20as\x20follows:</p>\x0a<table\x20style=\x22height:\x20121px;\x20width:\x20271px;\x22>\x0a<tbody>\x0a<tr>\x0a<td\x20style=\x22width:\x20114.1875px;\x22>A.\x20Trastuzumab&nbsp;</td>\x0a<td\x20style=\x22width:\x20142.8125px;\x22>4.\x20HER2/neu</td>\x0a</tr>\x0a<tr>\x0a<td\x20style=\x22width:\x20114.1875px;\x22>B.\x20Infliximab</td>\x0a<td\x20style=\x22width:\x20142.8125px;\x22>3.&nbsp;\x20TNF\x20&alpha;&nbsp;&nbsp;</td>\x0a</tr>\x0a<tr>\x0a<td\x20style=\x22width:\x20114.1875px;\x22>C.\x20Sirolimus&nbsp;</td>\x0a<td\x20style=\x22width:\x20142.8125px;\x22>2.&nbsp;mTOR</td>\x0a</tr>\x0a<tr>\x0a<td\x20style=\x22width:\x20114.1875px;\x22>D.\x20Imatinib</td>\x0a<td\x20style=\x22width:\x20142.8125px;\x22>1.&nbsp;BCR-ABL\x20tyrosine\x20kinase&nbsp;&nbsp;</td>\x0a</tr>\x0a</tbody>\x0a</table>\x0a<p>&nbsp;</p>\x0a<p><strong>Trastuzumab</strong>\x20is\x20a\x20<strong>humanized\x20monoclonal\x20antibody\x20against</strong>&nbsp;the\x20external\x20domain\x20of\x20<strong>HER2/neu</strong>.\x20It&nbsp;is\x20indicated\x20as\x20an\x20adjuvant\x20in\x20the\x20management\x20of&nbsp;<strong>metastatic\x20HER-2-positive\x20breast\x20cancer</strong>.</p>\x0a<div\x20class=\x22page\x22\x20title=\x22Page\x20657\x22>\x0a<div\x20class=\x22section\x22>\x0a<div\x20class=\x22layoutArea\x22>\x0a<div\x20class=\x22column\x22>\x0a<p><strong>Infliximab</strong>\x20binds\x20with\x20high\x20affinity\x20to\x20<strong>TNF-&alpha;</strong>\x20and\x20prevents\x20the\x20cytokine\x20from\x20binding\x20to\x20its\x20receptors.\x20Infliximab\x20is\x20used\x20for\x20the\x20treatment\x20of\x20<strong>rheumatoid\x20arthritis</strong>;&nbsp;it\x20is\x20used&nbsp;<strong>in\x20combination\x20with\x20methotrexate</strong>&nbsp;in\x20patients\x20who\x20do\x20not\x20respond\x20to\x20methotrexate\x20alone.\x20Infliximab\x20is\x20also\x20used\x20for\x20the\x20treatment\x20of\x20the\x20symptoms\x20of\x20<strong>moderate-to-severe\x20Crohn\x27s\x20disease</strong>.</p>\x0a</div>\x0a</div>\x0a</div>\x0a</div>\x0a<p><strong>Sirolimus</strong>\x20is\x20an\x20antimetabolic\x20and\x20antiproliferative\x20drug.\x20It\x20acts\x20by\x20forming\x20a\x20complex\x20with\x20an\x20immunophilin\x20called&nbsp;<strong>FKBP-12</strong>,\x20which\x20in\x20turn\x20inhibits\x20the&nbsp;mammalian\x20target\x20of\x20rapamycin\x20(<strong>mTOR</strong>).\x20mTOR\x20is\x20a\x20protein\x20kinase\x20that\x20blocks\x20cell\x20cycle\x20progression\x20at\x20the\x20G1\x20phase\x20to\x20S\x20phase\x20transition.\x20It\x20is\x20used\x20in\x20the\x20prophylaxis\x20of\x20organ\x20transplant\x20rejection.</p>\x0a<div\x20class=\x22page\x22\x20title=\x22Page\x201218\x22>\x0a<div\x20class=\x22section\x22>\x0a<div\x20class=\x22layoutArea\x22>\x0a<div\x20class=\x22column\x22>\x0a<p><strong>Imatinib&nbsp;</strong>is\x20a\x20first-generation&nbsp;<strong>tyrosine\x20kinase\x20inhibitor.\x20</strong>Imatinib\x20attacks\x20<strong>BCR-ABL\x20translocation</strong>&nbsp;and\x20is\x20used\x20in&nbsp;<strong>chronic\x20myelocytic\x20leukemia.</strong>\x20It\x20also\x20inhibits\x20c-kit\x20and\x20produces\x20extended\x20control\x20of\x20<strong>GI\x20stromal\x20tumors</strong>.</p>\x0a</div>\x0a</div>\x0a</div>\x0a</div>','explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x2c7093(0x1e8),'choices':[{'id':0x1,'text':_0x2c7093(0x1f0)},{'id':0x2,'text':'Diazepam'},{'id':0x3,'text':_0x2c7093(0x2c3)},{'id':0x4,'text':_0x2c7093(0x2ac)}],'correct_choice_id':0x4,'solution':'<p><strong>Oxazepam&nbsp;</strong>can\x20be\x20used\x20in\x20patients\x20with\x20elevated\x20transaminases.\x20It\x20is\x20<strong>short-acting</strong>&nbsp;and\x20so,\x20can\x20be\x20used\x20in\x20patients\x20with<strong>\x20liver\x20impairment</strong>\x20or\x20<strong>brain\x20damage.</strong></p>\x0a<p>Oxazepam\x20is\x20an\x20orally\x20available\x20benzodiazepine\x20used\x20to\x20treat\x20anxiety\x20and\x20alcohol\x20withdrawal\x20states.\x20Hepatic\x20oxidation\x20is\x20decreased\x20in\x20persons\x20with\x20liver\x20disease\x20and\x20the\x20elderly.\x20Oxazepam\x20and\x20lorazepam&nbsp;undergo\x20<strong>only</strong>\x20<strong>hepatic\x20glucuronidation</strong>.</p>\x0a<p>Other\x20options:</p>\x0a<p>Option\x20A:<strong>\x20Midazolam</strong>\x20is\x20the\x20<strong>benzodiazepine\x20of\x20choice</strong>\x20for<strong>\x20induction</strong>\x20of\x20anesthesia.\x20The\x20onset\x20of\x20anesthesia\x20is\x20within\x20<strong>30\x20to\x2060</strong>\x20seconds.\x20It\x20can\x20also\x20be\x20used\x20to\x20control\x20seizures,\x20but\x20there\x20is\x20<strong>no\x20difference</strong>\x20in\x20the\x20efficacy\x20of\x20intravenous\x20midazolam\x20and\x20intravenous\x20diazepam.</p>\x0a<p>Option\x20B:<strong>\x20Diazepam</strong>\x20is\x20a\x20long-acting\x20benzodiazepine.\x20It\x20is\x20<strong>metabolized</strong>\x20in\x20the\x20<strong>liver</strong>\x20to\x20active\x20metabolites\x20like\x20nordazepam\x20which\x20are\x20long-acting.&nbsp;Diazepam\x20and\x20its\x20long-acting\x20metabolites\x20can\x20<strong>accumulate</strong>\x20significantly\x20in\x20<strong>elderly</strong>\x20patients\x20with\x20<strong>liver\x20disease</strong>\x20and\x20therefore\x20should<strong>\x20not</strong>\x20be\x20used\x20in\x20such\x20cases.</p>\x0a<p>Option\x20C:<strong>\x20Alprazolam</strong>&nbsp;is\x20metabolized\x20by\x20hepatic\x20oxidation\x20which\x20is\x20significantly\x20decreased\x20in\x20liver\x20impairment\x20and\x20elderly\x20patients.</p>\x0a<p>&nbsp;</p>','explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x2c7093(0x342),'choices':[{'id':0x1,'text':_0x2c7093(0x213)},{'id':0x2,'text':_0x2c7093(0x1aa)},{'id':0x3,'text':_0x2c7093(0x2df)},{'id':0x4,'text':_0x2c7093(0xde)}],'correct_choice_id':0x4,'solution':_0x2c7093(0x278),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x2c7093(0x253),'choices':[{'id':0x1,'text':_0x2c7093(0x183)},{'id':0x2,'text':_0x2c7093(0x285)},{'id':0x3,'text':_0x2c7093(0x141)},{'id':0x4,'text':'Lignocaine'}],'correct_choice_id':0x3,'solution':_0x2c7093(0x3b5),'explanation_video':'','question_images':[_0x2c7093(0x19e)],'explanation_images':[_0x2c7093(0x2e3),'https://dhmbxeygs57ff.cloudfront.net/uploads/e807614673e74d1abc58bf1072520068x1280x719.PNG','https://dhmbxeygs57ff.cloudfront.net/uploads/222629548464450caaf40ff6f14c9debx1280x681.PNG']},{'text':_0x2c7093(0x270),'choices':[{'id':0x1,'text':_0x2c7093(0xc4)},{'id':0x2,'text':_0x2c7093(0x134)},{'id':0x3,'text':_0x2c7093(0x22f)},{'id':0x4,'text':'With\x20the\x20long\x20term\x20use,\x20there\x20is\x20slight\x20increase\x20in\x20the\x20incidence\x20of\x20type\x202\x20diabetes\x20mellitus.'}],'correct_choice_id':0x3,'solution':_0x2c7093(0x3d4),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x2c7093(0x30f),'choices':[{'id':0x1,'text':_0x2c7093(0x358)},{'id':0x2,'text':'A\x20-\x20Aspirin,\x20B\x20-\x20Eptifibatide,\x20C\x20-\x20Vorapaxar'},{'id':0x3,'text':_0x2c7093(0x234)},{'id':0x4,'text':_0x2c7093(0xb6)}],'correct_choice_id':0x2,'solution':_0x2c7093(0x36f),'explanation_video':'','question_images':[_0x2c7093(0x113)],'explanation_images':[_0x2c7093(0x1f3)]},{'text':_0x2c7093(0x1e1),'choices':[{'id':0x1,'text':_0x2c7093(0x1c6)},{'id':0x2,'text':_0x2c7093(0xaf)},{'id':0x3,'text':_0x2c7093(0x3b7)},{'id':0x4,'text':_0x2c7093(0x1de)}],'correct_choice_id':0x1,'solution':_0x2c7093(0x1b5),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':'G6PD\x20can\x20manifest\x20with\x20which\x20of\x20the\x20following\x20drugs?','choices':[{'id':0x1,'text':_0x2c7093(0x32f)},{'id':0x2,'text':'Chloroquine'},{'id':0x3,'text':_0x2c7093(0x135)},{'id':0x4,'text':'Tetracycline'}],'correct_choice_id':0x1,'solution':_0x2c7093(0x23b),'explanation_video':'','question_images':[],'explanation_images':[_0x2c7093(0x2d5),_0x2c7093(0x2f4)]},{'text':_0x2c7093(0x286),'choices':[{'id':0x1,'text':'1,3'},{'id':0x2,'text':_0x2c7093(0x1b9)},{'id':0x3,'text':_0x2c7093(0xfb)},{'id':0x4,'text':_0x2c7093(0x361)}],'correct_choice_id':0x3,'solution':_0x2c7093(0x12c),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x2c7093(0x316),'choices':[{'id':0x1,'text':_0x2c7093(0x267)},{'id':0x2,'text':_0x2c7093(0x2ad)},{'id':0x3,'text':_0x2c7093(0x14c)},{'id':0x4,'text':_0x2c7093(0x78)}],'correct_choice_id':0x2,'solution':'<div\x20class=\x22ng-star-inserted\x22>\x0a<div\x20class=\x22table-responsive\x20font-weight-light\x20answer-scroll\x20ng-star-inserted\x22>\x0a<p>Treatment\x20of\x20the\x20infection\x20includes\x204\x20steps:</p>\x0a<ol>\x0a<li>Initiation\x20of\x20therapy\x20<strong>(amphotericin</strong>\x20<strong>B</strong>)\x20as\x20early\x20as\x20possible.\x20Posaconazole\x20can\x20also\x20be\x20used\x20in\x20the\x20management\x20of\x20this\x20condition.</li>\x0a<li><strong>Surgical</strong>\x20debridement</li>\x0a<li><strong>Reversal</strong>\x20of\x20underlying\x20conditions\x20and\x20<strong>risk\x20factors</strong></li>\x0a<li><strong>Treatment</strong>\x20of\x20underlying\x20<strong>malignancy</strong>\x20if\x20present</li>\x0a</ol>\x0a<p><strong>Amphotericin\x20B</strong>&nbsp;is\x20a\x20<strong>broad-spectrum\x20antifungal</strong>.&nbsp;It&nbsp;binds\x20to\x20<strong>ergosterol</strong>\x20in\x20the\x20fungal\x20membrane\x20and\x20forms\x20<strong>pores\x20or\x20channels</strong>\x20in\x20the<strong>\x20fungal\x20cell\x20membrane</strong>.\x20This\x20allows\x20the\x20leakage\x20of\x20cytosolic\x20molecules\x20and\x20ions,\x20leading\x20to\x20a\x20loss\x20of\x20membrane\x20integrity.</p>\x0a<p>Other\x20options:</p>\x0a<p>Option\x20A:\x20<strong>Itraconazole\x20</strong>can\x20be\x20used\x20for\x20the\x20treatment\x20of\x20<strong>chronic</strong>\x20aspergillosis\x20if\x20there\x20is\x20<strong>resistance\x20</strong>or<strong>\x20failure\x20of\x20voriconazole</strong>.&nbsp;<span\x20data-preserver-spaces=\x22true\x22><span\x20class=\x22s1\x22><strong>Ketoconazole\x20</strong>is\x20used\x20for\x20both\x20<strong>dermatophytosis</strong>\x20and\x20deep\x20mycosis,\x20but\x20it\x20has\x20been\x20replaced\x20by\x20<strong>itraconazole</strong>.</span></span></p>\x0a<p><span\x20data-preserver-spaces=\x22true\x22><span\x20class=\x22s1\x22>Option\x20C:\x20<strong>Fluconazole\x20</strong>is\x20used\x20for\x20the\x20treatment\x20of\x20<strong>candidiasis</strong>&nbsp;and\x20cryptococcosis.</span></span></p>\x0a<p>Option\x20D:\x20<strong>Amphotericin\x20B</strong>&nbsp;in\x20combination\x20with\x205-flucytosine\x20is\x20used\x20as&nbsp;<strong>induction\x20treatment</strong>\x20for\x20<strong>cryptococcal\x20meningitis.</strong>&nbsp;</p>\x0a</div>\x0a</div>','explanation_video':'','question_images':[_0x2c7093(0x29f)],'explanation_images':['https://dhmbxeygs57ff.cloudfront.net/uploads/d2ce95171f29405e8b920760512c5d76x800x600.JPEG']},{'text':_0x2c7093(0x1fb),'choices':[{'id':0x1,'text':_0x2c7093(0x90)},{'id':0x2,'text':'Activates\x20PPAR\x20alpha'},{'id':0x3,'text':_0x2c7093(0x334)},{'id':0x4,'text':_0x2c7093(0x98)}],'correct_choice_id':0x2,'solution':_0x2c7093(0xf2),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x2c7093(0x208),'choices':[{'id':0x1,'text':_0x2c7093(0x2e1)},{'id':0x2,'text':_0x2c7093(0x12b)},{'id':0x3,'text':_0x2c7093(0x228)},{'id':0x4,'text':_0x2c7093(0x2bd)}],'correct_choice_id':0x3,'solution':_0x2c7093(0x1bc),'explanation_video':'','question_images':[_0x2c7093(0x1c7)],'explanation_images':[]},{'text':_0x2c7093(0x304),'choices':[{'id':0x1,'text':_0x2c7093(0x2cf)},{'id':0x2,'text':_0x2c7093(0xfd)},{'id':0x3,'text':_0x2c7093(0x73)},{'id':0x4,'text':_0x2c7093(0xe1)}],'correct_choice_id':0x3,'solution':_0x2c7093(0x223),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':'What\x20is\x20the\x20mechanism\x20of\x20action\x20of\x20sildenafil?','choices':[{'id':0x1,'text':'Inhibition\x20of\x205α-reductase'},{'id':0x2,'text':_0x2c7093(0x15d)},{'id':0x3,'text':_0x2c7093(0x176)},{'id':0x4,'text':_0x2c7093(0x2fb)}],'correct_choice_id':0x2,'solution':_0x2c7093(0x20b),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x2c7093(0xae),'choices':[{'id':0x1,'text':'A,B,D'},{'id':0x2,'text':_0x2c7093(0x327)},{'id':0x3,'text':_0x2c7093(0x188)},{'id':0x4,'text':_0x2c7093(0x37d)}],'correct_choice_id':0x2,'solution':_0x2c7093(0xd6),'explanation_video':'','question_images':[],'explanation_images':[_0x2c7093(0xc2)]},{'text':_0x2c7093(0x12d),'choices':[{'id':0x1,'text':_0x2c7093(0x26a)},{'id':0x2,'text':_0x2c7093(0x261)},{'id':0x3,'text':_0x2c7093(0x28b)},{'id':0x4,'text':_0x2c7093(0x13d)}],'correct_choice_id':0x3,'solution':_0x2c7093(0x8c),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':'Which\x20of\x20the\x20following\x20is\x20the\x20most\x20effective\x20oral\x20drug\x20in\x20smoking\x20cessation?','choices':[{'id':0x1,'text':'Varenicline'},{'id':0x2,'text':'Cevimeline'},{'id':0x3,'text':_0x2c7093(0xfc)},{'id':0x4,'text':'Atropine'}],'correct_choice_id':0x1,'solution':_0x2c7093(0xd9),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x2c7093(0x1d7),'choices':[{'id':0x1,'text':_0x2c7093(0x95)},{'id':0x2,'text':_0x2c7093(0x172)},{'id':0x3,'text':_0x2c7093(0xb3)},{'id':0x4,'text':_0x2c7093(0x368)}],'correct_choice_id':0x3,'solution':_0x2c7093(0x1fd),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x2c7093(0x297),'choices':[{'id':0x1,'text':_0x2c7093(0x1c3)},{'id':0x2,'text':_0x2c7093(0x77)},{'id':0x3,'text':_0x2c7093(0x373)},{'id':0x4,'text':'Acetazolamide'}],'correct_choice_id':0x2,'solution':_0x2c7093(0x287),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x2c7093(0x25e),'choices':[{'id':0x1,'text':_0x2c7093(0x318)},{'id':0x2,'text':_0x2c7093(0x3d6)},{'id':0x3,'text':_0x2c7093(0x1b2)},{'id':0x4,'text':'Phosphodiesterase'}],'correct_choice_id':0x3,'solution':_0x2c7093(0x2f2),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x2c7093(0x310),'choices':[{'id':0x1,'text':_0x2c7093(0x39d)},{'id':0x2,'text':_0x2c7093(0x394)},{'id':0x3,'text':_0x2c7093(0x9f)},{'id':0x4,'text':_0x2c7093(0xcc)}],'correct_choice_id':0x3,'solution':_0x2c7093(0x10b),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x2c7093(0x15a),'choices':[{'id':0x1,'text':'4'},{'id':0x2,'text':'3'},{'id':0x3,'text':'2'},{'id':0x4,'text':'1'}],'correct_choice_id':0x2,'solution':_0x2c7093(0x2cb),'explanation_video':'','question_images':[],'explanation_images':[]}],quizName=_0x2c7093(0x1ab),hierarchy=[_0x2c7093(0x102),_0x2c7093(0x1b0),_0x2c7093(0x8d)];if(window[_0x2c7093(0xd4)]['pathname']['endsWith']('custom_quiz.html')){const customData=JSON[_0x2c7093(0xb5)](localStorage[_0x2c7093(0x148)](_0x2c7093(0x1c9)));if(customData){const WgeUIQ=_0x2c7093(0x386)[_0x2c7093(0x3a4)]('|');let jNUaPH=0x0;while(!![]){switch(WgeUIQ[jNUaPH++]){case'0':document['getElementById'](_0x2c7093(0x6f))['textContent']=questionsData[_0x2c7093(0x22c)];continue;case'1':quizName=customData[_0x2c7093(0x33d)];continue;case'2':document[_0x2c7093(0x11c)]=quizName+_0x2c7093(0x16b);continue;case'3':questionsData=customData['questions'];continue;case'4':hierarchy=customData['hierarchy'];continue;case'5':document[_0x2c7093(0x2a6)](_0x2c7093(0xa3))[_0x2c7093(0x3c5)]=hierarchy[_0x2c7093(0x3b2)](_0x2c7093(0x170));continue;}break;}}}let currentQuestionIndex=0x0,selectedOption=null,currentMode=_0x2c7093(0x10d),timer=null,timeRemaining=0x0,questionStartTime=Date[_0x2c7093(0x362)](),quizStartTime=Date[_0x2c7093(0x362)](),isQuizCompleted=![],questionStates=new Array(questionsData[_0x2c7093(0x22c)])[_0x2c7093(0x22e)](null)['map'](()=>({'status':_0x2c7093(0x238),'bookmarked':![],'markedForReview':![],'selectedAnswer':null,'timeSpent':0x0})),stats={'correctAnswers':0x0,'incorrectAnswers':0x0,'totalAttempted':0x0,'totalTime':0x0,'notAttempted':questionsData['length']};const urlParams=new URLSearchParams(window[_0x2c7093(0xd4)][_0x2c7093(0x17d)]);currentQuestionIndex=Math[_0x2c7093(0x275)](parseInt(urlParams[_0x2c7093(0x226)](_0x2c7093(0x217)))||0x0,questionsData['length']-0x1);function goBack(){const _0x12ddaf=_0x2c7093,_0x2a317f={'FHBEB':_0x12ddaf(0x1cc)};(isQuizCompleted||confirm(_0x2a317f[_0x12ddaf(0x147)]))&&window['history'][_0x12ddaf(0x250)]();}function selectMode(_0x5a9c3c){const _0x4b676f=_0x2c7093,_0x2fcbb9={'FfXtR':_0x4b676f(0x159),'OLAqC':function(_0xbd6baa){return _0xbd6baa();}};currentMode=_0x5a9c3c,document[_0x4b676f(0x2a6)](_0x4b676f(0x1d6))['style'][_0x4b676f(0x1e6)]=_0x2fcbb9[_0x4b676f(0x1a2)],_0x2fcbb9[_0x4b676f(0x2ec)](initializeQuiz);}function initializeQuiz(){const _0x2591ea=_0x2c7093,_0x368eb3={'juVHZ':_0x2591ea(0x1e7),'YzOrq':_0x2591ea(0x12f),'rrwqI':'test','ndryE':function(_0x59b5c2,_0x651e54){return _0x59b5c2===_0x651e54;},'aGvnl':_0x2591ea(0x3a2),'CruQy':_0x2591ea(0x379),'pWoPI':'none','GBGhS':_0x2591ea(0xb0),'YdBbm':'studyModeLegend','HxtQa':_0x2591ea(0x20a),'ospvj':_0x2591ea(0x3ac),'BXFKk':_0x2591ea(0x23e),'MedIq':function(_0x2b5985,_0x350b28){return _0x2b5985===_0x350b28;},'GmfMh':'hidden','BeLGd':function(_0x3cb84f){return _0x3cb84f();}};quizStartTime=Date[_0x2591ea(0x362)]();const _0x4bcf51=document['getElementById'](_0x368eb3[_0x2591ea(0x380)]),_0x38d63a=document[_0x2591ea(0x2a6)](_0x368eb3[_0x2591ea(0x1f1)]),_0x27fd14=document[_0x2591ea(0x2a6)]('testModeReviewLegend'),_0x415594=currentMode===_0x368eb3[_0x2591ea(0x18e)]||_0x368eb3[_0x2591ea(0x3c2)](currentMode,_0x368eb3[_0x2591ea(0x1ef)]);document[_0x2591ea(0x2a6)](_0x368eb3['CruQy'])[_0x2591ea(0x22d)][_0x2591ea(0x1e6)]=_0x415594?_0x368eb3[_0x2591ea(0x203)]:_0x368eb3[_0x2591ea(0x313)],document[_0x2591ea(0x2a6)](_0x368eb3['YdBbm'])[_0x2591ea(0x22d)][_0x2591ea(0x1e6)]=_0x415594?'none':_0x368eb3['GBGhS'],document[_0x2591ea(0x2a6)](_0x368eb3[_0x2591ea(0x27a)])[_0x2591ea(0x22d)][_0x2591ea(0x1e6)]=_0x415594?_0x2591ea(0xb0):_0x368eb3[_0x2591ea(0x203)],document[_0x2591ea(0x2a6)](_0x2591ea(0x1f2))[_0x2591ea(0x22d)][_0x2591ea(0x1e6)]=_0x415594?_0x368eb3[_0x2591ea(0x313)]:_0x368eb3['pWoPI'],_0x4bcf51['style'][_0x2591ea(0x1e6)]=_0x415594?_0x2591ea(0x159):_0x2591ea(0x3ac),_0x38d63a[_0x2591ea(0x22d)][_0x2591ea(0x1e6)]=_0x415594?_0x368eb3[_0x2591ea(0x1b3)]:_0x2591ea(0x159),_0x27fd14[_0x2591ea(0x22d)][_0x2591ea(0x1e6)]=_0x415594?_0x368eb3[_0x2591ea(0x1b3)]:_0x368eb3[_0x2591ea(0x203)],(_0x368eb3[_0x2591ea(0x3c2)](currentMode,_0x368eb3[_0x2591ea(0x2d9)])||_0x368eb3['MedIq'](currentMode,_0x368eb3['aGvnl']))&&document[_0x2591ea(0x2a6)]('timerContainer')[_0x2591ea(0x1bd)][_0x2591ea(0x3d2)](_0x368eb3[_0x2591ea(0xec)]),_0x368eb3[_0x2591ea(0x2a9)](loadBookmarkedQuestions),_0x368eb3[_0x2591ea(0x2a9)](generateQuestionNav),_0x368eb3['BeLGd'](updateStats),displayQuestion();}function generateQuestionNav(){const _0x3b6527=_0x2c7093,_0x59ced7={'Kisro':_0x3b6527(0x11f),'JWQDO':function(_0x248f67,_0x8b285e){return _0x248f67<_0x8b285e;},'XcbSQ':_0x3b6527(0x38e),'xVBtl':_0x3b6527(0x293),'VVplc':function(_0x1fc541){return _0x1fc541();}},_0x44d370=document['getElementById'](_0x59ced7['Kisro']);_0x44d370[_0x3b6527(0x219)]='';for(let _0x1b9d23=0x0;_0x59ced7['JWQDO'](_0x1b9d23,questionsData[_0x3b6527(0x22c)]);_0x1b9d23++){if(_0x59ced7[_0x3b6527(0x298)]!==_0x59ced7['xVBtl']){const _0xc1df78=document[_0x3b6527(0x1d0)](_0x3b6527(0x16d));_0xc1df78[_0x3b6527(0x3c5)]=_0x1b9d23+0x1,_0xc1df78[_0x3b6527(0x3d8)]=_0x3b6527(0x210),_0xc1df78[_0x3b6527(0x7a)]=()=>jumpToQuestion(_0x1b9d23),_0xc1df78['id']=_0x3b6527(0x2e2)+_0x1b9d23,_0x44d370[_0x3b6527(0x201)](_0xc1df78);}else _0x1f0f30[_0x3b6527(0x219)]+=_0x3b6527(0xee)+_0x537591[_0x3b6527(0x328)]+_0x3b6527(0xf8);}_0x59ced7[_0x3b6527(0x32e)](updateQuestionNav);}function updateQuestionNav(){const _0x51657c=_0x2c7093,_0x448c3a={'EdTMV':_0x51657c(0x128),'VeDtW':function(_0x511596,_0x775b1){return _0x511596<_0x775b1;},'vEDZH':'ZGJSc','kPALA':'nav-btn-marked-review','amnLh':function(_0x31b570,_0x368564){return _0x31b570===_0x368564;},'wpKHc':_0x51657c(0x10d),'pzTGl':function(_0x32a1ad,_0x56d5c9){return _0x32a1ad===_0x56d5c9;},'jNBqH':_0x51657c(0x10c),'kQQsF':_0x51657c(0x1f4),'PbArp':_0x51657c(0x233),'KLDcC':_0x51657c(0x36b),'wTVeA':function(_0x27206e,_0x1ea8ba){return _0x27206e!==_0x1ea8ba;},'wJmOa':_0x51657c(0xb4)};for(let _0x46e7c8=0x0;_0x448c3a['VeDtW'](_0x46e7c8,questionsData[_0x51657c(0x22c)]);_0x46e7c8++){if(_0x448c3a[_0x51657c(0x3b3)]===_0x448c3a[_0x51657c(0x3b3)]){const _0x4daa89=document['getElementById'](_0x51657c(0x2e2)+_0x46e7c8),_0x5da18e=questionStates[_0x46e7c8];let _0x18fca7='';if(_0x46e7c8===currentQuestionIndex)_0x18fca7=_0x51657c(0xbf);else{if(_0x5da18e[_0x51657c(0xa1)])_0x18fca7=_0x51657c(0x339);else{if(_0x5da18e[_0x51657c(0x206)])_0x18fca7=_0x448c3a[_0x51657c(0x37e)];else{if(_0x448c3a[_0x51657c(0x28e)](currentMode,_0x448c3a[_0x51657c(0x8a)])||_0x448c3a['amnLh'](currentMode,_0x51657c(0x23e))){if(_0x448c3a[_0x51657c(0x2c1)](_0x5da18e[_0x51657c(0x209)],_0x448c3a['jNBqH']))_0x18fca7=_0x448c3a[_0x51657c(0x1fa)];else{if(_0x5da18e[_0x51657c(0x209)]===_0x448c3a[_0x51657c(0x140)])_0x18fca7=_0x51657c(0x126);else _0x18fca7=_0x448c3a[_0x51657c(0x17f)];}}else{if(_0x448c3a['wTVeA'](_0x5da18e[_0x51657c(0x153)],null))_0x18fca7=_0x448c3a[_0x51657c(0x246)];else _0x18fca7=_0x448c3a[_0x51657c(0x17f)];}}}}_0x4daa89[_0x51657c(0x3d8)]='w-8\x20h-8\x20text-sm\x20font-medium\x20rounded\x20'+_0x18fca7;}else _0x33c5d0[_0x29828a][_0x51657c(0x209)]=_0x448c3a[_0x51657c(0x227)],_0x55b3fc[_0x51657c(0x124)]++,_0x565764[_0x51657c(0xd8)]--;}}function jumpToQuestion(_0x592f5f){const _0x44907b=_0x2c7093,_0x7ccd4b={'YGNea':_0x44907b(0x233),'AGvms':_0x44907b(0x2dc),'IxMmI':function(_0x29e7ca,_0x3c341c){return _0x29e7ca<_0x3c341c;},'fWUaM':function(_0x813384,_0x4619f7){return _0x813384!==_0x4619f7;},'tfAFi':_0x44907b(0x268),'SiSoT':function(_0x3b4903,_0x5f04ac){return _0x3b4903-_0x5f04ac;},'RamHi':function(_0xcc594b){return _0xcc594b();}};_0x592f5f>=0x0&&_0x7ccd4b['IxMmI'](_0x592f5f,questionsData[_0x44907b(0x22c)])&&(questionStartTime&&(_0x7ccd4b['fWUaM'](_0x7ccd4b[_0x44907b(0xd0)],_0x44907b(0x117))?questionStates[currentQuestionIndex][_0x44907b(0xc7)]+=_0x7ccd4b[_0x44907b(0x37a)](Date[_0x44907b(0x362)](),questionStartTime):(_0x4a8430=_0x7ccd4b[_0x44907b(0x2e8)],_0x5edc65=_0x7ccd4b[_0x44907b(0x383)])),currentQuestionIndex=_0x592f5f,_0x7ccd4b[_0x44907b(0x137)](displayQuestion));}function updateStats(){const _0x28d9fe=_0x2c7093,_0x485c36={'oSoir':function(_0x2e451b,_0x439db0){return _0x2e451b===_0x439db0;},'iXBwt':'study','xbCkp':function(_0x333fbc,_0xfec719){return _0x333fbc===_0xfec719;},'kNnHz':_0x28d9fe(0x23e),'ncqfN':_0x28d9fe(0x291),'jbGaM':_0x28d9fe(0x124),'QEJZu':function(_0x4e99cc,_0x31be89){return _0x4e99cc*_0x31be89;},'RDIbS':function(_0x2cfccc,_0x1050a1){return _0x2cfccc/_0x1050a1;},'gYrJr':_0x28d9fe(0x169),'fUIKz':function(_0x498630,_0x256063){return _0x498630/_0x256063;},'XSCPB':function(_0x26ef96,_0x57f80c){return _0x26ef96%_0x57f80c;},'wsZTK':_0x28d9fe(0xc7),'leRki':function(_0x1ac8fd,_0xc6d07f){return _0x1ac8fd+_0xc6d07f;},'ySWBx':function(_0x14e7ac,_0x4de32a){return _0x14e7ac+_0x4de32a;}};if(_0x485c36[_0x28d9fe(0x3c8)](currentMode,_0x485c36[_0x28d9fe(0x118)])||_0x485c36[_0x28d9fe(0x224)](currentMode,_0x485c36[_0x28d9fe(0xe7)])){document[_0x28d9fe(0x2a6)](_0x485c36[_0x28d9fe(0x247)])[_0x28d9fe(0x3c5)]=stats[_0x28d9fe(0x2e6)],document['getElementById'](_0x28d9fe(0x12a))['textContent']=stats[_0x28d9fe(0x390)],document[_0x28d9fe(0x2a6)](_0x485c36[_0x28d9fe(0x115)])['textContent']=stats[_0x28d9fe(0x124)];const _0x39772f=stats[_0x28d9fe(0x124)]>0x0?Math['round'](_0x485c36[_0x28d9fe(0x376)](_0x485c36['RDIbS'](stats['correctAnswers'],stats[_0x28d9fe(0x124)]),0x64)):0x0;document[_0x28d9fe(0x2a6)](_0x485c36['gYrJr'])['textContent']=_0x39772f+'%',stats[_0x28d9fe(0x2fe)]=questionStates[_0x28d9fe(0x364)]((_0x1cbb5e,_0x23abf1)=>_0x1cbb5e+_0x23abf1[_0x28d9fe(0xc7)],0x0);const _0x514630=Math[_0x28d9fe(0x2b3)](_0x485c36[_0x28d9fe(0x369)](stats[_0x28d9fe(0x2fe)],0x3e8)),_0x5aec5b=Math[_0x28d9fe(0x2b3)](_0x485c36['fUIKz'](_0x514630,0x3c)),_0x2483e3=_0x485c36[_0x28d9fe(0x1c4)](_0x514630,0x3c);document[_0x28d9fe(0x2a6)](_0x485c36[_0x28d9fe(0x306)])[_0x28d9fe(0x3c5)]=_0x485c36[_0x28d9fe(0x2d3)](_0x485c36[_0x28d9fe(0x1a4)](_0x5aec5b,':'),_0x2483e3[_0x28d9fe(0x1b1)]()[_0x28d9fe(0x1af)](0x2,'0'));}}function setupVideo(_0x35f450,_0x365b3a){const _0x23bc68=_0x2c7093,_0x4da77d={'WzThz':'application/vnd.apple.mpegurl'};if(Hls[_0x23bc68(0x175)]()){const _0xf6a263=new Hls();_0xf6a263['loadSource'](_0x365b3a),_0xf6a263[_0x23bc68(0x331)](_0x35f450);}else _0x35f450[_0x23bc68(0x311)](_0x4da77d[_0x23bc68(0x1a5)])&&(_0x35f450[_0x23bc68(0xf6)]=_0x365b3a);}function displayQuestion(){const _0x284faf=_0x2c7093,_0xd23d66={'QlDLb':function(_0x54537c,_0x554210){return _0x54537c===_0x554210;},'URauN':'div','vOrwc':_0x284faf(0x75),'HaLbz':_0x284faf(0x37f),'bgUYM':function(_0x29b114,_0x14b8db){return _0x29b114+_0x14b8db;},'MIglu':_0x284faf(0x1d6),'FflMD':_0x284faf(0x159),'hjyIL':_0x284faf(0x1b8),'aFIMJ':_0x284faf(0x7e),'dQZLn':_0x284faf(0x370),'aXiyO':function(_0x2f2429,_0x5516f8){return _0x2f2429(_0x5516f8);},'wZWbk':_0x284faf(0x396),'vOXrj':_0x284faf(0x1be),'biqIX':function(_0x391af5,_0x470b87){return _0x391af5===_0x470b87;},'eKTSv':function(_0x4cd9e7,_0x49e62d){return _0x4cd9e7*_0x49e62d;},'tERRL':function(_0xda292c,_0x3ebaac){return _0xda292c/_0x3ebaac;},'mUwVe':'progressBar','QpZjZ':function(_0x34288b,_0x52c4e7){return _0x34288b+_0x52c4e7;},'PUrLa':_0x284faf(0x96),'ZuBmJ':function(_0x571116,_0x378888){return _0x571116+_0x378888;},'CdKlz':function(_0x1230d9){return _0x1230d9();},'qAeTq':_0x284faf(0x161),'JQraY':function(_0x64833a,_0x487a34){return _0x64833a===_0x487a34;},'USAVC':_0x284faf(0x107),'TFtYo':'questionText','Juyii':_0x284faf(0x19c),'cPgOK':'questionMedia','BjIdy':'optionsContainer','ETzgV':_0x284faf(0x128),'xRltg':_0x284faf(0x3b4),'HtccU':_0x284faf(0x14f),'RcTKH':_0x284faf(0x2db),'VHlhR':function(_0x448199){return _0x448199();},'ehPnD':_0x284faf(0x23e),'pQlJB':_0x284faf(0x3a2)};if(!questionsData||_0xd23d66[_0x284faf(0xa0)](questionsData[_0x284faf(0x22c)],0x0)){document[_0x284faf(0x2a6)](_0x284faf(0x192))[_0x284faf(0x219)]=_0x284faf(0x14e);return;};const _0x5224c2=questionsData[currentQuestionIndex];questionStartTime=Date['now'](),selectedOption=questionStates[currentQuestionIndex][_0x284faf(0x153)];const _0x18da25=_0xd23d66[_0x284faf(0x29e)](_0xd23d66['tERRL'](_0xd23d66[_0x284faf(0x1c0)](currentQuestionIndex,0x1),questionsData[_0x284faf(0x22c)]),0x64);document[_0x284faf(0x2a6)](_0xd23d66[_0x284faf(0xf9)])[_0x284faf(0x22d)][_0x284faf(0x37b)]=_0xd23d66[_0x284faf(0x110)](_0x18da25,'%'),document[_0x284faf(0x2a6)](_0xd23d66[_0x284faf(0xfe)])[_0x284faf(0x3c5)]=_0xd23d66[_0x284faf(0x2a7)](currentQuestionIndex,0x1),_0xd23d66['CdKlz'](updateQuestionNav),document['getElementById'](_0xd23d66[_0x284faf(0xd5)])[_0x284faf(0x241)]=_0xd23d66[_0x284faf(0x2d8)](currentQuestionIndex,0x0),document[_0x284faf(0x2a6)](_0xd23d66[_0x284faf(0x2f1)])[_0x284faf(0x1bd)][_0x284faf(0x130)](_0x284faf(0x106)),document['getElementById'](_0xd23d66[_0x284faf(0x348)])[_0x284faf(0x219)]=_0x5224c2[_0x284faf(0x15c)]||_0xd23d66[_0x284faf(0x26f)];let _0x374412='';if(_0x5224c2[_0x284faf(0x23c)])_0x374412+='<div\x20class=\x22glass-light\x20p-4\x20mb-4\x22><audio\x20src=\x22'+_0x5224c2[_0x284faf(0x23c)]+_0x284faf(0xf8);if(_0x5224c2[_0x284faf(0x325)])_0x374412+=_0x284faf(0x1a1)+_0x5224c2['question_video']+_0x284faf(0x330);_0x5224c2[_0x284faf(0x2fc)]&&_0x5224c2[_0x284faf(0x2fc)][_0x284faf(0x7b)](_0x2a06d1=>{const _0x44aa60=_0x284faf;if(_0x2a06d1)_0x374412+=_0x44aa60(0x272)+_0x2a06d1+_0x44aa60(0x31c);});document[_0x284faf(0x2a6)](_0xd23d66[_0x284faf(0x299)])['innerHTML']=_0x374412;const _0xa2ecb7=document[_0x284faf(0x2a6)](_0xd23d66[_0x284faf(0x8e)]);_0xa2ecb7['innerHTML']='',_0xa2ecb7['classList']['remove'](_0xd23d66[_0x284faf(0x3bc)]),_0x5224c2[_0x284faf(0x335)]&&Array['isArray'](_0x5224c2['choices'])&&(_0xd23d66[_0x284faf(0x87)]!==_0xd23d66[_0x284faf(0x225)]?(_0x5224c2[_0x284faf(0x335)][_0x284faf(0x7b)]((_0x14d27d,_0x5aa796)=>{const _0x2d162f=_0x284faf,_0x1d8aef=String[_0x2d162f(0x21b)](0x41+_0x5aa796),_0xa8894=_0xd23d66[_0x2d162f(0x2b1)](selectedOption,_0x5aa796),_0x5e1b82=document[_0x2d162f(0x1d0)](_0xd23d66[_0x2d162f(0x38d)]);_0x5e1b82['innerHTML']='\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<button\x20type=\x22button\x22\x20class=\x22option-button\x20'+(_0xa8894?_0xd23d66[_0x2d162f(0x2fd)]:'')+_0x2d162f(0x1f5)+_0x5aa796+'\x22>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<div\x20class=\x22option-letter\x22>'+_0x1d8aef+_0x2d162f(0xe6)+(_0x14d27d[_0x2d162f(0x15c)]||_0xd23d66[_0x2d162f(0x3ab)]+_0xd23d66[_0x2d162f(0x1c0)](_0x5aa796,0x1))+'</div>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20</button>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20',_0xa2ecb7[_0x2d162f(0x201)](_0x5e1b82);}),_0xa2ecb7[_0x284faf(0x1da)](_0xd23d66[_0x284faf(0x156)],function(_0x12f46e){const _0x418470=_0x284faf;if(_0x418470(0x25f)!==_0xd23d66[_0x418470(0x3d0)]){const _0x18e332=_0x12f46e[_0x418470(0x2b2)][_0x418470(0x344)](_0xd23d66[_0x418470(0xeb)]);if(_0x18e332){if(_0x418470(0x97)===_0xd23d66[_0x418470(0x343)])_0x21d2ca=_0x4144db,_0x20403f[_0x418470(0x2a6)](_0xd23d66[_0x418470(0x26c)])[_0x418470(0x22d)][_0x418470(0x1e6)]=_0xd23d66[_0x418470(0x2c0)],_0x3ce009();else{const _0x3d5480=_0xd23d66[_0x418470(0x27e)](parseInt,_0x18e332[_0x418470(0x105)](_0xd23d66[_0x418470(0xab)]));_0xd23d66[_0x418470(0x27e)](selectOption,_0x3d5480);}}}else _0x4d708a=_0x418470(0x339);})):(_0x3f3d7d[_0x284faf(0xd4)][_0x284faf(0x319)][_0x284faf(0x389)](_0xd23d66[_0x284faf(0x2bb)])&&_0x4e1b34['removeItem']('customQuizData'),_0x2ba4c7[_0x284faf(0x180)]())),_0xd23d66[_0x284faf(0x355)](updateBookmarkButton),_0xd23d66['VHlhR'](updateMarkReviewButton),(currentMode===_0xd23d66[_0x284faf(0x92)]||currentMode===_0xd23d66[_0x284faf(0x101)])&&!isQuizCompleted&&_0xd23d66['VHlhR'](startTimer);}function selectOption(_0x5671da){const _0x6794d2=_0x2c7093,_0x692aa7={'hCtdt':function(_0x2f32b2,_0x129be5){return _0x2f32b2(_0x129be5);},'QydSO':_0x6794d2(0x7e),'PSMxt':function(_0x37fdfa,_0x49c584){return _0x37fdfa!==_0x49c584;},'UtfjM':_0x6794d2(0x395),'geSJm':_0x6794d2(0x75),'UmRff':function(_0x3d7263,_0x22c6e3){return _0x3d7263===_0x22c6e3;},'kUaaT':_0x6794d2(0x14a),'GdxPQ':'open','AMJxS':_0x6794d2(0x1c9),'ZaDMl':_0x6794d2(0x211),'PLQLi':'answered','VIXZm':function(_0x2bfbae,_0x4870ba){return _0x2bfbae-_0x4870ba;},'HtxRR':function(_0x274fa6,_0x1c2497){return _0x274fa6===_0x1c2497;},'PPxwm':_0x6794d2(0x23e),'sqZNX':function(_0x26c46d,_0x23c746,_0x2d3c06){return _0x26c46d(_0x23c746,_0x2d3c06);},'yfqnF':function(_0x4f5405,_0x922ea4){return _0x4f5405!==_0x922ea4;},'lmMfp':_0x6794d2(0x251),'OYosY':function(_0xdc3606,_0x3c8916){return _0xdc3606===_0x3c8916;},'eqtDk':_0x6794d2(0x238),'kUmhv':_0x6794d2(0x85)},_0x571852=document[_0x6794d2(0x2a6)](_0x692aa7[_0x6794d2(0x157)]);if(_0x571852[_0x6794d2(0x1bd)][_0x6794d2(0x356)](_0x692aa7['PLQLi']))return;questionStartTime&&(questionStates[currentQuestionIndex][_0x6794d2(0xc7)]+=_0x692aa7[_0x6794d2(0x2c8)](Date[_0x6794d2(0x362)](),questionStartTime),questionStartTime=Date[_0x6794d2(0x362)]()),selectedOption=_0x5671da,questionStates[currentQuestionIndex][_0x6794d2(0x153)]=_0x5671da,document[_0x6794d2(0x195)](_0x692aa7[_0x6794d2(0x2b7)])[_0x6794d2(0x7b)]((_0x346d26,_0x14dc71)=>{const _0x2c87bb=_0x6794d2,_0x40036c={'PJtHn':function(_0x1a74ba,_0x183098){return _0x1a74ba-_0x183098;},'hwLqn':function(_0x17627,_0x33a5dd){return _0x692aa7['hCtdt'](_0x17627,_0x33a5dd);},'byqBG':_0x692aa7['QydSO']};if(_0x692aa7['PSMxt']('nwgJD',_0x692aa7['UtfjM'])){const _0x52bcd6=_0x40036c['PJtHn'](_0x40036c[_0x2c87bb(0x242)](_0x2e4f0f,_0x17f488['key']),0x1),_0x2f1ea0=_0x4aef47[_0x2c87bb(0x195)](_0x40036c['byqBG']);if(_0x52bcd6<_0x2f1ea0[_0x2c87bb(0x22c)])_0x40036c['hwLqn'](_0x41f0c7,_0x52bcd6);}else _0x346d26[_0x2c87bb(0x1bd)][_0x2c87bb(0x3d7)](_0x692aa7[_0x2c87bb(0x314)],_0x692aa7['UmRff'](_0x14dc71,_0x5671da));}),_0x692aa7['HtxRR'](currentMode,'study')||_0x692aa7[_0x6794d2(0x305)](currentMode,_0x692aa7[_0x6794d2(0xed)])?_0x692aa7[_0x6794d2(0x26e)](setTimeout,processAnswer,0x12c):_0x692aa7[_0x6794d2(0x131)]('IGhRD',_0x692aa7[_0x6794d2(0x2de)])?(_0x692aa7[_0x6794d2(0x23a)](questionStates[currentQuestionIndex][_0x6794d2(0x209)],_0x692aa7[_0x6794d2(0x32a)])&&(_0x692aa7[_0x6794d2(0x3cf)]!==_0x6794d2(0x20c)?(questionStates[currentQuestionIndex][_0x6794d2(0x209)]=_0x692aa7[_0x6794d2(0x387)],stats[_0x6794d2(0x124)]++,stats[_0x6794d2(0xd8)]--):_0x2028eb[_0x6794d2(0x2a6)](_0x692aa7[_0x6794d2(0x2c4)])['classList']['toggle'](_0x692aa7[_0x6794d2(0x1ce)])),updateQuestionNav()):_0x4c9c9b[_0x6794d2(0x15e)](_0x692aa7[_0x6794d2(0x363)]);}function processAnswer(){const _0x5e0e4f=_0x2c7093,_0x10a2cc={'RGcfg':function(_0x99c57){return _0x99c57();},'SjwGD':function(_0x16bdde,_0x11db31){return _0x16bdde===_0x11db31;},'Fukvh':'not_attempted','dEmDV':function(_0x19ea26,_0x42f6e0){return _0x19ea26===_0x42f6e0;},'hxCHU':_0x5e0e4f(0x72),'shuYw':_0x5e0e4f(0x82),'YUNwm':_0x5e0e4f(0x10c),'arwpo':_0x5e0e4f(0x233),'yxRKR':function(_0x3ce677){return _0x3ce677();},'spgnJ':function(_0x1548c0,_0x2cdc02){return _0x1548c0(_0x2cdc02);}},_0x1dfcd8=questionsData[currentQuestionIndex],_0x124f67=_0x1dfcd8[_0x5e0e4f(0x1df)];if(selectedOption===null)return;const _0x32f95e=_0x1dfcd8[_0x5e0e4f(0x335)][selectedOption],_0x1955a9=_0x10a2cc[_0x5e0e4f(0x2c9)](_0x32f95e['id'],_0x124f67);if(questionStates[currentQuestionIndex]['status']===_0x10a2cc[_0x5e0e4f(0x8b)]){if(_0x10a2cc[_0x5e0e4f(0x32d)](_0x10a2cc[_0x5e0e4f(0x34e)],_0x10a2cc[_0x5e0e4f(0x1ad)]))_0x287c5c[_0x5e0e4f(0x12e)](),_0x10a2cc['RGcfg'](_0x2cdcf9);else{stats['totalAttempted']++,stats['notAttempted']--;if(_0x1955a9)stats[_0x5e0e4f(0x2e6)]++;else stats[_0x5e0e4f(0x390)]++;}}questionStates[currentQuestionIndex][_0x5e0e4f(0x209)]=_0x1955a9?_0x10a2cc[_0x5e0e4f(0x2ea)]:_0x10a2cc[_0x5e0e4f(0x168)],_0x10a2cc['yxRKR'](updateStats),_0x10a2cc[_0x5e0e4f(0x2cc)](showInlineFeedback,_0x1955a9),_0x10a2cc[_0x5e0e4f(0x17a)](updateQuestionNav);}function showInlineFeedback(_0x17ee1e){const _0x2e7432=_0x2c7093,_0x3cd629={'ekAtW':function(_0xa75157,_0x39328b){return _0xa75157!==_0x39328b;},'fMBHn':_0x2e7432(0xdb),'RfWlj':'selected','qLTAJ':function(_0x30f732,_0x55d8c1){return _0x30f732===_0x55d8c1;},'kpdOe':'correct','vhZRJ':_0x2e7432(0x233),'rhIwe':_0x2e7432(0x10d),'oYLER':function(_0x51d8a4,_0x21675a){return _0x51d8a4!==_0x21675a;},'YTgff':_0x2e7432(0x23e),'LgInF':_0x2e7432(0x7e),'froCS':_0x2e7432(0x128),'SOFcm':function(_0x479f31,_0x4d5161,_0x33d755){return _0x479f31(_0x4d5161,_0x33d755);}};if(_0x3cd629['ekAtW'](currentMode,_0x3cd629['rhIwe'])&&_0x3cd629[_0x2e7432(0x11e)](currentMode,_0x3cd629['YTgff']))return;const _0x875ec5=document[_0x2e7432(0x2a6)](_0x2e7432(0x211)),_0x343dc9=_0x875ec5[_0x2e7432(0x195)](_0x3cd629['LgInF']),_0x3f0423=questionsData[currentQuestionIndex],_0x5848ae=_0x3f0423[_0x2e7432(0x1df)];let _0x5ec7c5=_0x3f0423[_0x2e7432(0x335)][_0x2e7432(0x274)](_0x3a91e1=>_0x3a91e1['id']===_0x5848ae);_0x875ec5[_0x2e7432(0x1bd)][_0x2e7432(0x130)](_0x3cd629[_0x2e7432(0x3ad)]),_0x343dc9[_0x2e7432(0x7b)]((_0x2a7388,_0xcf825e)=>{const _0x9395=_0x2e7432;if(_0x3cd629[_0x9395(0x2d0)](_0x3cd629['fMBHn'],_0x3cd629[_0x9395(0x2b9)])){const _0x5caa50={'quizName':_0x3e73db,'quizFile':_0x3ff9de['location'][_0x9395(0x319)][_0x9395(0x3a4)]('/')['pop'](),'questionIndex':_0x3e6417,'question':_0x22aa83[_0x51298b],'hierarchy':_0x1b8003,'timestamp':_0x111957[_0x9395(0x362)]()};_0x327ee3['push'](_0x5caa50);}else{_0x2a7388['classList'][_0x9395(0x3d2)](_0x3cd629[_0x9395(0x100)]);if(_0x3cd629[_0x9395(0x231)](_0xcf825e,_0x5ec7c5))_0x2a7388[_0x9395(0x1bd)]['add'](_0x3cd629['kpdOe']);else{if(_0xcf825e===selectedOption&&!_0x17ee1e)_0x2a7388[_0x9395(0x1bd)][_0x9395(0x130)](_0x3cd629[_0x9395(0x1ea)]);}}}),_0x3cd629[_0x2e7432(0x38f)](setTimeout,showSolution,0x5dc);}function showSolution(){const _0x579acc=_0x2c7093,_0x2ea88c={'WYWzr':function(_0xa69f75,_0x3e21c3){return _0xa69f75>_0x3e21c3;},'ggWHb':function(_0x4ace6c,_0x48d071){return _0x4ace6c-_0x48d071;},'EZCzj':function(_0xb46e4a){return _0xb46e4a();},'qFAiJ':function(_0x522330,_0x56b56d){return _0x522330!==_0x56b56d;},'lmewZ':_0x579acc(0x91),'Lmapq':'study','hmcDL':_0x579acc(0x23e),'jLNRc':_0x579acc(0x10f),'COvHo':_0x579acc(0x1c1),'bXMJu':_0x579acc(0x2ca),'MSbMN':function(_0x5363ba,_0x211147){return _0x5363ba!==_0x211147;},'mSGDV':_0x579acc(0x3c0),'ookrk':'hidden','DjVVC':function(_0x554e98,_0x5769f7,_0x2aecc2){return _0x554e98(_0x5769f7,_0x2aecc2);},'OdcoT':_0x579acc(0x1eb),'LFnON':function(_0x182e15,_0x2b2dfc){return _0x182e15===_0x2b2dfc;},'cRjXt':'NlNbH'};if(currentMode!==_0x2ea88c[_0x579acc(0x2eb)]&&_0x2ea88c[_0x579acc(0x1a9)](currentMode,_0x2ea88c['hmcDL']))return;const _0x13c780=questionsData[currentQuestionIndex];document[_0x579acc(0x2a6)](_0x2ea88c['jLNRc'])[_0x579acc(0x219)]=_0x13c780['solution']||_0x2ea88c[_0x579acc(0xcd)];const _0x3eadbe=document[_0x579acc(0x2a6)](_0x579acc(0x15f)),_0xafc3eb=document[_0x579acc(0x2a6)](_0x2ea88c[_0x579acc(0x1ec)]),_0x56f2f9=_0x13c780[_0x579acc(0x321)];if(_0x56f2f9){if(_0x2ea88c['MSbMN'](_0x579acc(0x280),_0x2ea88c[_0x579acc(0xc3)])){_0x3eadbe[_0x579acc(0x1bd)][_0x579acc(0x3d2)](_0x2ea88c[_0x579acc(0x189)]);if(_0x56f2f9[_0x579acc(0x360)]('.m3u8'))_0x2ea88c['DjVVC'](setupVideo,_0xafc3eb,_0x56f2f9);else _0xafc3eb['src']=_0x56f2f9;}else _0x353bf7[_0x579acc(0xf6)]=_0x2fb74f;}else _0x3eadbe['classList'][_0x579acc(0x130)](_0x579acc(0x106));const _0x289411=document[_0x579acc(0x2a6)](_0x2ea88c[_0x579acc(0x1cd)]);_0x289411[_0x579acc(0x219)]='';_0x13c780[_0x579acc(0xa4)]&&(_0x289411['innerHTML']+=_0x579acc(0x179)+_0x13c780[_0x579acc(0xa4)]+'\x22\x20controls\x20class=\x22w-full\x22></audio></div>');_0x13c780[_0x579acc(0x328)]&&(_0x289411[_0x579acc(0x219)]+=_0x579acc(0xee)+_0x13c780[_0x579acc(0x328)]+_0x579acc(0xf8));const _0x2a613a=document[_0x579acc(0x2a6)](_0x579acc(0x385));_0x2a613a[_0x579acc(0x219)]='',_0x13c780['explanation_images']&&(_0x2ea88c[_0x579acc(0x93)](_0x2ea88c[_0x579acc(0x382)],_0x579acc(0x1dc))?_0x2ea88c[_0x579acc(0x2d6)](_0x2e5d5a,0x0)&&(_0x4fbd26&&(_0x4a4e3a[_0x3ce08e][_0x579acc(0xc7)]+=_0x2ea88c[_0x579acc(0x182)](_0x2f9a24[_0x579acc(0x362)](),_0x24d7a4)),_0x25b6e4--,_0x4f9828()):_0x13c780[_0x579acc(0x3a8)][_0x579acc(0x7b)](_0x31f216=>{const _0x2ec65b=_0x579acc;if(_0x2ea88c[_0x2ec65b(0x1a9)](_0x2ec65b(0x91),_0x2ea88c['lmewZ']))_0x2ea88c['EZCzj'](_0x338a29);else{if(_0x31f216)_0x2a613a[_0x2ec65b(0x219)]+=_0x2ec65b(0x393)+_0x31f216+_0x2ec65b(0x39c);}})),document[_0x579acc(0x2a6)](_0x579acc(0x107))[_0x579acc(0x1bd)][_0x579acc(0x3d2)](_0x2ea88c['ookrk']);}function submitQuiz(){const _0x2ad5d0=_0x2c7093,_0x59a1bf={'aahzq':function(_0xd9d221,_0x1987ce){return _0xd9d221(_0x1987ce);},'Bldoz':'You\x20have\x20reached\x20the\x20end\x20of\x20the\x20quiz.\x20Would\x20you\x20like\x20to\x20submit\x20your\x20answers\x20now?','sRHxx':function(_0x46c3a3){return _0x46c3a3();},'IOwkm':function(_0x7f1c88,_0x33d12b){return _0x7f1c88!==_0x33d12b;},'TTsik':function(_0x5e0922,_0x4a5518){return _0x5e0922===_0x4a5518;},'TwdMC':function(_0x584c5b,_0x3b608d){return _0x584c5b===_0x3b608d;},'VcypI':'lxsZz','hcgWB':_0x2ad5d0(0x10c),'mjxnx':'Oitba','YwBfC':'Are\x20you\x20sure\x20you\x20want\x20to\x20submit\x20the\x20quiz?','qodOn':function(_0x170e0f,_0x3e49a6){return _0x170e0f-_0x3e49a6;},'bxJNr':_0x2ad5d0(0x109),'yEMFo':function(_0x35dee5,_0x46e33c){return _0x35dee5+_0x46e33c;},'pgyaM':function(_0x3647ad,_0x367962,_0x1d9aba,_0x5a6eb1,_0x3615fd){return _0x3647ad(_0x367962,_0x1d9aba,_0x5a6eb1,_0x3615fd);},'mmukd':function(_0x1c257d,_0x3aa692){return _0x1c257d+_0x3aa692;}};if(timer)_0x59a1bf['aahzq'](clearInterval,timer);if(!_0x59a1bf[_0x2ad5d0(0x11d)](confirm,_0x59a1bf[_0x2ad5d0(0x308)]))return;isQuizCompleted=!![];let _0x38dd9f=0x0,_0x10ea72=0x0;const _0x1a4220=_0x59a1bf[_0x2ad5d0(0x15b)](Date['now'](),quizStartTime);questionsData[_0x2ad5d0(0x7b)]((_0x2d4bf6,_0x32fae8)=>{const _0x1961e9=_0x2ad5d0,_0x226c8d=questionStates[_0x32fae8];if(_0x59a1bf[_0x1961e9(0x3b1)](_0x226c8d[_0x1961e9(0x153)],null)){if(_0x59a1bf['TTsik'](_0x2d4bf6[_0x1961e9(0x335)][_0x226c8d[_0x1961e9(0x153)]]['id'],_0x2d4bf6[_0x1961e9(0x1df)])){if(_0x59a1bf[_0x1961e9(0xe5)](_0x59a1bf[_0x1961e9(0x1b6)],_0x1961e9(0x2e9))){if(_0x16eaf3){const _0x3d2310=_0x476052[_0x1961e9(0x282)](_0x547952,arguments);return _0x3b786b=null,_0x3d2310;}}else _0x38dd9f++,_0x226c8d[_0x1961e9(0x209)]=_0x59a1bf[_0x1961e9(0x30e)];}else _0x59a1bf[_0x1961e9(0x70)]!==_0x59a1bf[_0x1961e9(0x70)]?_0x59a1bf[_0x1961e9(0x11d)](_0x2e00fd,_0x59a1bf[_0x1961e9(0x32c)])&&_0x59a1bf[_0x1961e9(0x2fa)](_0x212cd3):(_0x10ea72++,_0x226c8d[_0x1961e9(0x209)]='incorrect');}});const _0x359353=JSON[_0x2ad5d0(0xb5)](localStorage['getItem'](_0x59a1bf[_0x2ad5d0(0x332)]))||[];_0x359353[_0x2ad5d0(0x132)]({'quizName':quizName,'hierarchy':hierarchy,'timestamp':Date[_0x2ad5d0(0x362)](),'totalTime':_0x1a4220,'stats':{'correct':_0x38dd9f,'incorrect':_0x10ea72,'notAttempted':_0x59a1bf[_0x2ad5d0(0x15b)](questionsData[_0x2ad5d0(0x22c)],_0x59a1bf['yEMFo'](_0x38dd9f,_0x10ea72))}}),localStorage[_0x2ad5d0(0x37c)](_0x59a1bf[_0x2ad5d0(0x332)],JSON[_0x2ad5d0(0x166)](_0x359353)),_0x59a1bf[_0x2ad5d0(0x260)](showPerformanceAnalysis,_0x38dd9f,_0x10ea72,_0x59a1bf[_0x2ad5d0(0x15b)](questionsData[_0x2ad5d0(0x22c)],_0x59a1bf[_0x2ad5d0(0x365)](_0x38dd9f,_0x10ea72)),_0x1a4220);}function showPerformanceAnalysis(_0x1b8091,_0x1bfe66,_0x3f3a41,_0x360c27){const _0xd50bdc=_0x2c7093,_0x37dedc={'UTvYC':_0xd50bdc(0x220),'WjhNw':function(_0x32af07,_0x5367a4){return _0x32af07>_0x5367a4;},'pkIQE':function(_0x253825,_0xec5c4f){return _0x253825+_0xec5c4f;},'lzwhZ':function(_0x1c75c7,_0xdde4a8){return _0x1c75c7*_0xdde4a8;},'YiRsF':function(_0x195fcf,_0x34b0b7){return _0x195fcf+_0x34b0b7;},'VGNfj':function(_0x59a423,_0x1574c3){return _0x59a423*_0x1574c3;},'DMOoL':'scoreCircle','PVdHq':function(_0x15630d,_0x57c573){return _0x15630d-_0x57c573;},'NQhNv':function(_0x10092e,_0x4cb3f9){return _0x10092e*_0x4cb3f9;},'SQjQn':'accuracyScore','MRjwy':'totalQuestionsResult','iVPUC':_0xd50bdc(0x353),'dliei':_0xd50bdc(0xce),'Hiaps':_0xd50bdc(0x32b),'Dbuxj':function(_0x31abbb,_0x3b1756){return _0x31abbb/_0x3b1756;},'MSKdI':_0xd50bdc(0xe2),'CfFhy':function(_0x3b2d8a,_0x5459bd){return _0x3b2d8a/_0x5459bd;},'zoMCu':function(_0x26ad45,_0x18cc48){return _0x26ad45/_0x18cc48;},'OFgdr':function(_0x2273ca,_0x41eb4f){return _0x2273ca/_0x41eb4f;},'JXVyF':function(_0x1a163b,_0x4f6ba3){return _0x1a163b%_0x4f6ba3;},'HJpXT':_0xd50bdc(0x106)},_0x13aee8=document[_0xd50bdc(0x2a6)](_0x37dedc[_0xd50bdc(0x1d1)]),_0x4aa533=_0x37dedc[_0xd50bdc(0x262)](_0x37dedc[_0xd50bdc(0x20d)](_0x1b8091,_0x1bfe66),0x0)?Math[_0xd50bdc(0x26d)](_0x37dedc['lzwhZ'](_0x1b8091/_0x37dedc[_0xd50bdc(0x1d3)](_0x1b8091,_0x1bfe66),0x64)):0x0,_0x1ed07e=_0x37dedc['lzwhZ'](_0x37dedc['VGNfj'](0x2,Math['PI']),0x41),_0x4fb677=document[_0xd50bdc(0x2a6)](_0x37dedc['DMOoL']);_0x4fb677['style'][_0xd50bdc(0x258)]=_0x1ed07e+'\x20'+_0x1ed07e,_0x4fb677[_0xd50bdc(0x22d)][_0xd50bdc(0x263)]=_0x37dedc[_0xd50bdc(0x345)](_0x1ed07e,_0x37dedc[_0xd50bdc(0x33c)](_0x4aa533/0x64,_0x1ed07e)),document[_0xd50bdc(0x2a6)](_0x37dedc[_0xd50bdc(0x21d)])[_0xd50bdc(0x3c5)]=_0x4aa533+'%',document[_0xd50bdc(0x2a6)](_0x37dedc[_0xd50bdc(0x259)])[_0xd50bdc(0x3c5)]=questionsData[_0xd50bdc(0x22c)],document[_0xd50bdc(0x2a6)](_0x37dedc[_0xd50bdc(0x1a0)])[_0xd50bdc(0x3c5)]=_0x1b8091,document[_0xd50bdc(0x2a6)](_0x37dedc[_0xd50bdc(0x320)])[_0xd50bdc(0x3c5)]=_0x1bfe66,document[_0xd50bdc(0x2a6)](_0x37dedc[_0xd50bdc(0x214)])[_0xd50bdc(0x3c5)]=_0x3f3a41;const _0x462b3a=Math[_0xd50bdc(0x2b3)](_0x37dedc['Dbuxj'](_0x360c27,0xea60)),_0xbf0a92=Math[_0xd50bdc(0x2b3)](_0x360c27%0xea60/0x3e8);document[_0xd50bdc(0x2a6)](_0x37dedc['MSKdI'])['textContent']=_0x462b3a+':'+_0xbf0a92[_0xd50bdc(0x1b1)]()['padStart'](0x2,'0');const _0x41c492=_0x37dedc[_0xd50bdc(0x265)](_0x360c27,questionsData[_0xd50bdc(0x22c)]),_0xbea16c=Math[_0xd50bdc(0x2b3)](_0x37dedc[_0xd50bdc(0x294)](_0x41c492,0xea60)),_0x245d3c=Math[_0xd50bdc(0x2b3)](_0x37dedc[_0xd50bdc(0x178)](_0x37dedc[_0xd50bdc(0x30b)](_0x41c492,0xea60),0x3e8));document[_0xd50bdc(0x2a6)](_0xd50bdc(0x236))[_0xd50bdc(0x3c5)]=_0xbea16c+':'+_0x245d3c['toString']()[_0xd50bdc(0x1af)](0x2,'0'),_0x13aee8[_0xd50bdc(0x1bd)][_0xd50bdc(0x3d2)](_0x37dedc['HJpXT']);}function closePerformanceModal(){const _0x5bbc56=_0x2c7093,_0x2654c3={'VVULy':_0x5bbc56(0x220)};document[_0x5bbc56(0x2a6)](_0x2654c3[_0x5bbc56(0xbe)])['classList'][_0x5bbc56(0x130)](_0x5bbc56(0x106));}function reviewQuestions(){const _0x5cef6e=_0x2c7093,_0x5c365e={'wbPXh':function(_0x28f4b2,_0x27e6da){return _0x28f4b2(_0x27e6da);},'yRVlc':_0x5cef6e(0x396),'Gdsny':function(_0x55bfc3,_0x32a13f){return _0x55bfc3(_0x32a13f);},'AGqYI':function(_0x1d18f9,_0x4bc6c6){return _0x1d18f9===_0x4bc6c6;},'NSjqZ':function(_0x7fa55e,_0x1fcc85){return _0x7fa55e===_0x1fcc85;},'ClJZP':'border-green-500','dOfUB':_0x5cef6e(0x2be),'LOyPC':function(_0x5afb08,_0x35505e){return _0x5afb08+_0x35505e;},'IiqPy':_0x5cef6e(0x18d),'BUMnK':function(_0x12ff9b,_0x4e3ba5){return _0x12ff9b!==_0x4e3ba5;},'VnyRM':function(_0x34087b,_0x49c8b4){return _0x34087b!==_0x49c8b4;},'Jipkw':'wEIry','uejlX':function(_0x169f91,_0x59c16a){return _0x169f91===_0x59c16a;},'PORAb':_0x5cef6e(0x10c),'nKpuV':_0x5cef6e(0xff),'CMRea':_0x5cef6e(0x233),'ncFXc':_0x5cef6e(0x2dc),'ndwJC':function(_0x3b02ba,_0x4baa7d){return _0x3b02ba===_0x4baa7d;},'WgRRc':'green','BLweU':function(_0x641ac,_0x3161ec){return _0x641ac===_0x3161ec;},'Vhcsd':_0x5cef6e(0x357),'IClqz':_0x5cef6e(0x207),'zuGIs':'No\x20solution\x20available.','uvdkR':_0x5cef6e(0x36c),'NpfMM':_0x5cef6e(0x106),'jyIDc':_0x5cef6e(0x2a5)};document[_0x5cef6e(0x2a6)](_0x5c365e[_0x5cef6e(0x1b4)])[_0x5cef6e(0x1bd)]['remove'](_0x5c365e[_0x5cef6e(0xc1)]);const _0x222cec=document['getElementById'](_0x5c365e['jyIDc']);_0x222cec[_0x5cef6e(0x219)]='',questionsData[_0x5cef6e(0x7b)]((_0x16975b,_0x52e870)=>{const _0x488040=_0x5cef6e,_0x1e2025=questionStates[_0x52e870],_0xfb9fe2=_0x16975b[_0x488040(0x1df)];let _0x4385a8=_0x5c365e[_0x488040(0x2f9)],_0x5512f2=_0x488040(0x13a);if(_0x5c365e[_0x488040(0x33e)](_0x1e2025[_0x488040(0x153)],null)){if(_0x5c365e[_0x488040(0x35b)](_0x5c365e[_0x488040(0x271)],_0x488040(0x326))){const _0x37de0b=_0x5cb939['target'][_0x488040(0x344)](_0x488040(0x7e));if(_0x37de0b){const _0x32d68a=_0x5c365e[_0x488040(0x1e4)](_0x5be8a9,_0x37de0b[_0x488040(0x105)](_0x5c365e[_0x488040(0x184)]));_0x5c365e['Gdsny'](_0x3fae03,_0x32d68a);}}else{const _0x527b57=_0x16975b['choices'][_0x1e2025[_0x488040(0x153)]];_0x5c365e[_0x488040(0x74)](_0x527b57['id'],_0xfb9fe2)?(_0x4385a8=_0x5c365e[_0x488040(0x374)],_0x5512f2=_0x5c365e[_0x488040(0x158)]):(_0x4385a8=_0x5c365e[_0x488040(0x84)],_0x5512f2=_0x5c365e[_0x488040(0x218)]);}}const _0x3f1c82=document['createElement'](_0x488040(0x177));_0x3f1c82['className']=_0x488040(0xa2)+_0x4385a8;let _0x20bcf2=(_0x16975b['choices']||[])['map']((_0x5af16f,_0x48c68c)=>{const _0x48307d=_0x488040,_0x4fa979=_0x5c365e['AGqYI'](_0x1e2025[_0x48307d(0x153)],_0x48c68c),_0x4bbcb4=_0x5c365e['NSjqZ'](_0x5af16f['id'],_0xfb9fe2);let _0x317457=_0x48307d(0x3cd);if(_0x4bbcb4)_0x317457=_0x5c365e['ClJZP'];else{if(_0x4fa979)_0x317457=_0x5c365e[_0x48307d(0x160)];}return _0x48307d(0x142)+_0x317457+'\x22><span\x20class=\x22font-bold\x20mr-3\x22>'+String[_0x48307d(0x21b)](_0x5c365e[_0x48307d(0x371)](0x41,_0x48c68c))+_0x48307d(0x2f3)+_0x5af16f['text']+_0x48307d(0x243);})[_0x488040(0x3b2)]('');const _0x246b51=_0x16975b['explanation_video']?_0x488040(0x2c6)+_0x52e870+_0x488040(0x112)+_0x16975b[_0x488040(0x321)]+_0x488040(0x2b5):'';let _0x542939='';if(_0x16975b[_0x488040(0xa4)])_0x542939+='<div\x20class=\x22mt-2\x22><p\x20class=\x22text-sm\x20text-white\x20text-opacity-70\x20mb-1\x22>English:</p><audio\x20src=\x22'+_0x16975b[_0x488040(0xa4)]+_0x488040(0xf8);if(_0x16975b[_0x488040(0x328)])_0x542939+=_0x488040(0x31d)+_0x16975b[_0x488040(0x328)]+'\x22\x20controls\x20class=\x22w-full\x22></audio></div>';let _0x53b55e=(_0x16975b[_0x488040(0x3a8)]||[])[_0x488040(0x336)](_0x5c6505=>_0x5c6505?'<div\x20class=\x22mt-4\x22><img\x20src=\x22'+_0x5c6505+'\x22\x20alt=\x22Explanation\x20Image\x22\x20class=\x22w-full\x20rounded-lg\x22></div>':'')[_0x488040(0x3b2)]('');_0x3f1c82[_0x488040(0x219)]=_0x488040(0x1fe)+_0x5c365e[_0x488040(0x371)](_0x52e870,0x1)+'</h4>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<span\x20class=\x22text-sm\x20px-3\x20py-1\x20rounded-full\x20bg-'+(_0x5c365e[_0x488040(0x29c)](_0x4385a8,_0x5c365e[_0x488040(0x374)])?_0x5c365e[_0x488040(0x222)]:_0x5c365e[_0x488040(0x2f5)](_0x4385a8,_0x5c365e[_0x488040(0x84)])?_0x5c365e[_0x488040(0x221)]:_0x5c365e[_0x488040(0x1ac)])+'-600\x20text-white\x22>'+_0x5512f2+'</span>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20</div>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<div\x20class=\x22text-white\x20mb-4\x22>'+_0x16975b[_0x488040(0x15c)]+_0x488040(0x205)+_0x20bcf2+_0x488040(0x235)+(_0x16975b[_0x488040(0x34b)]||_0x5c365e['zuGIs'])+_0x488040(0x103)+_0x246b51+_0x488040(0x284)+_0x542939+_0x488040(0x284)+_0x53b55e+_0x488040(0x248),_0x222cec[_0x488040(0x201)](_0x3f1c82);}),initializeReviewVideos();}function initializeReviewVideos(){const _0x1f3f77=_0x2c7093,_0x16004b={'dArjv':function(_0x32bd14){return _0x32bd14();},'cfQtV':_0x1f3f77(0x1fc),'YhIeN':function(_0x17d0f5,_0x132d65,_0x3d94b3){return _0x17d0f5(_0x132d65,_0x3d94b3);},'geNID':function(_0x5a4208,_0x3db3a8){return _0x5a4208!==_0x3db3a8;},'hjvMd':_0x1f3f77(0x1f9),'rhmfG':_0x1f3f77(0x24f),'DNzbN':_0x1f3f77(0x116)};document[_0x1f3f77(0x195)](_0x16004b['DNzbN'])['forEach'](_0x9c0572=>{const _0x1409f8=_0x1f3f77,_0x2f871f={'exUdr':function(_0x7203ed){const _0x4ad1b3=_0x2f70;return _0x16004b[_0x4ad1b3(0x1c2)](_0x7203ed);}},_0x5ba1b1=_0x9c0572[_0x1409f8(0x20f)][_0x1409f8(0xf6)];if(_0x5ba1b1&&_0x5ba1b1[_0x1409f8(0x360)](_0x16004b[_0x1409f8(0x3cb)]))_0x16004b[_0x1409f8(0x9b)](setupVideo,_0x9c0572,_0x5ba1b1);else _0x5ba1b1&&(_0x16004b['geNID'](_0x16004b[_0x1409f8(0x111)],_0x16004b[_0x1409f8(0x80)])?_0x9c0572[_0x1409f8(0xf6)]=_0x5ba1b1:(_0x69d8a2&&(_0x80fa1b[_0x3c2c50][_0x1409f8(0xc7)]+=_0xa927b9['now']()-_0x4e86fc),_0x54cf6a--,_0x2f871f[_0x1409f8(0x237)](_0x6c0ab4)));});}function retakeQuiz(){const _0x4d93b5=_0x2c7093,_0x4e548e={'xjSmB':function(_0x2d77d0,_0x5def1b){return _0x2d77d0(_0x5def1b);},'RmfAg':_0x4d93b5(0x1cc),'YBWLs':function(_0x191207,_0x230128){return _0x191207(_0x230128);},'DRMcW':_0x4d93b5(0x391),'nuLjK':function(_0x3e228d,_0x4d0a3d){return _0x3e228d===_0x4d0a3d;},'pHdft':_0x4d93b5(0xca),'jbBkr':_0x4d93b5(0xf1),'HLQpX':_0x4d93b5(0x1c9)};_0x4e548e[_0x4d93b5(0x9d)](confirm,_0x4e548e[_0x4d93b5(0x28f)])&&(window[_0x4d93b5(0xd4)]['pathname']['endsWith'](_0x4d93b5(0x1be))&&(_0x4e548e[_0x4d93b5(0x29b)](_0x4e548e[_0x4d93b5(0x2c2)],_0x4e548e[_0x4d93b5(0x388)])?(_0x55b1be||_0x4e548e['xjSmB'](_0x4078e4,_0x4e548e[_0x4d93b5(0x375)]))&&_0x5ea8ed[_0x4d93b5(0x252)][_0x4d93b5(0x250)]():localStorage[_0x4d93b5(0x15e)](_0x4e548e[_0x4d93b5(0x1a8)])),location[_0x4d93b5(0x180)]());}function loadBookmarkedQuestions(){const _0x1119bf=_0x2c7093,_0x7132f7={'kIMzF':function(_0x5aac56){return _0x5aac56();},'ZtRZg':function(_0x463dbe,_0x5079fd){return _0x463dbe!==_0x5079fd;},'jjyoB':'GTvkT','MBXlo':function(_0x716fce,_0x372787){return _0x716fce===_0x372787;},'ekwzB':_0x1119bf(0x1f6),'uVkjs':'bookmarkedQuestions'},_0x33a825=JSON[_0x1119bf(0xb5)](localStorage['getItem'](_0x7132f7['uVkjs']))||[];_0x33a825[_0x1119bf(0x7b)](_0x1c3232=>{const _0x4aef5f=_0x1119bf;_0x1c3232[_0x4aef5f(0x121)][_0x4aef5f(0x360)](quizName[_0x4aef5f(0x24c)]()[_0x4aef5f(0x38a)](/ /g,'-'))&&(_0x7132f7[_0x4aef5f(0xa7)](_0x7132f7['jjyoB'],_0x4aef5f(0x3a0))?_0x1c3232[_0x4aef5f(0x2ae)]<questionsData[_0x4aef5f(0x22c)]&&(_0x7132f7['MBXlo'](_0x4aef5f(0x1f6),_0x7132f7[_0x4aef5f(0x3a6)])?questionStates[_0x1c3232[_0x4aef5f(0x2ae)]][_0x4aef5f(0xa1)]=!![]:_0x4c86e5(_0x1eb95a,0x12c)):_0x7132f7['kIMzF'](_0x2a32bf));});}function toggleBookmark(){const _0x3f5980=_0x2c7093,_0x4636f2={'OLNyi':function(_0x26e62d,_0x4e13fd){return _0x26e62d(_0x4e13fd);},'cbecS':function(_0x16d8dc,_0x5d1223){return _0x16d8dc+_0x5d1223;},'cEpEr':'return\x20(function()\x20','aGfyM':function(_0x17953f,_0x105f75){return _0x17953f===_0x105f75;},'FgVol':_0x3f5980(0x10c),'XpEaD':_0x3f5980(0x232),'HrgDn':function(_0x551011,_0x20a2a4){return _0x551011!==_0x20a2a4;},'OEsAS':_0x3f5980(0x23d),'mKNlS':_0x3f5980(0x216),'uGjGI':function(_0x2efb62,_0x5d1afd){return _0x2efb62===_0x5d1afd;},'rWIek':function(_0x4526bd){return _0x4526bd();},'WkkvW':function(_0x4d6e41){return _0x4d6e41();}},_0x15cdc3=!questionStates[currentQuestionIndex][_0x3f5980(0xa1)];questionStates[currentQuestionIndex]['bookmarked']=_0x15cdc3;let _0x482c81=JSON[_0x3f5980(0xb5)](localStorage[_0x3f5980(0x148)](_0x4636f2[_0x3f5980(0x190)]))||[];if(_0x15cdc3){if(_0x4636f2[_0x3f5980(0x165)](_0x4636f2[_0x3f5980(0x398)],_0x4636f2[_0x3f5980(0x2bf)])){const _0x2f7a79={'quizName':quizName,'quizFile':window[_0x3f5980(0xd4)][_0x3f5980(0x319)][_0x3f5980(0x3a4)]('/')[_0x3f5980(0xc0)](),'questionIndex':currentQuestionIndex,'question':questionsData[currentQuestionIndex],'hierarchy':hierarchy,'timestamp':Date[_0x3f5980(0x362)]()};_0x482c81[_0x3f5980(0x132)](_0x2f7a79);}else{let _0xd3f513;try{_0xd3f513=UpeRFl[_0x3f5980(0x3bd)](_0x57098d,UpeRFl[_0x3f5980(0x16a)](UpeRFl[_0x3f5980(0x13b)]+_0x3f5980(0x3a3),');'))();}catch(_0x2a5c81){_0xd3f513=_0x54766d;}return _0xd3f513;}}else _0x4636f2[_0x3f5980(0x266)]('PsJUd',_0x3f5980(0x324))?_0x4636f2[_0x3f5980(0x136)](_0x1a5b0b[_0x3f5980(0x335)][_0x18f85c[_0x3f5980(0x153)]]['id'],_0x390773[_0x3f5980(0x1df)])?(_0x1fac17++,_0x4c09d2[_0x3f5980(0x209)]=_0x4636f2[_0x3f5980(0x2a3)]):(_0x498b9d++,_0x510f16[_0x3f5980(0x209)]=_0x3f5980(0x233)):_0x482c81=_0x482c81[_0x3f5980(0x19a)](_0xc93670=>!(_0xc93670[_0x3f5980(0x121)]['includes'](quizName[_0x3f5980(0x24c)]()[_0x3f5980(0x38a)](/ /g,'-'))&&_0xc93670[_0x3f5980(0x2ae)]===currentQuestionIndex));localStorage[_0x3f5980(0x37c)]('bookmarkedQuestions',JSON[_0x3f5980(0x166)](_0x482c81)),_0x4636f2[_0x3f5980(0x2b0)](updateBookmarkButton),_0x4636f2[_0x3f5980(0x22a)](updateQuestionNav);}function updateBookmarkButton(){const _0x32c943=_0x2c7093,_0x1523e3={'EOIZf':_0x32c943(0x1e7),'zLFuU':_0x32c943(0x1ca),'XnqCz':_0x32c943(0x200),'oKDpM':'Bookmarked'},_0x2aaf44=document[_0x32c943(0x2a6)](_0x1523e3[_0x32c943(0x20e)]),_0x39fbcf=document[_0x32c943(0x2a6)](_0x1523e3[_0x32c943(0x2e5)]),_0xac730f=questionStates[currentQuestionIndex][_0x32c943(0xa1)];_0x2aaf44['className']=_0xac730f?_0x1523e3['XnqCz']:'glass-light\x20px-6\x20py-3\x20text-white\x20hover:bg-yellow-500\x20hover:bg-opacity-20\x20transition-all\x20duration-300\x20flex\x20items-center',_0x39fbcf[_0x32c943(0x3c5)]=_0xac730f?_0x1523e3[_0x32c943(0x36a)]:_0x32c943(0x341);}function _0x5b7e(){const _0x1ad39f=['SQjQn','Misbranded\x20drug','OixIE','performanceModal','Vhcsd','WgRRc','<p><strong>Dipivefrine\x20</strong>and<strong>\x20dopexamine\x20</strong>are&nbsp;&beta;<sub>2</sub>-adrenergic\x20receptor\x20agonists.</p>\x0a<p><strong>Dipivefrine</strong>\x20causes\x20a\x20decrease\x20in\x20aqueous\x20production\x20and\x20increases\x20outflow.\x20It\x20was\x20used\x20in\x20the\x20treatment\x20of<strong>\x20open-angle\x20glaucoma</strong>\x20and<strong>\x20ocular\x20hypertension</strong>&nbsp;but\x20has\x20since\x20been\x20replaced.</p>\x0a<p><strong>Dopexamine</strong>\x20is\x20a\x20synthetic\x20analogue\x20related\x20to\x20dopamine\x20with\x20activity\x20at\x20<strong>D1\x20</strong>and\x20<strong>D2</strong>\x20receptors\x20as\x20well\x20as\x20at\x20<strong>&beta;2\x20receptors</strong>.\x20It\x20is\x20used\x20in\x20patients\x20with\x20severe\x20congestive\x20heart\x20failure,\x20sepsis,\x20and\x20shock.</p>\x0a<p>Other\x20options:</p>\x0a<p>B.\x20<strong>Fenoldopam</strong>\x20is\x20a\x20peripheral\x20<strong>D1\x20agonist</strong>\x20with\x20moderate\x20affinity\x20for\x20<strong>&alpha;2-adrenergic\x20receptors</strong>.\x20It\x20is\x20a\x20rapidly\x20acting\x20<strong>vasodilator</strong>\x20that\x20is\x20used\x20in\x20<strong>severe\x20hypertension.</strong></p>\x0a<p>D.\x20<strong>Mirabegron</strong>\x20is\x20a\x20<strong>&beta;3-adrenergic\x20receptor\x20agonist</strong>\x20which\x20is\x20used\x20for\x20<strong>bladder\x20incontinence</strong>.\x20Activation\x20of\x20this\x20receptor\x20in\x20the\x20bladder\x20leads\x20to\x20detrusor\x20muscle\x20relaxation\x20and\x20increased\x20bladder\x20capacity.\x20This\x20action\x20prevents\x20voiding\x20and\x20provides\x20relief\x20for\x20those\x20with\x20an\x20overactive\x20bladder\x20and\x20urinary\x20incontinence.&nbsp;&nbsp;</p>','xbCkp','HtccU','get','EdTMV','Drug\x20A\x20&\x20drug\x20B\x20are\x20agonists.','yFcDB','WkkvW','mNemR','length','style','fill','They\x20can\x20be\x20given\x20with\x20verapamil\x20and\x20other\x20enzyme\x20inhibitors.','Ethambutol','qLTAJ','bookmarkedQuestions','incorrect','A\x20-\x20Aspirin,\x20B\x20-\x20Eptifibatide,\x20C\x20-\x20Prasugrel','</div>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<div\x20class=\x22bg-green-900\x20bg-opacity-20\x20p-4\x20rounded-lg\x20border\x20border-green-700\x22>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<h5\x20class=\x22text-green-400\x20font-bold\x20mb-2\x22>Explanation:</h5>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<div\x20class=\x22text-white\x20text-opacity-90\x22>','avgTimeResult','exUdr','not_attempted','YtZwy','OYosY','<p>Drugs\x20that\x20carry\x20a\x20risk\x20of\x20clinical\x20hemolysis\x20in\x20persons\x20with\x20G6PD\x20deficiency:</p>\x0a<table\x20style=\x22width:\x20494px;\x20height:\x20420px;\x22>\x0a<tbody>\x0a<tr\x20style=\x22height:\x2053px;\x22>\x0a<td\x20style=\x22width:\x20159.36142px;\x20height:\x2053px;\x22>\x0a<p><strong>CLASS</strong></p>\x0a</td>\x0a<td\x20style=\x22width:\x20319.470123px;\x20height:\x2053px;\x22>\x0a<p><strong>DRUGS</strong></p>\x0a</td>\x0a</tr>\x0a<tr\x20style=\x22height:\x2054px;\x22>\x0a<td\x20style=\x22width:\x20159.36142px;\x20height:\x2054px;\x22>\x0a<p>Antimalarials</p>\x0a</td>\x0a<td\x20style=\x22width:\x20319.470123px;\x20height:\x2054px;\x22>\x0a<p><strong>Primaquine\x20&gt;&nbsp;</strong><strong>Chloroquine</strong></p>\x0a<p>Dapsone/chlorproguanil</p>\x0a</td>\x0a</tr>\x0a<tr\x20style=\x22height:\x2055px;\x22>\x0a<td\x20style=\x22width:\x20159.36142px;\x20height:\x2055px;\x22>\x0a<p>Sulphonamides/sulphones</p>\x0a</td>\x0a<td\x20style=\x22width:\x20319.470123px;\x20height:\x2055px;\x22>\x0a<p><strong>Sulfamethoxazole</strong></p>\x0a<p>Sulfasalazine,\x20Sulfisoxazole</p>\x0a</td>\x0a</tr>\x0a<tr\x20style=\x22height:\x2020px;\x22>\x0a<td\x20style=\x22width:\x20159.36142px;\x20height:\x2020px;\x22>\x0a<p>Antibacterial/antibiotics</p>\x0a</td>\x0a<td\x20style=\x22width:\x20319.470123px;\x20height:\x2020px;\x22>\x0a<p><strong>Cotrimoxazole,&nbsp;</strong>Ciprofloxacin,\x20Chloramphenicol,\x20Nalidixic\x20acid,\x20Norfloxacin,&nbsp;<strong>Nitrofurantoin</strong></p>\x0a</td>\x0a</tr>\x0a<tr\x20style=\x22height:\x2016px;\x22>\x0a<td\x20style=\x22width:\x20159.36142px;\x20height:\x2016px;\x22>\x0a<p>Others</p>\x0a</td>\x0a<td\x20style=\x22width:\x20319.470123px;\x20height:\x2016px;\x22>\x0a<p>Naphthalene,\x20Rasburicase&nbsp;</p>\x0a<p><strong>Methylene\x20blue</strong></p>\x0a<p>&nbsp;</p>\x0a</td>\x0a</tr>\x0a</tbody>\x0a</table>','question_audio','jHJoN','timed_study','Enfuvirtide','https://dhmbxeygs57ff.cloudfront.net/uploads/004ea54ec8dd43dab6444638a0d26247x1184x1162.PNG','disabled','hwLqn','</span></div>','YpnBV','PZfWe','wJmOa','ncqfN','\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20</div>','kWVrS','https://dhmbxeygs57ff.cloudfront.net/uploads/644ef3e20c3a40cd848cbccfa38d4188x1280x1006.JPEG','Pembrolizumab','toLowerCase','uZWPH','The\x20image\x20below\x20shows\x20the\x20life\x20cycle\x20of\x20a\x20virus.\x20Which\x20of\x20the\x20following\x20drugs\x20acts\x20at\x20step\x205?','bqDCf','back','bkprQ','history','An\x20anti-arrhythmic\x20drug\x20is\x20shown\x20to\x20have\x20the\x20following\x20effect.\x20It\x20is\x20effective\x20in\x20both\x20atrial\x20and\x20ventricular\x20arrhythmias.\x20Identify\x20the\x20drug.','Match\x20the\x20following\x20drugs\x20with\x20the\x20targets\x20of\x20their\x20actions.','wCHBY','The\x20given\x20diagram\x20shows\x20the\x20steps\x20in\x20bacterial\x20cell\x20wall\x20formation.\x20Identify\x20the\x20site\x20of\x20action\x20of\x20beta-lactam\x20antibiotics.','UjWfN','strokeDasharray','MRjwy','Pyrazinamide','pWMqA','table','Urinary\x20alkalinization\x20will\x20be\x20most\x20useful\x20in\x20toxicity\x20of\x20which\x20of\x20the\x20following\x20drugs?','Finasteride\x20is\x20used\x20to\x20treat\x20male-pattern\x20baldness\x20acts\x20by\x20inhibiting\x20which\x20of\x20the\x20following\x20enzymes?','faUaV','pgyaM','Metoprolol','WjhNw','strokeDashoffset','HhcZM','CfFhy','uGjGI','Inj.\x20Amphotericin\x20B\x204-8\x20weeks,\x20followed\x20by\x20oral\x20itraconazole','LEAoo','4\x20-\x20hydroxy\x20cyclophosphamide','Amlodipine','BzPDm','MIglu','round','sqZNX','Juyii','Which\x20among\x20the\x20following\x20is\x20the\x20false\x20statement\x20regarding\x20statins?','Jipkw','<div\x20class=\x22glass-light\x20p-4\x20mb-4\x22><img\x20src=\x22','JsqyP','findIndex','min','cuVCJ','oyHaI','<p><strong>Atorvastatin\x2080\x20mg</strong>\x20can\x20be\x20used\x20to\x20treat\x20this\x20condition.&nbsp;The\x20first\x20line\x20of\x20therapy\x20in\x20controlling\x20cholesterol\x20in\x20patients\x20with\x20atherosclerotic\x20cardiovascular\x20disease\x20(ASCVD)\x20is\x20starting\x20a\x20high-intensity\x20statin.\x20<strong>High-intensity\x20statins</strong>\x20include\x20<strong>atorvastatin</strong>\x20(40-80\x20mg)\x20and\x20<strong>rosuvastatin\x20</strong>(20-40\x20mg)<strong>.</strong></p>\x0a<p>Statins\x20are\x20<strong>competitive\x20inhibitors</strong>\x20of\x20<strong>HMG-CoA\x20reductase</strong>.\x20This\x20leads\x20to\x20a\x20decrease\x20in\x20cholesterol\x20biosynthesis.\x20Statins\x20are\x20also\x20effective\x20in\x20reducing\x20LDL\x20and\x20triglyceride\x20levels.&nbsp;</p>\x0a<p>Other\x20options:&nbsp;</p>\x0a<p>Option\x20A.\x20<strong>Fenofibrate</strong>\x20reduces\x20lipoprotein\x20levels\x20by\x20interacting\x20with\x20Peroxisome\x20proliferator-activated\x20receptor\x20(PPAR-&alpha;)\x20and\x20stimulating\x20<strong>lipoprotein\x20lipase</strong>.\x20They\x20are\x20used\x20as\x20drugs\x20of\x20choice\x20for\x20treating\x20hyperlipoproteinemia\x20and\x20severe\x20hypertriglyceridemia\x20(&gt;1000\x20mg/dL).</p>\x0a<p>Option\x20B.\x20<strong>Rosuvastatin\x20and\x20fenofibrate</strong>\x20combination\x20was\x20previously\x20used\x20to\x20reduce\x20atherosclerotic\x20cardiovascular\x20disease\x20risk.\x20But\x20recent\x20studies\x20have\x20indicated\x20no\x20change\x20in\x20reduction\x20and\x20hence\x20is\x20<strong>not\x20recommended\x20anymore</strong>.&nbsp;</p>\x0a<p>Option\x20C:\x20<strong>Rosuvastatin\x2010\x20mg</strong>\x20is\x20a<strong>\x20low-intensity\x20statin</strong>\x20and\x20is\x20mainly\x20used\x20for\x20<strong>primary\x20prevention</strong>\x20against\x20atherosclerotic\x20cardiovascular\x20disease.</p>','Bookmarked','HxtQa','vPiHl','Can\x20be\x20stopped\x20and\x20conceived\x20soon\x20after\x20stopping','Drug\x203\x20represents\x20agonist\x20and\x20drug\x204\x20represents\x20inverse\x20agonist','aXiyO','1202343rVQJWV','WYxsi','ifaOl','apply','__proto__','\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20','Propranolol','Choose\x20the\x20correctly\x20matched\x20pairs\x20regarding\x20the\x20drugs\x20used\x20in\x20schizophrenia:','<p>The\x20drug\x20that\x20increases\x20trabecular\x20outflow\x20is\x20<strong>netarsudil</strong>.</p>\x0a<p>Netarsudil\x20is\x20a\x20<strong>rho-kinase\x20inhibitor</strong>\x20used\x20in\x20the\x20treatment\x20and\x20management\x20of\x20<strong>glaucoma</strong>\x20and\x20ocular\x20hypertension.\x20It\x20lowers\x20the\x20intra-ocular\x20pressure\x20directly\x20through\x20the\x20relaxation\x20of\x20the\x20<strong>trabecular\x20meshwork</strong>,\x20leading\x20to\x20an\x20<strong>increase</strong>\x20in\x20<strong>aqueous\x20outflow</strong>.\x20It\x20also\x20reduces\x20aqueous\x20humor\x20production.&nbsp;</p>\x0a<p>Netarsudil\x20ophthalmic\x20solution\x20is\x20instilled\x20in\x20<strong>one\x20drop</strong>\x20into\x20the\x20affected\x20eye\x20once\x20daily\x20in\x20the\x20<strong>evening</strong>.\x20Adverse\x20effects\x20are\x20conjunctival\x20hyperemia,\x20and\x20<strong>corneal\x20verticillata</strong>.</p>\x0a<p>Other\x20options:</p>\x0a<p>Option\x20A-\x20Timolol\x20is\x20a\x20<strong>non-selective&nbsp;&beta;-blocker</strong>\x20that\x20decreases\x20the\x20IOP\x20by\x20<strong>reducing</strong>\x20the\x20<strong>aqueous\x20humor\x20production</strong>\x20through\x20the\x20blockade\x20of\x20the&nbsp;<strong>&beta;-receptors</strong>\x20on\x20the\x20<strong>ciliary\x20epithelium.\x20</strong>Ocular\x20adverse\x20effects\x20are\x20allergy,\x20decreased\x20corneal\x20sensation,\x20and\x20<strong>punctate\x20keratitis.</strong></p>\x0a<p>Option\x20C-&nbsp;<strong>Brimonidine</strong>&nbsp;is\x20a\x20<strong>selective\x20alpha-2</strong>\x20<strong>agonist&nbsp;</strong>which\x20decreases\x20aqueous\x20synthesis\x20and\x20increases\x20<strong>uveoscleral\x20outflow</strong>.\x20It\x20can\x20cross\x20the\x20blood-brain\x20barrier\x20and,\x20hence,\x20causes\x20<strong>drowsiness\x20and\x20CNS\x20depression</strong>.\x20It\x20is&nbsp;<strong>contraindicated</strong>\x20in\x20<strong>infants</strong>\x20and\x20<strong>children</strong>.</p>\x0a<p>Option\x20D-\x20<strong>Acetazolamide</strong>\x20is\x20a\x20topical\x20<strong>carbonic\x20anhydrase\x20inhibitor</strong>\x20that\x20decreases\x20IOP\x20by\x20reducing\x20<strong>aqueous\x20formation</strong>.\x20The\x20main\x20adverse\x20effect\x20is\x20the\x20<strong>bitter\x20taste</strong>\x20following\x20administration.\x20It\x20is\x20<strong>contraindicated</strong>\x20in\x20people\x20with\x20allergies\x20to\x20sulfonamide\x20antibiotics.&nbsp;</p>','Unethical\x20drug','wFxQB','iZYhh','Losartan','<p>The\x20most\x20likely\x20drug\x20causing\x20hyperpigmentation\x20of\x20the\x20hands\x20and\x20soles\x20would\x20be\x20<strong>emtricitabine.&nbsp;</strong></p>\x0a<p>Emtricitabine\x20is\x20an\x20anti-retroviral\x20drug\x20that\x20acts\x20by\x20<strong>inhibiting\x20nucleoside\x20reverse\x20transcriptase</strong>\x20(<strong>NRTI</strong>).\x20It\x20is\x20well-tolerated\x20and\x20has\x20minimal\x20toxic\x20effects.\x20Adverse\x20effects\x20include\x20<strong>hyperpigmentation</strong>\x20of<strong>&nbsp;</strong>the\x20<strong>skin</strong>\x20(especially\x20sun-exposed\x20areas,\x20palms,\x20and\x20soles),\x20headache,\x20vomiting,\x20and\x20nausea.</p>\x0a<p>Other\x20options:</p>\x0a<p>Option\x20A:\x20Nelfinavir\x20is\x20a\x20protease\x20inhibitor\x20that\x20causes\x20<strong>diarrhea</strong>\x20or\x20loose\x20stools.\x20It\x20usually\x20<strong>resolves\x20within\x20a\x20month</strong>\x20of\x20starting\x20the\x20drug.&nbsp;</p>\x0a<p>Option\x20C:\x20Abacavir\x20is\x20an\x20NRTI\x20that\x20can\x20cause\x20a\x20life-threatening\x20hypersensitivity\x20syndrome.\x20The\x20syndrome\x20presents\x20with\x20<strong>fever,\x20abdominal\x20pain,</strong>\x20and&nbsp;<strong>maculopapular\x20rash</strong>&nbsp;<strong>within\x206\x20weeks</strong>\x20of\x20initiating\x20abacavir.\x20The\x20drug\x20must\x20be\x20immediately\x20discontinued\x20and\x20must\x20not\x20be\x20administered\x20to\x20the\x20patient\x20thereafter.\x20Rarely,\x20there\x20might\x20be\x20respiratory\x20and\x20musculoskeletal\x20side\x20effects.&nbsp;</p>\x0a<p>Option\x20D:\x20Zidovudine\x20is\x20an\x20NRTI\x20that\x20causes\x20malaise,\x20fatigue,\x20myalgia,\x20anorexia,\x20and\x20insomnia.\x20Chronic\x20use\x20leads\x20to\x20<strong>nail\x20hyperpigmentation</strong>.\x20It\x20can\x20also\x20cause\x20bone\x20marrow\x20suppression.</p>','<p>Option\x20C:&nbsp;<strong>Oxcarbazepine\x20</strong>was\x20earlier\x20associated\x20with\x20teratogenicity\x20and\x20fetal\x20malformations,\x20however,\x20recent\x20studies\x20suggest\x20that\x20oxcarbazepine\x20monotherapy\x20during\x20pregnancy\x20does\x20not\x20carry\x20a\x20significant\x20risk\x20of\x20fetal\x20malformations.</p>\x0a<p>Option\x20D:&nbsp;<strong>Olanzapine</strong>&nbsp;is\x20an\x20antipsychotic\x20and\x20an\x20antimanic\x20and\x20it\x20is\x20not\x20associated\x20with&nbsp;teratogenicity.&nbsp;</p>','amnLh','DRMcW','Raltegravir','correctCount','Prazosin','WcjMO','zoMCu','A-2,\x20B-3,\x20C-1,\x20D-4','Abacavir','Which\x20of\x20the\x20following\x20drugs\x20increases\x20trabecular\x20outflow?','XcbSQ','cPgOK','WxmLc','nuLjK','ndwJC','UnQht','eKTSv','https://cdn1.dailyrounds.org/uploads/b742dd38b7fe4bfb8634f08f18183953.JPEG','Which\x20among\x20the\x20following\x20drugs\x20is\x20the\x20new\x20FDA\x20approved\x20immune\x20check\x20point\x20inhibitor\x20for\x20carcinoma\x20endometrium?','GItAJ','<p><strong>Phospholipase\x20C</strong>\x20acts\x20via\x20the&nbsp;<strong>Gq</strong>\x20type\x20of\x20G\x20protein-coupled\x20receptors.</p>\x0a<p><strong>G\x20protein-coupled\x20receptors</strong>\x20(GPCRs)\x20are<strong>&nbsp;cell\x20membrane\x20receptors</strong>&nbsp;that\x20span\x20across\x20the\x20membrane\x207\x20times.\x20They\x20also\x20serve\x20as\x20receptors\x20for\x20various\x20<strong>peptide\x20hormones</strong>,\x20neurotransmitters,\x20amino\x20acids,\x20etc.</p>\x0a<p>Subtypes\x20of\x20GPCRs\x20are\x20distinguished\x20by\x20their\x20alpha\x20subunits.\x20The\x20important\x20subtypes\x20of\x20GPCRs\x20are\x20Gs,\x20Gp,\x20<strong>Gq</strong>,\x20and\x20Go.</p>\x0a<p>GPCRs\x20act\x20via\x20various\x20second\x20messengers.&nbsp;The\x20important\x20ones\x20with\x20their\x20action\x20on\x20the\x20effector\x20are:</p>\x0a<ul>\x0a<li>Gs\x20causes\x20activation\x20of\x20adenylyl\x20cyclase\x20and\x20results\x20in\x20Ca2+\x20channel\x20opening.</li>\x0a<li>Gi\x20causes\x20inhibition\x20of\x20adenylyl\x20cyclase\x20and\x20results\x20in\x20K+\x20channel\x20opening.</li>\x0a<li>Go\x20causes\x20Ca2+\x20channel\x20inhibition.</li>\x0a<li><strong>Gq</strong>\x20causes\x20activation\x20of\x20<strong>p</strong><strong>hospholipase\x20C</strong>&nbsp;which\x20generates\x20the\x20second\x20messengers\x20inositol\x201,4,5-trisphosphate\x20(<strong>IP3</strong>)\x20and\x20diacylglycerol\x20(<strong>DAG</strong>).\x20The&nbsp;water-soluble\x20IP3\x20diffuses\x20to\x20the\x20cytosol\x20and\x20mobilizes\x20<strong>Ca2+</strong>\x20from\x20endoplasmic\x20reticular\x20depots.</li>\x0a</ul>\x0a<p>The\x20given\x20below\x20image\x20shows\x20the\x20effects\x20of\x20phospholipase\x20C\x20after\x20activation\x20by\x20<strong>Gq</strong></p>','FgVol','Tgorx','reviewQuestionsContainer','getElementById','ZuBmJ','A\x20young\x20boy\x20with\x20a\x20history\x20of\x20multiple\x20blood\x20transfusions\x20presents\x20with\x20bone\x20pain\x20for\x20the\x20past\x206\x20months.\x20\x20A\x20peripheral\x20smear\x20showed\x20sickle-shaped\x20RBCs.\x20Which\x20of\x20the\x20following\x20drugs\x20are\x20not\x20used\x20in\x20the\x20treatment\x20of\x20his\x20condition?','BeLGd','accuracyScore','KBoZd','Oxazepam','Inj.\x20Amphotericin\x20\x20B\x208\x20weeks,\x20followed\x20by\x20oral\x20posaconazole','questionIndex','LOskZ','rWIek','QlDLb','target','floor','iXanl','\x22\x20class=\x22w-full\x20rounded-lg\x22\x20controls></video></div>','wPuMV','QydSO','<p>The\x20correct\x20match\x20is\x20as\x20follows:</p>\x0a<table\x20style=\x22height:\x20115px;\x22\x20width=\x22348\x22>\x0a<tbody>\x0a<tr>\x0a<td\x20style=\x22width:\x20166.3px;\x22>Column\x20A</td>\x0a<td\x20style=\x22width:\x20166.3px;\x22>Column\x20B</td>\x0a</tr>\x0a<tr>\x0a<td\x20style=\x22width:\x20166.3px;\x22>A.\x20Acetazolamide</td>\x0a<td\x20style=\x22width:\x20166.3px;\x22>4.\x20Proximal\x20convoluted\x20tubule</td>\x0a</tr>\x0a<tr>\x0a<td\x20style=\x22width:\x20166.3px;\x22>B.\x20Torsemide</td>\x0a<td\x20style=\x22width:\x20166.3px;\x22>1.\x20Thick\x20ascending\x20loop\x20of\x20Henle</td>\x0a</tr>\x0a<tr>\x0a<td\x20style=\x22width:\x20166.3px;\x22>C.\x20Chlorthalidone</td>\x0a<td\x20style=\x22width:\x20166.3px;\x22>3.\x20Distal\x20convoluted\x20tubule</td>\x0a</tr>\x0a<tr>\x0a<td\x20style=\x22width:\x20166.3px;\x22>D.\x20Vasopressin</td>\x0a<td\x20style=\x22width:\x20166.3px;\x22>2.\x20Collecting\x20duct</td>\x0a</tr>\x0a</tbody>\x0a</table>\x0a<p>&nbsp;</p>\x0a<p><strong>Acetazolamide,</strong>\x20a\x20<strong>carbonic\x20anhydrase\x20inhibitor,</strong>\x20acts\x20on\x20the\x20enzyme\x20in\x20epithelial\x20cells\x20of\x20the\x20<strong>proximal\x20convoluted\x20tubule.</strong>\x20Acetazolamide\x20is\x20mainly\x20used\x20in\x20patients\x20with\x20secondary\x20glaucoma\x20to\x20reduce\x20intra-ocular\x20pressure,\x20provide\x20symptomatic\x20relief\x20in\x20acute\x20mountain\x20sickness,\x20and\x20as\x20treatment\x20for\x20absence\x20seizures.</p>\x0a<p><strong>Torsemide,</strong>\x20a\x20loop\x20diuretic,\x20inhibits\x20the\x20Na<sup>+</sup>-K<sup>+</sup>-ATPase\x20symporter\x20in\x20the\x20<strong>thick\x20ascending\x20loop\x20of\x20Henle.</strong>&nbsp;It\x20is\x20used\x20in\x20<strong>acute\x20pulmonary\x20edema,</strong>\x20edema\x20associated\x20with\x20<strong>congestive\x20cardiac\x20failure,\x20hypertension</strong>\x20with\x20renal\x20insufficiency,\x20and\x20hyponatremia.</p>\x0a<p><strong>Chlorthalidone</strong>,\x20a\x20thiazide-like\x20diuretic,\x20inhibits\x20the<strong>\x20Na<sup>+</sup>-Cl<sup>-</sup>\x20symporter</strong>\x20in\x20the\x20<strong>distal\x20convoluted\x20tubule</strong>.\x20It\x20is\x20used\x20in&nbsp;<strong>hypertension\x20and</strong>&nbsp;in&nbsp;<strong>edema</strong>\x20associated\x20with\x20<strong>congestive\x20cardiac\x20failure,\x20hepatic\x20cirrhosis,</strong>\x20nephrotic\x20syndrome,\x20and\x20<strong>chronic\x20renal\x20failure</strong><strong>.</strong></p>\x0a<p><strong>Vasopressin</strong>,\x20also\x20known\x20as\x20<strong>anti-diuretic\x20hormone</strong>,\x20is\x20secreted\x20by\x20the\x20<strong>posterior\x20pituitary</strong>\x20and\x20mainly\x20acts\x20on\x20the\x20<strong>collecting\x20duct,</strong>\x20and\x20increases\x20the\x20<strong>reabsorption\x20of\x20water</strong>\x20(anti-diuresis).\x20Vasopressin\x20or\x20its\x20agonists\x20(such\x20as\x20desmopressin)\x20are\x20used\x20in\x20cases\x20of\x20<strong>diabetes\x20insipidus</strong>,\x20<strong>type\x20I\x20and\x20type\x20II\x20von\x20Willebrand\x27s\x20disease</strong>,\x20primary\x20nocturnal\x20enuresis,\x20and\x20postoperative\x20ileus.</p>','fMBHn','1roNAdA','vOXrj','70\x20hours','Drug\x20C\x20is\x20a\x20non-competitive\x20antagonist.','border-red-500','mKNlS','FflMD','pzTGl','pHdft','Alprazolam','kUaaT','SQZZv','<div\x20class=\x22mt-4\x22><video\x20id=\x22review-video-','CrBit','VIXZm','SjwGD','explanationVideoPlayer','<p>New\x20drug\x20application\x20is\x20filed\x20after<strong>\x20phase\x203\x20</strong>of\x20clinical\x20trials.</p>\x0a<p>Other\x20options:</p>\x0a<p>Option\x20A:&nbsp;<strong>Phase\x204</strong>\x20clinical\x20trials\x20are\x20also\x20called\x20<strong>post-marketing\x20surveillance.</strong></p>\x0a<p>Option\x20C:&nbsp;<strong>Phase\x202</strong>\x20trials\x20are\x20the\x20first\x20round\x20of\x20trials\x20in\x20<strong>patients</strong>.</p>\x0a<p>Option\x20D:&nbsp;<strong>Phase\x201</strong>\x20trials\x20are\x20done\x20in\x20<strong>healthy</strong>\x20volunteers.</p>','spgnJ','bZsnn','mWxSu','1,\x202,\x203','ekAtW','Potentiation\x20of\x20acetylcholine','XxDxU','leRki','IYEmi','https://dhmbxeygs57ff.cloudfront.net/uploads/4dc646e0a7344b62b2f3ad958aed8038x1279x914.JPEG','WYWzr','UfPgp','JQraY','BXFKk','https://dhmbxeygs57ff.cloudfront.net/uploads/796e4a43627f4b17b0530b4e3b118f9ex1280x2080.JPEG','click','Incorrect','Phase\x204','lmMfp','Rosuvastatin\x2010\x20mg','Mydriasis','Efficacy\x20of\x20drug\x20A\x20is\x20more\x20than\x20that\x20of\x20drug\x20B.','navBtn_','https://dhmbxeygs57ff.cloudfront.net/uploads/290d9cdbaa444b8590f4728bb58ece8fx1280x647.PNG','XRwcY','zLFuU','correctAnswers','EaNkg','YGNea','rgHrX','YUNwm','Lmapq','OLAqC','Ipilimumab','Hypotension','GXYaH','Match\x20the\x20following\x20diuretics\x20in\x20column\x20A\x20to\x20their\x20site\x20of\x20action\x20in\x20column\x20B.','USAVC','<p>Finasteride\x20is\x20used\x20to\x20treat\x20male\x20pattern\x20baldness\x20acts\x20by\x20inhibiting&nbsp;<strong>5-alpha\x20reductase.</strong></p>\x0a<p>Finasteride&nbsp;is\x20a\x20competitive\x20inhibitor\x20of\x20the&nbsp;5-alpha-reductase\x20enzyme\x20that<strong>\x20inhibits\x20the\x20conversion</strong>\x20of\x20<strong>testosterone</strong>\x20into\x20its\x20active\x20form\x20<strong>dihydrotestosterone</strong>\x20(DHT).&nbsp;</p>\x0a<p>Finasteride\x20inhibits\x20<strong>type\x202\x205-alpha\x20reductase</strong>\x20within\x20the\x20hair\x20follicle\x20and\x20reduces\x20the\x20production\x20of\x20DHT.\x20Hence,\x20it\x20is\x20used\x20in\x20the\x20treatment\x20of\x20male\x20pattern\x20hair\x20loss.\x20But,&nbsp;<strong>new\x20hair\x20growth\x20will\x20be\x20lost</strong>\x20when\x20finasteride\x20is\x20discontinued,\x20similar\x20to\x20minoxidil.</p>\x0a<p>On\x20long-term\x20use\x20(nearly\x206\x20months),\x20it\x20produces\x20an\x20effect\x20by\x20<strong>reducing\x20prostatic\x20epithelial\x20cell\x20proliferation,&nbsp;</strong>thereby\x20reducing\x20the\x20size\x20of\x20the\x20prostate\x20and\x20improving\x20urine\x20flow.</p>\x0a<p>Adverse\x20effects\x20of\x20finasteride:</p>\x0a<ul>\x0a<li>Decreased\x20libido</li>\x0a<li>Erectile\x20dysfunction</li>\x0a<li>Ejaculation\x20disorder\x20and\x20decreased\x20ejaculate\x20volume</li>\x0a</ul>\x0a<p>Finasteride&nbsp;is\x20<strong>highly\x20teratogenic</strong>\x20and<strong>\x20pregnant\x20women</strong>\x20should\x20not\x20be\x20exposed\x20to\x20the\x20drug\x20because\x20of\x20the\x20<strong>potential\x20for\x20inducing\x20genital\x20abnormalities\x20in\x20male\x20fetuses.</strong></p>','</span><span>','https://dhmbxeygs57ff.cloudfront.net/uploads/1fed3123012943dd8852893c0cf05c83x1279x914.JPEG','BLweU','bind','KXzmf','opgwf','IiqPy','sRHxx','Blockage\x20of\x20voltage-gated\x20calcium\x20channels','question_images','vOrwc','totalTime','A\x20young\x20man\x20sustained\x20a\x20scorpion\x20sting\x202\x20hours\x20ago.\x20On\x20examination,\x20his\x20blood\x20pressure\x20is\x20108/\x2060\x20mm\x20Hg;\x20HR,\x2072\x20beats/minute,\x20and\x20respiratory\x20rate,\x2032\x20breaths/minute.\x20He\x20also\x20complains\x20of\x20breathlessness.\x20How\x20do\x20you\x20manage\x20this\x20patient?','Zbhti','exception','It\x20cannot\x20be\x20reversed\x20by\x20levallorphan.','https://cdn1.dailyrounds.org/uploads/ebe55c0cc99a42b383d1f16c8023a2ff.JPEG','Which\x20of\x20the\x20following\x20drugs\x20is\x20a\x20β2\x20agonist?','UmRff','wsZTK','922727MAOHfP','YwBfC','https://dhmbxeygs57ff.cloudfront.net/uploads/c7d2d20a09874772b14772066b893f24x720x542.JPEG','You\x20have\x20reached\x20the\x20end\x20of\x20the\x20quiz.\x20Would\x20you\x20like\x20to\x20submit\x20your\x20answers\x20now?','JXVyF','nAqhv','Synthesized\x20from\x20arachidonic\x20acid','hcgWB','Identify\x20the\x20drugs\x20marked\x20as\x20A,\x20B,\x20and\x20C.','Rituximab\x20is\x20a:','canPlayType','https://dhmbxeygs57ff.cloudfront.net/uploads/8d7167c153aa42a5bdc0787fd454473ex1280x1252.JPEG','GBGhS','geSJm','NBmWj','A\x20patient\x20presented\x20with\x20a\x20lesion,\x20as\x20shown\x20in\x20the\x20image\x20below.\x20She\x20is\x20an\x20immunocompromised\x20patient\x20currently\x20on\x20HAART.\x20What\x20are\x20the\x20systemic\x20antifungal\x20drugs\x20that\x20can\x20be\x20added\x20along\x20with\x20the\x20HAART\x20in\x20this\x20patient?','VJaiQ','Aromatase','pathname','Beta\x20blockers','KNqyZ','\x22\x20alt=\x22Question\x20Image\x22\x20class=\x22w-full\x20rounded-lg\x22></div>','<div\x20class=\x22mt-2\x22><p\x20class=\x22text-sm\x20text-white\x20text-opacity-70\x20mb-1\x22>Hinglish:</p><audio\x20src=\x22','Adulterated\x20drug','Rash','dliei','explanation_video','warn','keydown','YVnuO','question_video','wEIry','A,C,D','explanation_audio_hin','<p>In\x20a\x20post-mastectomy\x20patient\x20undergoing\x20therapy\x20with\x20<strong>tamoxifen</strong>,\x20it\x20should\x20be\x20<strong>stopped</strong>\x20<strong>for</strong>\x20<strong>3\x20months</strong>\x20before\x20she\x20can\x20<strong>conceive</strong>.</p>\x0a<p><strong>Tamoxifen</strong>&nbsp;is\x20a\x20selective\x20estrogen\x20receptor\x20modulator&nbsp;<strong>(SERM)</strong>&nbsp;and\x20is\x20used\x20as\x20a\x20chemotherapeutic\x20agent\x20in&nbsp;<strong>receptor\x20positive\x20breast\x20cancer&nbsp;</strong>patients\x20to\x20prevent\x20recurrence\x20after\x20surgery.\x20It\x20is\x20the\x20drug\x20of\x20choice\x20in&nbsp;<strong>pre-menopausal\x20women.</strong>&nbsp;It\x20has\x20an\x20agonistic\x20action\x20on\x20the\x20endometrium,\x20leading\x20to\x20an&nbsp;<strong>increased\x20risk</strong>&nbsp;of&nbsp;<strong>endometrial\x20cancers</strong>\x20(2\x20fold\x20risk)<strong>.</strong>&nbsp;Hence,\x20it\x20is\x20not\x20used\x20in\x20post-menopausal\x20women.</p>\x0a<p>It\x20is\x20<strong>contraindicated</strong>\x20in\x20<strong>pregnancy</strong>\x20due\x20to\x20teratogenic\x20effects\x20such\x20as\x20<strong>craniofacial\x20abnormalities&nbsp;</strong>and\x20reproductive\x20tract\x20abnormalities.\x20For\x20the\x20same\x20reason,\x20it\x20has\x20to\x20be\x20stopped\x20for\x20<strong>3\x20months</strong>\x20(due\x20to\x20long\x20half-life)\x20prior\x20to\x20<strong>conceiving</strong>.&nbsp;It\x20is\x20also\x20stopped\x20during\x20lactation\x20as\x20it\x20is\x20secreted\x20in\x20breast\x20milk.\x20Other\x20complications\x20of\x20tamoxifen\x20include\x20deep\x20vein\x20thrombosis,\x20pulmonary\x20embolism,\x20and\x20hot\x20flashes.</p>\x0a<p><strong>Other\x20breast\x20cancer\x20risk\x20reduction\x20techniques:</strong></p>\x0a<ol>\x0a<li\x20aria-level=\x221\x22><strong>Lifestyle\x20modification:</strong>&nbsp;Low-calorie\x20diet,\x20daily\x20exercise,\x20no\x20smoking,\x20no\x20drinking,\x20etc.</li>\x0a<li\x20aria-level=\x221\x22>More&nbsp;<strong>frequent\x20screening</strong>&nbsp;with\x20mammogram\x20+/-\x20MRI</li>\x0a<li\x20aria-level=\x221\x22>Chemoprevention<strong>:</strong>&nbsp;Preferred\x20in\x20women\x20&gt;35\x20years\x20of\x20age\x20in\x20patients\x20who\x20are\x20ER/PR\x20positive.\x20Given\x20for\x205-10\x20years.</li>\x0a<ul>\x0a<li\x20aria-level=\x222\x22><strong>SERMS</strong>&nbsp;(selective\x20estrogen\x20receptor\x20modulators)\x20-\x20Tamoxifen\x20and\x20raloxifene.\x20These\x20have\x20adverse\x20effects.&nbsp;</li>\x0a<li\x20aria-level=\x222\x22><strong>Aromatase\x20Inhibitors</strong>&nbsp;(AIs):\x20They\x20are\x20used\x20only\x20in\x20<strong>post-menopausal\x20women.</strong></li>\x0a</ul>\x0a<li\x20aria-level=\x221\x22><strong>Risk-reduction\x20surgeries:</strong>&nbsp;preferred\x20in\x20patients\x20with&nbsp;<strong>BRCA1/2</strong>&nbsp;mutations&nbsp;or\x20patients\x20with\x20first-degree\x20relatives\x20with\x20breast\x20cancers.\x20Provides\x20&gt;90%\x20risk-reduction.\x20preferred\x20in\x20patients\x20who\x20have\x20completed\x20their\x20family.</li>\x0a<ul>\x0a<li\x20aria-level=\x222\x22><strong>Bilateral\x20mastectomy</strong></li>\x0a<li\x20aria-level=\x222\x22><strong>Salpingo-oophorectomy:</strong>&nbsp;Best\x20results\x20when\x20done\x20&lt;\x2040\x20years\x20of\x20age.</li>\x0a</ul>\x0a</ol>','eqtDk','notAttemptedResult','Bldoz','dEmDV','VVplc','Primaquine','\x22\x20controls\x20class=\x22w-full\x20rounded-lg\x22></video></div>','attachMedia','bxJNr','1,\x204','Binds\x20to\x20deoxycholic\x20acid','choices','map','Drug\x20\x201\x20represents\x20agonist\x20and\x20drug\x204\x20represents\x20inverse\x20agonist','ikPpx','nav-btn-bookmarked','iEuVy','1-d,\x202-c,\x203-b,\x204-a','NQhNv','name','BUMnK','Nicotinic\x20action\x20of\x20acetylcholine','MZDfY','Bookmark','The\x20lipid\x20profile\x20of\x20a\x20patient\x20who\x20suffered\x20from\x20acute\x20coronary\x20syndrome\x20is\x20given\x20below.\x20What\x20drug\x20can\x20be\x20used\x20to\x20treat\x20this\x20condition?','dQZLn','closest','PVdHq','Ketorolac','AKYiA','TFtYo','jBqvU','A\x20man\x20was\x20brought\x20to\x20the\x20emergency\x20room\x20after\x20poisoning\x20with\x20an\x20unknown\x20substance.\x20Muscarinic\x20poisoning\x20was\x20suspected\x20and\x20he\x20was\x20treated\x20for\x20the\x20same.\x20What\x20is\x20the\x20possible\x20presenting\x20feature\x20which\x20led\x20to\x20the\x20diagnosis?','solution','SiDNz','A-1,\x20B-2,\x20C-4,\x20D-3','hxCHU','No\x20need\x20to\x20stop','Cmax','https://dhmbxeygs57ff.cloudfront.net/uploads/faee105612ff4db99088f395111a460ex1280x1008.JPEG','<p><strong>Bebtelovimab</strong>\x20is\x20not\x20used\x20in\x20the\x20treatment\x20of\x20<strong>sickle\x20cell\x20disease</strong>.\x20The\x20clinical\x20features\x20of\x20<strong>multiple\x20blood\x20transfusions</strong>,\x20<strong>bone\x20pain,</strong>\x20and\x20<strong>sickle\x20cells</strong>\x20on\x20peripheral\x20smear\x20are\x20suggestive\x20of\x20<strong>sickle\x20cell\x20disease</strong>.</p>\x0a<p>Bebtelovimab\x20is\x20the\x20new\x20monoclonal\x20antibody\x20used\x20for\x20the\x20treatment\x20of\x20COVID-19.\x20It&nbsp;works\x20by\x20binding\x20to\x20the\x20<strong>spike\x20protein</strong>\x20of\x20the\x20COVID-19\x20virus.\x20It\x20has\x20been\x20found\x20useful\x20in\x20reducing\x20the\x20risk\x20of\x20hospitalization\x20or\x20death.&nbsp;Bebtelovimab\x20retains\x20the\x20activity\x20against\x20the\x20<strong>omicron</strong>\x20variant.</p>\x0a<p>Other\x20options:</p>\x0a<p>Option\x20B:\x20<strong>Voxelotor</strong>\x20is\x20an\x20inhibitor\x20of&nbsp;<strong>hemoglobin\x20S</strong>\x20<strong>polymerase\x20</strong>and<strong>&nbsp;stabilizer\x20</strong>of\x20sickle\x20cell\x20hemoglobin<strong>\x20(HbS)</strong>\x20that\x20is\x20used\x20in\x20the\x20therapy\x20of\x20sickle\x20cell\x20disease.</p>\x0a<p>Option\x20C:&nbsp;<strong>Hydroxyurea</strong>\x20improves\x20fetal\x20haemoglobin\x20<strong>(HbF)</strong>\x20and\x20is\x20the\x20primary\x20drug\x20for\x20<strong>controlling\x20HbS</strong>\x20in\x20sickle\x20cell\x20disease.\x20Thus\x20improving\x20the\x20oxygen-carrying\x20capacity\x20of\x20the\x20blood.&nbsp;Hydroxyurea\x20also\x20inhibits\x20the\x20enzyme\x20<strong>ribonucleotide\x20reductase\x20(RNR)</strong>,\x20which\x20is\x20a\x20rate-limiting\x20step\x20in\x20the\x20biosynthesis\x20of\x20DNA.\x20This\x20property\x20of\x20hydroxyurea\x20is\x20used\x20in\x20the\x20treatment\x20of\x20various\x20cancers,\x20and\x20myeloproliferative\x20disorders\x20like\x20chronic\x20myelogenous\x20leukemia,\x20and\x20polycythemia.</p>\x0a<p>Option\x20D:\x20<strong>L-glutamine</strong>&nbsp;is\x20a\x20naturally\x20occurring\x20amino\x20acid\x20with\x20<strong>antioxidant\x20properties</strong>.\x20It&nbsp;increases\x20the\x20availability\x20of\x20reduced\x20glutathione\x20which\x20may\x20lessen\x20oxidative\x20damage\x20in\x20sickle\x20red\x20blood\x20cells.</p>','correctResult','https://dhmbxeygs57ff.cloudfront.net/uploads/52b96313ea0e49d49c0cf2421b8a135cx720x527.PNG','CdKlz','contains','red','A\x20-\x20Aspirin,\x20B\x20-Vorapaxar,\x20C\x20-\x20Prasugrel','open','1-d,\x202-a,\x203-d,\x204-c','VnyRM','Phase\x201','<p>The\x20new\x20FDA-approved\x20<strong>immune\x20checkpoint\x20inhibitor</strong>\x20for\x20carcinoma\x20endometrium\x20is\x20<strong>pembrolizumab</strong>.</p>\x0a<p>Pembrolizumab\x20acts\x20by\x20inhibiting\x20programmed\x20death\x20receptor\x20-\x201\x20(<strong>PD-1</strong>)\x20and\x20was\x20used\x20for\x20the\x20treatment\x20of&nbsp;<strong>advanced\x20melanoma</strong>.\x20Now,\x20the\x20FDA\x20has&nbsp;approved\x20the\x20use\x20of\x20pembrolizumab\x20for\x20any\x20cancer\x20with\x20mismatch\x20repair\x20(<strong>MMR</strong>)\x20deficiency\x20or\x20high\x20microsatellite\x20instability\x20(<strong>MSI-H</strong>).</p>\x0a<p>On\x20March\x2021,\x202022,\x20the\x20food\x20and\x20drug\x20administration\x20approved\x20pembrolizumab,\x20as\x20a\x20single\x20agent,\x20for\x20patients\x20with\x20<strong>advanced\x20endometrial\x20carcinoma</strong>\x20that\x20is\x20microsatellite\x20instability-high\x20(MSI-H)\x20or\x20mismatch\x20repair\x20deficient\x20(dMMR),\x20as\x20determined\x20by\x20an\x20FDA-approved\x20test.</p>\x0a<p>Other\x20options:</p>\x0a<p>Option\x20A:&nbsp;<strong>Nivolumab</strong>\x20is\x20an&nbsp;immune\x20checkpoint\x20inhibitor\x20that\x20acts\x20by\x20inhibiting\x20programmed\x20death\x20receptor\x20-\x201\x20(<strong>PD-1</strong>)\x20and\x20is\x20used\x20for\x20the\x20treatment\x20of&nbsp;<strong>advanced\x20melanoma\x20</strong>and<strong>&nbsp;</strong>relapsed/refractory<strong>&nbsp;classical\x20Hodgkin\x20lymphoma.</strong></p>\x0a<p>Option\x20C:<strong>&nbsp;\x20Trastuzumab&nbsp;</strong>is\x20a\x20monoclonal\x20antibody\x20that\x20inhibits\x20the\x20<strong>HER2\x20receptor</strong>.\x20It\x20is\x20used\x20in\x20the\x20treatment\x20of\x20<strong>HER2-positive\x20breast\x20cancer</strong>.</p>\x0a<p>Option\x20D:&nbsp;<strong>Ipilimumab</strong>\x20is\x20a\x20monoclonal\x20antibody\x20that\x20binds\x20to\x20cytotoxic\x20T\x20lymphocyte&ndash;associated\x20Protein\x204\x20(<strong>CTLA-4</strong>)\x20and\x20is\x20approved\x20for\x20the\x20treatment\x20of\x20late-stage\x20<strong>melanoma</strong>.</p>','TuRBE','mFloS','includes','1,2,3,4','now','AMJxS','reduce','mmukd','Ivabradine','https://dhmbxeygs57ff.cloudfront.net/uploads/61c1774501b74506af250308d493739ax850x704.PNG','1-d,\x202-c,\x203-a,\x204-b','fUIKz','oKDpM','nav-btn-not-attempted\x20hover:bg-white\x20hover:bg-opacity-20','questionReviewSection','NNMuM','<p><strong>Bradycardia</strong>\x20is\x20the\x20possible\x20presenting\x20feature\x20which\x20led\x20to\x20the\x20diagnosis\x20of\x20<strong>muscarinic</strong>\x20<strong>poisoning</strong>.</p>\x0a<p>Muscarinic\x20poisoning\x20occurs\x20due\x20to\x20the\x20consumption\x20of\x20<strong>poisonous\x20mushroom</strong>-like\x20<em>Inocybe</em>.\x20<strong>Muscarinic\x20symptoms</strong>\x20appear\x20within\x20an\x20hour\x20of\x20eating\x20the\x20mushroom.\x20These\x20symptoms\x20(along\x20with\x20nicotinic\x20symptoms)\x20can\x20also\x20be\x20seen\x20in\u00a0<strong>organophosphate\x20poisoning</strong>.</p>\x0a<p>There\x20are\x20<strong>5\u00a0subtypes</strong>\x20of\x20muscarinic\x20receptors\x20they\x20are\x20M<sub>1</sub>,\x20M<sub>2</sub>,\x20M<sub>3</sub>,\x20M<sub>4</sub>,\x20and\x20M<sub>5</sub>.\x20The\x20effects\x20exerted\x20by\x20the\x20<strong>M\x20receptors</strong>\x20are\x20given\x20below:</p>\x0a<ul>\x0a<li>M<sub>1</sub>:\x20Increased\x20seizure\x20activity.</li>\x0a<li>M<sub>2</sub>:\x20<strong>Tremors</strong>,\x20<span\x20class=\x22ILfuVd\x22\x20lang=\x22en\x22><span\x20class=\x22hgKElc\x22>bronchoconstriction,<strong>\x20bradycardia</strong>,\x20abdominal\x20cramping</span></span><sub><br\x20/></sub></li>\x0a<li>M<sub>3</sub>:\x20Increased\x20bladder\x20contraction,\x20<strong>miosis</strong>,\x20increased\x20salivary\x20secretion</li>\x0a<li>M<sub>4</sub>:\x20Cataplexy(sudden\x20muscle\x20weakness)</li>\x0a</ul>\x0a<p><strong>Atropine\u00a0</strong>is\x20used\x20for\x20the\x20management\x20of\x20muscarinic\x20poisoning.\x20It\x20<strong>competitively\x20</strong>blocks\x20the\x20acetylcholine\x20at\x20the\x20muscarinic\x20receptors.</p>','<p>The\x20drugs\x20marked\x20A,\x20B\x20and\x20C\x20are\x20<strong>aspirin</strong>,\x20<strong>eptifibatide</strong>,\x20and\x20<strong>vorapaxar</strong>,<strong>&nbsp;</strong>respectively.</p>\x0a<p><strong>Aspirin</strong>\x20causes\x20inhibition\x20of\x20<strong>cyclooxygenase-1\x20(COX-1)</strong>,<strong>&nbsp;</strong>which\x20would\x20inhibit\x20the\x20formation\x20of\x20<strong>thromboxane\x20A2</strong>.\x20Thromboxane\x20A2\x20is\x20an\x20inducer\x20of\x20platelet\x20aggregation\x20and\x20is\x20a\x20potent\x20vasoconstrictor.\x20Hence,\x20inhibition\x20of\x20its\x20formation\x20is\x20responsible\x20for\x20antiplatelet\x20action.</p>\x0a<p>Aspirin\x20is\x20a\x20<strong>non-competitive,\x20irreversible\x20inhibitor</strong>\x20of\x20the\x20cyclooxygenase\x20(COX)\x20enzyme.\x20It\x20is\x20a\x20<strong>nonselective\x20COX\x20inhibitor</strong>\x20and\x20inhibits\x20both\x20COX-1\x20and\x20COX-2.&nbsp;</p>\x0a<p>Abciximab,\x20tirofiban,\x20and\x20<strong>eptifibatide</strong>\x20act\x20by&nbsp;<strong>blocking\x20Gp\x20IIb/IIIa\x20receptors</strong>.\x20They\x20are\x20mainly\x20used\x20during&nbsp;<strong>percutaneous\x20coronary\x20intervention</strong>&nbsp;for\x20acute\x20coronary\x20syndrome.\x20They\x20carry\x20a&nbsp;<strong>high\x20risk\x20of\x20bleeding</strong>&nbsp;and\x20can\x20cause&nbsp;<strong>thrombocytopenia</strong>.</p>\x0a<p><strong>Vorapaxar&nbsp;</strong>primarily\x20inhibits\x20platelet\x20aggregation\x20caused\x20by&nbsp;<strong>thrombin.&nbsp;</strong>PAR-1\x20activation\x20by\x20thrombin\x20contributes\x20to\x20platelet\x20aggregation.\x20Vorapaxar\x20is\x20a\x20competitive\x20antagonist\x20of\x20protease-activated\x20receptor-1\x20(PAR-1).\x20Vorapaxar\x20is&nbsp;<strong>indicated\x20in\x20combination</strong>&nbsp;with\x20aspirin\x20and/or\x20clopidogrel\x20to\x20reduce\x20thromboembolic\x20events\x20in\x20patients\x20with\x20MI\x20or\x20peripheral\x20vascular\x20disease.</p>\x0a<p><strong>Prasugrel&nbsp;</strong>is\x20an<strong>&nbsp;irreversible\x20P2Y12&nbsp;inhibitor\x20</strong>and\x20lasts\x20for\x20the\x20entire\x20lifetime\x20of\x20a\x20platelet.</p>\x0a<div\x20class=\x22page\x22\x20title=\x22Page\x20606\x22>\x0a<div\x20class=\x22section\x22>\x0a<div\x20class=\x22layoutArea\x22>\x0a<div\x20class=\x22column\x22>\x0a<p>Prasugrel\x20is\x20a&nbsp;<strong>prodrug</strong>&nbsp;that\x20is\x20used\x20in\x20patients\x20with\x20acute\x20coronary\x20syndrome\x20who\x20have\x20undergone&nbsp;<strong>percutaneous\x20coronary\x20intervention.</strong>&nbsp;It<strong>&nbsp;reduces</strong>&nbsp;the\x20rate\x20of&nbsp;<strong>thrombotic\x20cardiovascular\x20events</strong>&nbsp;in\x20such\x20patients.&nbsp;</p>\x0a</div>\x0a</div>\x0a</div>\x0a</div>','VgvMr','LOyPC','totalQuestionsResult','Brimonidine','PORAb','RmfAg','QEJZu','A\x20patient\x20with\x20erectile\x20dysfunction\x20is\x20given\x20sildenafil.\x20The\x20penile\x20erectile\x20function\x20is\x20found\x20to\x20be\x20improved\x20after\x20the\x20therapy.\x20Which\x20of\x20the\x20following\x20mediates\x20the\x20action\x20of\x20sildenafil?','(((.+)+)+)+$','statsBar','SiSoT','width','setItem','A\x20and\x20D','kPALA','Option\x20','juVHZ','<p>Mechanism\x20of\x20action\x20of\x20some\x20common\x20antiepileptics:</p>\x0a<table>\x0a<tbody>\x0a<tr>\x0a<td><strong>Mechanism\x20of\x20action</strong></td>\x0a<td><strong>Antiepileptics</strong></td>\x0a</tr>\x0a<tr>\x0a<td>Sodium-channel\x20blockers</td>\x0a<td>\x0a<p>Phenytoin</p>\x0a<p>Carbamazepine,\x20Oxcarbazepine</p>\x0a<p>Eslicarbazepine</p>\x0a<p>Lamotrigine</p>\x0a<p>Topiramate</p>\x0a<p>Felbamate</p>\x0a<p>Valproate</p>\x0a<p>Rufinamide</p>\x0a<p>Levetiracetam</p>\x0a</td>\x0a</tr>\x0a<tr>\x0a<td>Calcium-channel\x20blockers</td>\x0a<td>\x0a<p>Valproate</p>\x0a<p>Lamotrigine</p>\x0a<p>Ethosuximide</p>\x0a</td>\x0a</tr>\x0a<tr>\x0a<td>GABA<sub>A</sub>&nbsp;receptor\x20modulators</td>\x0a<td>\x0a<p>Benzodiazepines</p>\x0a<p>Phenobarbital</p>\x0a<p>Felbamate</p>\x0a<p>Primidone</p>\x0a<p>Topiramate</p>\x0a<p>Carbamazepine,\x20Oxcarbazepine</p>\x0a<p>Stiripentol</p>\x0a<p>Clobazam</p>\x0a</td>\x0a</tr>\x0a<tr>\x0a<td>\x0a<p\x20class=\x22p1\x22>GABA\x20uptake\x20inhibitors</p>\x0a</td>\x0a<td>\x0a<p\x20class=\x22p1\x22>Tiagabine</p>\x0a<p\x20class=\x22p1\x22>Vigabatrin</p>\x0a</td>\x0a</tr>\x0a<tr>\x0a<td>NMDA\x20receptor\x20antagonist</td>\x0a<td>Felbamate</td>\x0a</tr>\x0a<tr>\x0a<td>AMPA/Kainate\x20receptor\x20antagonist</td>\x0a<td>\x0a<p>Phenobarbital</p>\x0a<p>Topiramate</p>\x0a<p>Perampanel</p>\x0a</td>\x0a</tr>\x0a<tr>\x0a<td>HCN\x20channel\x20activity\x20enhancers</td>\x0a<td>Lamotrigine</td>\x0a</tr>\x0a<tr>\x0a<td>Inhibitors\x20of\x20brain\x20carbonic\x20anhydrase</td>\x0a<td>\x0a<p>Acetazolamide</p>\x0a<p>Zonisamide</p>\x0a<p>Topiramate</p>\x0a</td>\x0a</tr>\x0a<tr>\x0a<td>Potassium-channel\x20openers</td>\x0a<td>\x0a<p>Retigabine</p>\x0a<p>Topiramate</p>\x0a</td>\x0a</tr>\x0a</tbody>\x0a</table>','cRjXt','AGvms','tckEa','solutionImages','3|1|4|2|0|5','PLQLi','jbBkr','endsWith','replace','gradient-purple\x20px-6\x20py-3\x20text-white\x20transition-all\x20duration-300\x20flex\x20items-center','Voxelotor','URauN','rEpwV','SOFcm','incorrectAnswers','Are\x20you\x20sure\x20you\x20want\x20to\x20retake\x20the\x20quiz?\x20This\x20will\x20reset\x20all\x20your\x20answers.','A-4,\x20B-1,\x20C-3,\x20D-2','<div\x20class=\x22mt-4\x22><img\x20src=\x22','Polyclonal\x20antibody\x20which\x20acts\x20against\x20CD50','nwgJD','data-option-index','pkgsx','OEsAS','rOmBD','Verapamil\x20-\x20constipation','Which\x20of\x20the\x20following\x20statements\x20is\x20true\x20regarding\x20memantine?','\x22\x20alt=\x22Explanation\x20Image\x22\x20class=\x22w-full\x20rounded-lg\x22></div>','Polyclonal\x20antibody\x20which\x20acts\x20against\x20CD20','90\x20hours','RTzDj','hhpyT','120\x20hours','timed_exam','{}.constructor(\x22return\x20this\x22)(\x20)','split','84FSvfZK','ekwzB','You\x20have\x20completed\x20all\x20questions.\x20Would\x20you\x20like\x20to\x20review\x20from\x20the\x20beginning?','explanation_images','vUWYt','https://cdn1.dailyrounds.org/uploads/b656eec2969545cab6981b79ab874ed5.JPEG','HaLbz','flex','froCS','Valproate','461292xWhHlp','Drug\x201\x20represents\x20agonist\x20and\x20drug\x202\x20represents\x20inverse\x20agonist','IOwkm','join','vEDZH','HkrcO','<p>&nbsp;</p>\x0a<p>&nbsp;</p>\x0a<p>Option\x20B:&nbsp;<strong>Propranolol</strong>&nbsp;is\x20a&nbsp;<strong>&beta;-receptor-blocker\x20</strong>and&nbsp;a<strong>&nbsp;class\x20II\x20antiarrhythmic.</strong></p>','Match\x20the\x20following\x20drugs\x20in\x20Column\x20A\x20with\x20their\x20contraindications\x20in\x20Column\x20B.','1,\x203,\x20and\x204','<p>The\x20active\x20metabolite\x20of\x20cyclophosphamide\x20is&nbsp;<strong>4\x20-\x20hydroxy\x20cyclophosphamide.&nbsp;</strong></p>\x0a<p><strong>Cyclophosphamide&nbsp;</strong>is\x20an\x20<strong>alkylating\x20agent</strong>\x20with\x20antitumor\x20and\x20<strong>immunosuppressant</strong>\x20properties.\x20It\x20is\x20used\x20for\x20many\x20solid\x20tumors.\x20The\x20important\x20side\x20effects\x20are<strong>\x20cystitis</strong>\x20due\x20to\x20metabolite\x20<strong>acrolein</strong>\x20and\x20<strong>bladder\x20carcinoma</strong>.&nbsp;</p>\x0a<p><strong>Cystitis</strong>\x20caused\x20by\x20cyclophosphamide\x20is\x20treated\x20by&nbsp;systemic\x20administration\x20of\x20<strong>mesna</strong>\x20and\x20by\x20irrigating\x20the\x20bladder\x20with\x20<strong>acetylcysteine</strong>.\x20Both\x20these\x20drugs\x20contain\x20&ndash;SH\x20which\x20detoxifies\x20the\x20toxic\x20metabolites.\x20Plenty\x20of\x20fluids\x20and\x20frequent\x20bladder\x20voiding\x20are\x20also\x20helpful.</p>','Which\x20of\x20the\x20following\x20statement\x20is\x20correct\x20regarding\x20the\x20given\x20graph?','Which\x20of\x20the\x20following\x20anti-diabetic\x20drugs\x20is\x20associated\x20with\x20the\x20increased\x20risk\x20of\x20fractures?','LamhE','ETzgV','OLNyi','uqGtY','constructor','Hprby','Dorzolamide\x20is\x20a\x20______.','ndryE','Hukjd','key','textContent','N\x20-\x20hydroxy\x20cyclophosphamide','rDSgO','oSoir','markReviewText','The\x20extent\x20of\x20drug\x20absorption\x20is\x20represented\x20by:','cfQtV','AnUVn','border-gray-600','lEpCL','kUmhv','hjyIL','A\x20hospital\x20is\x20conducting\x20a\x20study\x20to\x20check\x20the\x20efficacy\x20of\x20statins\x20in\x20multiple\x20centers.\x20There\x20are\x204-5\x20patients\x20per\x20center\x20and\x20half\x20of\x20the\x20patients\x20receive\x20the\x20drug\x20and\x20the\x20other\x20half\x20receive\x20the\x20placebo.\x20Neither\x20the\x20patients\x20nor\x20clinicians\x20know\x20which\x20drug\x20is\x20being\x20administered.\x20What\x20phase\x20of\x20the\x20clinical\x20trial\x20describes\x20the\x20above\x20scenario?','remove','log','<p>The\x20<strong>false</strong>\x20statement\x20regarding\x20statins\x20is\x20that\x20they&nbsp;<strong>can\x20be\x20given\x20with\x20verapamil\x20and\x20other\x20enzyme\x20inhibitors</strong>.</p>\x0a<p>Statins\x20like\x20atorvastatin\x20and\x20rosuvastatin\x20are\x20metabolized\x20by\x20the\x20cytochrome\x203A4\x20enzymes\x20of\x20the\x20liver.\x20<strong>Verapamil</strong>\x20is\x20a\x20<strong>cytochrome\x203A4\x20inhibitor</strong>\x20and\x20may\x20interfere\x20with\x20statin\x20degradation.\x20This\x20leads\x20to\x20an\x20increase\x20in\x20serum\x20statin\x20levels.\x20The\x20most\x20important\x20feature\x20of\x20statin\x20toxicity\x20is\x20myopathy.\x20It\x20can\x20present\x20as\x20myalgia\x20but\x20can\x20sometimes\x20also\x20lead\x20to\x20fatal\x20<strong>rhabdomyolysis</strong>.&nbsp;</p>\x0a<p><strong>Statins</strong>&nbsp;are\x20the\x20most\x20commonly\x20used\x20hypolipidemic\x20drugs.\x20Statins\x20act\x20by&nbsp;<strong>inhibiting</strong>&nbsp;the\x20rate-limiting<strong>&nbsp;HMG-CoA\x20reductase</strong>&nbsp;enzyme,\x20which\x20in\x20turn&nbsp;<strong>inhibits\x20cholesterol\x20synthesis</strong>.\x20They\x20decrease\x20levels\x20of\x20low-density\x20lipoproteins\x20(LDL)\x20and\x20triglycerides\x20and\x20increase\x20the\x20levels\x20of\x20high-density\x20lipoproteins\x20(HDL)\x20in\x20plasma.</p>\x0a<p>Other\x20options:</p>\x0a<p>Option\x20A:<strong>\x20Lipoprotein\x20(lp)\x20a</strong>\x20is\x20an\x20LDL\x20molecule\x20that\x20has\x20apolipoprotein\x20b\x20and\x20an\x20additional\x20apolipoprotein\x20a.\x20Studies\x20indicate\x20that\x20these\x20molecules\x20are\x20atherogenic\x20and\x20may\x20independently\x20cause\x20cardiovascular\x20disease.\x20Although\x20<strong>HMG-CoA\x20reductase\x20inhibitors</strong>\x20substantially\x20reduce\x20the\x20risk\x20of\x20cardiovascular\x20events,\x20there\x20is\x20a\x20mild\x20<strong>increase</strong>\x20in\x20lipoprotein\x20a\x20levels.</p>\x0a<p>Option\x20B:\x20Statins\x20can\x20be\x20continued\x20during\x20<strong>surgery</strong>.\x20These\x20drugs\x20have\x20proved\x20to\x20decrease\x20overall\x20mortality\x20due\x20to\x20cardiovascular\x20events.\x20Statins\x20also\x20influence\x20inflammatory\x20responses\x20and\x20can\x20be\x20safely\x20used\x20in\x20<strong>trauma.</strong></p>\x0a<p>Option\x20D:\x20Chronic\x20administration\x20of\x20high\x20statin\x20doses\x20also\x20leads\x20to\x20an\x20<strong>increased\x20incidence</strong>\x20of\x20<strong>type\x202\x20diabetes\x20mellitus.</strong></p>','3055696pMzITV','17-hydrolase','toggle','className','XpVHA','Atezolimumab','totalQuestions','mjxnx','<p>The\x20half-life\x20of\x20<strong>letrozole</strong>\x20is\x20<strong>45\x20hours</strong>.</p>\x0a<p>Letrozole\x20is\x20a\x20<strong>reversible\x20aromatase\x20inhibitor</strong>.\x20It\x20is\x20a\x20non-steroidal\x20compound\x20that\x20inhibits\x20the\x20aromatization\x20of\x20estrogen\x20thereby\x20causing\x20<strong>estrogen\x20depletion</strong>.\x20Letrozole\x20is\x20rapidly\x20absorbed\x20with\x2099.9%\x20oral\x20bioavailability\x20and\x20has\x20a&nbsp;<strong>t&frac12;</strong>\x20of\x20around\x20<strong>41\x20hours</strong>.</p>\x0a<p>Letrozole\x20is\x20used\x20as\x20the\x20first-line\x20drug\x20for\x20<strong>estrogen-positive</strong>\x20breast\x20cancer\x20following\x20mastectomy\x20in\x20post-menopausal\x20women.</p>\x0a<p>Adverse\x20effects\x20of\x20letrozole\x20are\x20due\x20to\x20the\x20depletion\x20of\x20estrogen.\x20The\x20commonly\x20seen\x20adverse\x20effects\x20are\x20<strong>hot\x20flashes</strong>,\x20<strong>vaginal\x20dryness</strong>,\x20nausea,\x20diarrhea,\x20dyspepsia,\x20accelerated\x20bone\x20loss,\x20and\x20thinning\x20of\x20hair.</p>','Wihle','1,\x202','uejlX','selected','Oxcarbazepine','Netarsudil','Inj.\x20Amphotericin\x20\x20B,\x20followed\x20by\x20flucytosine','Elevated\x20levels\x20of\x20gamma\x20glutamyl\x20transpeptidases','onclick','forEach','NBFNd','<div\x20class=\x22ng-star-inserted\x22>\x0a<div\x20class=\x22table-responsive\x20font-weight-light\x20answer-scroll\x20ng-star-inserted\x22>\x0a<p>A\x20false\x20statement\x20about\x20eicosanoids\x20is\x20they\x20are\x20synthesized\x20from\x20arginine.\x20<strong>Eicosanoids</strong>\x20are\x20synthesized\x20from\x20<strong>arachidonic\x20acid\x20</strong>(Option\x20B)</p>\x0a<p><strong>Eicosanoids</strong>\x20are\x20the\x20most\x20universally\x20distributed\x20autocoids\x20in\x20the\x20body.\x20<strong>Prostaglandins,\x20thromboxanes,&nbsp;</strong>and\x20<strong>leukotrienes</strong>\x20comprise\x20eicosanoids.\x20Every\x20cell\x20is\x20capable\x20of\x20synthesizing\x20one\x20or\x20more\x20eicosanoids.\x20<strong>Platelets</strong>\x20primarily\x20synthesize\x20<strong>thromboxanes</strong>\x20(Option\x20D).</p>\x0a<p>Eicosanoids\x20are\x20synthesized\x20from\x20<strong>arachidonic\x20acid</strong>.\x20Arachidonic\x20acid\x20is\x20derived\x20from\x20membrane\x20phospholipids.\x20The\x20release\x20of\x20<strong>arachidonic\x20acid</strong>&nbsp;(AA)\x20from\x20the\x20membrane\x20phospholipids\x20is\x20mainly\x20mediated\x20by\x20<strong>phospholipase</strong>\x20<strong>A.</strong></p>\x0a<p>AA\x20is\x20metabolized\x20by\x20<strong>cyclooxygenases</strong>\x20to\x20produce\x20<strong>prostaglandins\x20</strong>and\x20<strong>lipoxygenases</strong>\x20to\x20produce\x20<strong>leukotrienes</strong>\x20and\x20lipoxins.</p>\x0a<div\x20class=\x22ng-star-inserted\x22>\x0a<div\x20class=\x22table-responsive\x20font-weight-light\x20answer-scroll\x20ng-star-inserted\x22>\x0a<p>Inhibitors\x20of\x20metabolism\x20of\x20arachidonic\x20acid:</p>\x0a<ul>\x0a<li><strong>Corticosteroids</strong>\x20cause\x20inhibition\x20of\x20prostaglandin\x20synthesis\x20by\x20inhibiting<strong>\x20phospholipase\x20A2.\x20<br\x20/></strong></li>\x0a<li>Non-steroidal\x20anti-inflammatory\x20(<strong>NSAIDs</strong>)\x20drugs\x20inhibit\x20the\x20synthesis\x20of\x20<strong>prostaglandins</strong>\x20by\x20inhibiting\x20the\x20enzyme\x20cyclooxygenase.</li>\x0a<li><strong>Zileuton</strong>\x20inhibits\x20the\x20enzyme\x20lipoxygenase\x20thereby\x20decreasing\x20the\x20synthesis\x20of\x20<strong>leukotrienes</strong>.</li>\x0a</ul>\x0a<p>Chemically,\x20all\x20prostaglandins\x20are\x20considered\x20to\x20be\x20derivatives\x20of\x20prostanoic\x20acid,\x20having&nbsp;a<strong>\x20five-carbon\x20ring&nbsp;</strong>(Option\x20C).</p>\x0a<p>The\x20image\x20given\x20below\x20shows\x20the\x20synthesis\x20of\x20various\x20eicosanoids\x20from\x20arachidonic\x20acid:</p>\x0a</div>\x0a</div>\x0a</div>\x0a</div>','.option-button','IEmMb','rhmfG','OHGVI','cTCtp','Phase\x202','CMRea','tcbKU','Which\x20of\x20the\x20following\x20is\x20not\x20an\x20immune\x20checkpoint\x20inhibitor?','xRltg','It\x20is\x20caused\x20by\x20activation\x20of\x20the\x20Edinger-Westphal\x20nucleus.','sIjod','wpKHc','Fukvh','<p>In\x20this\x20hypertensive\x20patient\x20with\x20<strong>hyperkalemia</strong>,\x20<strong>losartan</strong>\x20must\x20be\x20stopped.</p>\x0a<p><strong>Losartan</strong>&nbsp;is\x20competitive&nbsp;<strong>angiotensin\x20I\x20(AT1)\x20receptor\x20antagonist</strong>,&nbsp;which&nbsp;binds\x20to\x20the\x20AT<sub>1</sub>&nbsp;receptor\x20with\x20high\x20affinity.\x20Uses\x20of\x20losartan\x20are:</p>\x0a<ul>\x0a<li>Antihypertensive</li>\x0a<li>Renoprotective\x20drug\x20in\x20diabetes\x20mellitus</li>\x0a<li>Stroke\x20prophylaxis</li>\x0a<li>Portal\x20hypertension\x20in\x20cirrhosis\x20without\x20compromising\x20renal\x20function</li>\x0a<li>Anti-aggregant\x20as\x20it\x20is\x20a\x20competitive\x20antagonist\x20of\x20the\x20thromboxane\x20A2\x20receptor.</li>\x0a</ul>\x0a<p><strong>Hyperkalemia</strong>&nbsp;is\x20an\x20important\x20side\x20effect\x20of\x20ARBs.&nbsp;<span\x20class=\x22ILfuVd\x22\x20lang=\x22en\x22><span\x20class=\x22hgKElc\x22>Losartan\x20appears\x20to\x20be\x20a\x20safe\x20and\x20efficacious\x20agent\x20to&nbsp;<strong>lower\x20serum\x20uric\x20acid</strong>&nbsp;levels\x20in\x20patients\x20with\x20hyperuricemia.</span></span></p>\x0a<p>Option\x20A:\x20<strong>Gingival\x20hyperplasia</strong>&nbsp;and&nbsp;<strong>ankle\x20swelling</strong>&nbsp;are\x20side\x20effects\x20of&nbsp;<strong>calcium\x20channel\x20blockers</strong>&nbsp;like&nbsp;<strong>amlodipine.</strong>&nbsp;Ankle\x20edema\x20occurs\x20due\x20to&nbsp;<strong>increased</strong>&nbsp;<strong>hydrostatic\x20pressure</strong>&nbsp;in\x20the\x20capillaries\x20present\x20in\x20the&nbsp;<strong>dependent\x20parts</strong>&nbsp;of\x20the\x20body.\x20This\x20is\x20due\x20to&nbsp;<strong>reflex\x20constriction</strong>&nbsp;of&nbsp;<strong>postcapillary\x20vessels</strong>.\x20Other\x20common\x20side\x20effects\x20of\x20amlodipine\x20include\x20headache,\x20dizziness,\x20and\x20abdominal\x20pain.</p>\x0a<p>Option\x20B:\x20<strong>Metoprolol</strong>&nbsp;is\x20a\x20cardioselective\x20beta\x20blocker.<strong>\x20Cardioselective</strong>\x20beta\x20blockers\x20are\x20<strong>less\x20likely\x20to\x20cause\x20hyperkalemia</strong>\x20as\x20an\x20adverse\x20effect.\x20The\x20risk\x20of\x20metoprolol-induced\x20hyperkalemia\x20is\x20increased\x20if\x20the\x20patient\x20is\x20also\x20diabetic.</p>\x0a<p>Option\x20D:\x20<strong>Furosemide</strong>&nbsp;is\x20a&nbsp;<strong>loop\x20diuretic.\x20</strong>It\x20acts\x20by&nbsp;<strong>inhibiting</strong>&nbsp;the<strong>&nbsp;Na<sup>+</sup>-K<sup>+</sup>-2Cl<sup>-</sup>&nbsp;symporter\x20</strong>in\x20the&nbsp;thick\x20ascending\x20limb&nbsp;of\x20the&nbsp;loop&nbsp;of\x20Henle&nbsp;resulting\x20in\x20increased<strong>\x20excretion\x20of\x20sodium,\x20potassium,</strong>\x20and<strong>\x20chloride</strong>.&nbsp;<strong>Hypokalemia,\x20hyperuricemia,\x20hypocalcemia</strong>,\x20and\x20hypomagnesemia\x20are\x20the\x20important\x20side\x20effects.</p>','Pharmacology','BjIdy','3\x20months','Inhibits\x20HMG\x20CoA\x20reductase','EqXmQ','ehPnD','LFnON','A-1,\x20B-3,\x20C-2,\x20D-4','1-d,\x202-b,\x203-a,\x204-c','currentQuestion','rZWWd','Decreases\x20VLDL','WaufS','cGMP','YhIeN','odsdb','YBWLs','uMaVu','Monoclonal\x20antibody\x20which\x20acts\x20against\x20CD20','biqIX','bookmarked','review-question\x20','quizHierarchy','explanation_audio_eng','CdMHY','ABVoY','ZtRZg','The\x20active\x20metabolite\x20of\x20cyclophosphamide\x20is:','ArrowRight','<p><strong>1\x20and\x202</strong>\x20are\x20true\x20statements\x20regarding\x20memantine.</p>\x0a<p>Memantine\x20is\x20a\x20non-competitive&nbsp;<strong>NMDA\x20receptor\x20antagonist</strong>.\x20It\x20inhibits\x20glutamate\x20excitotoxicity.\x20It\x20delays\x20the\x20progression\x20of\x20dementia\x20in<strong>\x20Alzheimer\x27s\x20disease</strong>.\x20Commonly,\x20it\x20is\x20started\x20in\x20patients\x20with\x20<strong>moderate-to-severe</strong>\x20disease.</p>\x0a<p>It\x20can\x20be\x20given\x20both\x20as\x20<strong>monotherapy</strong>\x20or\x20can\x20be\x20given\x20<strong>along</strong>\x20with\x20<strong>cholinesterase\x20inhibitors</strong>.\x20It\x20can\x20be\x20started\x20at\x20a\x20dose\x20of\x20<strong>5\x20mg\x20once\x20daily</strong>\x20and\x20then\x20progressively\x20increased\x20<strong>up\x20to\x2010\x20mg\x20twice\x20daily</strong>\x20for\x20a\x20minimum\x20of\x206\x20months.&nbsp;</p>\x0a<p>It\x20can\x20cause\x20dizziness\x20and\x20headache.\x20Since\x20it\x20is\x20excreted\x20in\x20the\x20kidney,\x20careful\x20dose\x20adjustments\x20should\x20be\x20made\x20in\x20patients\x20with\x20renal\x20failure.</p>','wZWbk','4olUGJd','RVKQG','Choose\x20the\x20correct\x20options\x20regarding\x20the\x20route\x20of\x20administration\x20and\x20bioavailability.','1,\x20and\x203','block','fXkCU','<p><strong>Canagliflozin</strong>\x20is\x20associated\x20with\x20an\x20increased\x20risk\x20of\x20<strong>fractures</strong>.&nbsp;</p>\x0a<p>Canagliflozin\x20is\x20a\x20<strong>sodium-glucose\x20transporter-2\x20</strong>(SGLT2)\x20inhibitor.\x20SGLT2\x20is\x20a\x20Na+-glucose\x20<strong>cotransporter</strong>\x20that\x20is\x20located\x20in\x20the\x20<strong>proximal\x20convoluted\x20tubule</strong>.\x20They\x20reabsorb\x20glucose\x20and\x20sodium\x20from\x20the\x20tubular\x20lumen\x20back\x20into\x20the\x20blood\x20through\x20the\x20epithelial\x20cells.\x20SGLT2\x20inhibitors\x20block\x20the\x20transport\x20of\x20glucose&nbsp;in\x20the\x20proximal\x20tubule\x20and\x20promote\x20<strong>glycosuria</strong>\x20and\x20hence,&nbsp;lowering\x20blood\x20glucose.</p>\x0a<p>The\x20currently\x20available\x20SGLT2\x20inhibitors\x20are\x20canagliflozin,\x20dapagliflozin,\x20and\x20empagliflozin.\x20Other\x20than\x20decreasing\x20blood\x20glucose\x20they\x20also\x20decrease&nbsp;blood\x20pressure\x20and,&nbsp;cause\x20<strong>weight\x20loss</strong>\x20of\x202&ndash;4\x20kg.\x20Empagliflozin\x20and\x20canagliflozin\x20reduce\x20the\x20risk\x20for\x20major\x20cardiovascular\x20events.</p>\x0a<p>The\x20main\x20side\x20effect\x20of\x20SGLT2\x20inhibitors\x20is\x20an\x20increase\x20in\x20<strong>lower\x20urinary\x20tract\x20infections</strong>\x20and&nbsp;genital\x20mycotic\x20infections.\x20This\x20is\x20because\x20of\x20their\x20glycosuric\x20properties.\x20A\x20recent\x20warning\x20from\x20the\x20FDA\x20says\x20that\x20SGLT2\x20inhibitors\x20may\x20increase\x20the\x20risk\x20of\x20<strong>fractures</strong>.\x20They\x20also<strong>&nbsp;</strong>affect&nbsp;circulating\x20levels\x20of\x20parathyroid\x20hormone,\x20and\x201,25-hydroxy\x20vitamin\x20D\x20thereby\x20affecting&nbsp;the\x20mineral\x20balance\x20in\x20bone.</p>\x0a<p>Other\x20options:</p>\x0a<p>Option\x20A:\x20<strong>Rosiglitazone</strong>\x20is\x20a\x20thiazolidinedione\x20that\x20acts\x20as\x20a\x20peroxisome\x20proliferator-activated\x20receptor\x20&gamma;\x20agonist\x20in\x20the\x20adipose\x20tissue\x20which\x20increases\x20insulin\x20sensitivity\x20and\x20adipose\x20differentiation.\x20Side\x20effects\x20are\x20<strong>weight\x20gain,\x20edema,&nbsp;</strong>and<strong>\x20increased\x20risk\x20of\x20fractures.</strong>&nbsp;Compared\x20to\x20rosiglitazone,\x20canagliflozin\x20is\x20commonly\x20used\x20in\x20clinical\x20practice.\x20American\x20diabetes\x20association\x20recommends\x20canagliflozin\x20as\x20the\x20first-line\x20drug\x20along\x20with\x20metformin,\x20in\x20patients\x20with\x20a\x20high\x20risk\x20of\x20cardiovascular\x20disease,\x20renal\x20failure,\x20and\x20heart\x20failure.\x20Even\x20when\x20thiazolidinediones\x20are\x20required,\x20clinicians\x20prefer\x20pioglitazone\x20over\x20rosiglitazone\x20due\x20to\x20the\x20higher\x20risk\x20of\x20cardiovascular-related\x20mortality\x20in\x20rosiglitazone.\x20Therefore,\x20<strong>canagliflozin</strong>\x20would\x20be\x20a\x20<strong>better</strong>\x20option\x20compared\x20to\x20rosiglitazone.&nbsp;</p>\x0a<div\x20class=\x22ng-star-inserted\x22>\x0a<div\x20class=\x22table-responsive\x20font-weight-light\x20answer-scroll\x20ng-star-inserted\x22>\x0a<p>Option\x20B:\x20<strong>Liraglutide</strong>\x20is\x20a\x20long-acting\x20glucagon-like\x20peptide-1\x20agonist.\x20Nausea,\x20diarrhea,\x20and\x20<strong>acute\x20pancreatitis</strong>\x20are\x20some\x20frequent\x20side\x20effects.</p>\x0a</div>\x0a</div>\x0a<p>Option\x20C:\x20<strong>Voglibose</strong>\x20reduces\x20the\x20intestinal\x20absorption\x20of\x20starch,\x20dextrin,\x20and\x20disaccharides\x20by\x20inhibiting\x20the\x20action\x20of<strong>\x20&alpha;-glucosidase\x20</strong>in\x20the\x20intestinal\x20brush\x20border.\x20The\x20most\x20prominent\x20adverse\x20effects\x20are\x20malabsorption,\x20flatulence,\x20diarrhea,\x20and\x20abdominal\x20bloating.</p>','1-a,\x202-d,\x203-b,\x204-c','nav-btn-answered','parse','A\x20-\x20Aspirin,\x20B\x20-\x20Prasugrel,\x20C\x20-\x20Eptifibatide','RwzMU','DgNYe','console','<p>The\x20correctly\x20matched\x20pairs\x20of\x20teratogenic\x20drugs\x20and\x20their\x20effects\x20is\x20<strong>1-d,\x202-c,\x203-b,\x204-a</strong>.</p>\x0a<p><span\x20data-preserver-spaces=\x22true\x22>Lithium\x20use\x20in\x20early\x20pregnancy\x20causes\x20<strong>Ebstein\x20anomaly</strong>\x20in\x20the\x20fetus.\x20Fetal\x20lithium\x20exposure\x20is\x20associated\x20with\x20<strong>neonatal\x20goiter</strong>,\x20CNS\x20depression,\x20hypotonia\x20(floppy\x20baby\x20syndrome),\x20and\x20cardiac\x20murmur.</span></p>\x0a<p><strong>Gray\x20baby\x20syndrome\x20</strong>occurs\x20in\x20neonates,\x20especially\x20premature\x20ones,\x20exposed\x20to&nbsp;<strong>high\x20doses\x20of\x20chloramphenicol&nbsp;</strong>(100\x20mg/kg),\x20which\x20are\x20administered\x20prophylactically.</p>\x0a<p><span\x20data-preserver-spaces=\x22true\x22><strong>Fetal\x20warfarin\x20syndrome\x20</strong>or<strong>\x20warfarin\x20embryopathy&nbsp;</strong>presents\x20with&nbsp;</span><span\x20data-preserver-spaces=\x22true\x22>CNS\x20abnormalities,\x20<strong>d</strong></span><span\x20data-preserver-spaces=\x22true\x22><strong>epressed\x20nasal\x20bridge</strong>/\x20saddle\x20nose\x20at\x20birth,\x20b</span><span\x20data-preserver-spaces=\x22true\x22>leeding\x20diathesis,\x20and\x20g</span><span\x20data-preserver-spaces=\x22true\x22>rowth\x20retardation.\x20Hypoplasia\x20of\x20the\x20nose,\x20eye\x20sockets,\x20and\x20long\x20bones\x20with\x20stippling\x20of\x20epiphyses\x20are\x20also\x20seen.</span></p>\x0a<p>Fetal\x20thalidomide\x20exposure\x20causes\x20phocomelia.\x20This\x20disorder\x20is\x20associated\x20with\x20<strong>underdeveloped\x20limbs</strong>\x20and\x20<strong>absent\x20pelvic\x20bones.</strong>\x20Both\x20<strong>upper</strong>\x20and\x20<strong>lower</strong>\x20limbs\x20are\x20<strong>affected</strong>,\x20and\x20a\x20part\x20of\x20the\x20limbs\x20may\x20be\x20missing.\x20Fused\x20fingers\x20and\x20missing\x20thumbs\x20are\x20also\x20seen.\x20Thalidomide\x20was\x20originally\x20used\x20for\x20the\x20treatment\x20of\x20<strong>pregnancy-associated\x20morning\x20sickness</strong>\x20but\x20was\x20<strong>withdrawn</strong>\x20due\x20to\x20this\x20adverse\x20effect.&nbsp;It\x20re-entered\x20the\x20market\x20for\x20the\x20treatment\x20of\x20erythema\x20nodosum\x20leprosum.\x20It\x20also\x20has&nbsp;<strong>antiangiogenic</strong>\x20and\x20<strong>immunomodulatory</strong>\x20effects.</p>\x0a<p>&nbsp;</p>','Hydralazine\x20-\x20heart\x20failure','tOuXF','<p>True\x20statements\x20regarding\x20the\x20administration\x20of\x20<strong>5\x20alpha-reductase\x20inhibitors</strong>\x20are\x20<strong>1,4</strong>.\x20They\x20reduce\x20dihydrotestosterone\x20levels\x20and\x20decrease\x20prostate-specific\x20antigen\x20(PSA)\x20levels.</p>\x0a<p>5\x20alpha-reductase\x20inhibitors\x20are\x20the\x20<strong>competitive</strong>\x20inhibitors\x20of\x20the\x20enzyme\x205\x20α-reductase\x20which\x20converts\x20testosterone\x20into\x20the\x20more\x20active\x20dihydroxy\x20testosterone\x20(<strong>DHT</strong>).\x20This\x20enzyme\x20inhibition\x20results\x20in:</p>\x0a<ul>\x0a<li><strong>Decreased\x20DHT\x20</strong>levels</li>\x0a<li><strong>Decreased\x20PSA\x20</strong>levels</li>\x0a<li>Reduces\x20prostate\x20volume</li>\x0a</ul>\x0a<p>However,\x20plasma\x20<strong>testosterone</strong>\x20levels\x20and\u00a0<strong>LH</strong>\x20(luteinizing\x20hormone)\x20levels\x20remain\x20<strong>unchanged\u00a0</strong></p>\x0a<p><strong>Finasteride</strong>\x20and\x20<strong>dutasteride</strong>\x20are\x20the\x205\x20α-reductase\x20drugs\x20currently\x20in\x20use.\x20They\x20are\x20used\x20in\x20benign\x20prostatic\x20hyperplasia\x20(<strong>BPH</strong>)\x20along\x20with\x20surgery\x20and\x20adrenergic\x20α1\x20blockers\x20for\x20symptomatic\x20relief.\x20They\x20can\x20also\x20be\x20used\x20in\x20<strong>male\x20pattern\x20of\x20baldness</strong>\x20and\x20hirsutism.</p>\x0a<p>Side\x20effects\x20of\x205\x20α-reductase\x20drugs\x20are:</p>\x0a<ul>\x0a<li><strong>Impotence</strong></li>\x0a<li>Decreased\x20libido</li>\x0a<li>Gynecomastia</li>\x0a<li>Skin\x20rashes</li>\x0a</ul>','VVULy','nav-btn-current','pop','NpfMM','https://dhmbxeygs57ff.cloudfront.net/uploads/7548819eafdf43d6b3155642ccd9e678x1184x1162.PNG','mSGDV','Although\x20HMG-CoA\x20reductase\x20inhibitors\x20substantially\x20reduce\x20the\x20risk\x20of\x20cardiovascular\x20events,\x20there\x20is\x20mild\x20increase\x20in\x20lipoprotein\x20a\x20(Lpa)\x20levels.','Voglibose','1-a,\x202-b,\x203-c,\x204-d','timeSpent','Zidovudine','<p>This\x20type\x20of\x20drug\x20is\x20called\x20a\x20<strong>misbranded\x20drug</strong>.\x20A\x20drug\x20stating\x20that\x20500mg\x20of\x20paracetamol\x20is\x20present\x20in\x20each\x20tablet,\x20but\x20contains\x20only\x20200mg\x20is\x20a&nbsp;<strong>misbranded</strong>&nbsp;<strong>drug</strong>,\x20according\x20to\x20the\x20<strong>Drugs\x20and\x20Cosmetics\x20Act,\x201940</strong>\x20definition\x20of\x20misbranded\x20drugs.</p>\x0a<p>According\x20to\x20the\x20Drugs\x20and\x20Cosmetics\x20act,\x201940,&nbsp;a\x20misbranded\x20drug\x20is\x20a\x20drug\x20if\x20its\x20<strong>label</strong>\x20or\x20container\x20or\x20anything\x20accompanying\x20the\x20drug\x20bears\x20any\x20statement,\x20design,\x20or\x20device\x20which\x20makes\x20any\x20<strong>false\x20claim</strong>\x20for\x20the\x20drug\x20or\x20which\x20is\x20false\x20or\x20misleading\x20in\x20any\x20particular.</p>\x0a<p>Other\x20options:</p>\x0a<p>Option\x20A:&nbsp;<strong>Spurious\x20drugs</strong>&nbsp;include\x20drugs\x20manufactured\x20under&nbsp;<strong>another\x20drug&nbsp;</strong>or<strong>&nbsp;manufacturer\x27s\x20name</strong>,&nbsp;<strong>imitations</strong>&nbsp;of\x20other\x20drugs,\x20and\x20drugs\x20with\x20labels\x20from\x20a&nbsp;<strong>fictitious\x20company</strong>&nbsp;or\x20individual.\x20It\x20also\x20includes\x20drugs\x20substituted\x20partly\x20or\x20wholly\x20by\x20another\x20drug\x20or\x20substance.</p>\x0a<p>Option\x20B:&nbsp;<strong>Adulterated\x20drugs</strong>&nbsp;include\x20those\x20drugs\x20that\x20contain&nbsp;<strong>filthy</strong>,\x20or\x20decomposed&nbsp;<strong>substances</strong>,\x20substances\x20that\x20are&nbsp;<strong>injurious\x20to\x20health</strong>,\x20or\x20if\x20the\x20drug\x20harmful\x20substances\x20to&nbsp;<strong>reduce&nbsp;</strong>the<strong>&nbsp;quality&nbsp;</strong>or<strong>&nbsp;strength&nbsp;</strong>of\x20the\x20drug.\x20It\x20also\x20includes\x20drugs\x20that\x20were\x20prepared\x20in\x20unsanitary\x20conditions.</p>\x0a<p>Option\x20C:\x20The\x20term&nbsp;unethical\x20drug\x20is\x20not\x20standard\x20terminology\x20in\x20pharmacology.\x20However,\x20the\x20term<strong>\x20ethical\x20drug\x20</strong>is\x20sometimes\x20used\x20to\x20describe\x20those\x20<strong>drugs</strong>\x20that\x20are\x20available\x20<strong>only\x20by\x20prescription</strong>\x20of\x20a\x20medical\x20practitioner.</p>','RBksE','Atenolol\x20-\x20hemolytic\x20anemia','Monoclonal\x20antibody\x20which\x20acts\x20against\x20CD50','COvHo','incorrectResult','fHvcr','tfAFi','XWjZi','info','pePnf','location','qAeTq','<p><span\x20style=\x22font-size:\x2014px;\x22>The\x20correct\x20option\x20among\x20the\x20following\x20is<strong>\x20A,\x20C,\x20and\x20D.</strong></span></p>\x0a<div\x20class=\x22page\x22\x20title=\x22Page\x2061\x22>\x0a<div\x20class=\x22layoutArea\x22>\x0a<div\x20class=\x22column\x22>\x0a<p>Bioavailability\x20is\x20defined\x20as\x20the\x20<strong>fraction\x20</strong>of\x20a\x20<strong>drug</strong>\x20reaching<strong>\x20systemic\x20circulation\x20</strong>in\x20an&nbsp;unchanged\x20form\x20after\x20administration\x20by\x20any\x20route.<span\x20style=\x22font-size:\x2014px;\x22>&nbsp;The&nbsp;</span>area\x20under\x20the\x20blood\x20concentration-time\x20curve\x20(AUC)<span\x20style=\x22font-size:\x2014px;\x22>\x20is\x20proportional\x20to\x20the\x20dose\x20and\x20the\x20extent\x20of\x20bioavailability\x20for\x20a\x20drug.</span></p>\x0a</div>\x0a</div>\x0a</div>\x0a<p><strong>Bioavailability\x20(F)\x20=\x20Quantity\x20of\x20drug\x20reaching\x20systemic\x20circulation/Quantity\x20of\x20drug\x20administered</strong></p>\x0a<p>Bioavailability\x20depends\x20on\x20two\x20factors,\x20absorption\x20and&nbsp;1st\x20pass\x20metabolism.&nbsp;The\x20bioavailability\x20of\x20the\x20drug&nbsp;<strong>injected\x20intravenously</strong>\x20is\x20<strong>100%.</strong>&nbsp;But\x20it\x20is\x20lower&nbsp;after\x20<strong>oral\x20ingestion</strong>\x20because\x20of&nbsp;incomplete\x20absorption\x20and\x20first-pass&nbsp;metabolism\x20in\x20the\x20intestinal\x20wall\x20or\x20liver\x20and\x20lies\x20between\x20<strong>5%\x20to\x20&lt;100%</strong>.\x20The\x20bioavailability\x20of&nbsp;<strong>subcutaneous\x20</strong>and\x20<strong>intramuscular\x20</strong>routes\x20lies\x20between\x20<strong>75%\x20to&nbsp;<span\x20style=\x22font-size:\x2014px;\x22>&le;100%.</span></strong></p>\x0a<p>The\x20image\x20given\x20below\x20shows\x20the\x20difference\x20between\x20the\x20bioavailability\x20of\x20drugs\x20injected\x20intravenously\x20(IV)\x20and\x20administered\x20per\x20orally\x20(PO).\x20Note\x20the\x20area\x20under\x20the\x20respective\x20curves\x20shaded\x20in\x20red\x20and\x20blue\x20colors\x20which\x20represent\x20the\x20absorption\x20of\x20the\x20drug.</p>','test','notAttempted','<p><strong>Varenicline</strong>\x20is\x20the\x20most\x20effective\x20oral\x20drug\x20for\x20smoking\x20cessation.</p>\x0a<p><strong>Nicotine</strong>\x20is\x20the\x20principal\x20constituent\x20of\x20tobacco\x20responsible\x20for\x20its\x20addictive\x20behaviour.&nbsp;Varenicline\x20works\x20by\x20blocking\x20the\x20effects\x20of\x20nicotine\x20on\x20the\x20brain.\x20It\x20<strong>blocks</strong>\x20<strong>&alpha;4</strong>,\x20and<strong>\x20&beta;2\x20nicotinic\x20acetylcholine\x20receptor</strong>\x20subtypes\x20and&nbsp;<strong>inhibits\x20dopaminergic\x20activation</strong>\x20produced\x20by\x20smoking\x20through\x20their\x20<strong>partial\x20agonism.\x20</strong>It&nbsp;decreases\x20the\x20craving\x20and\x20withdrawal\x20syndrome\x20that\x20occurs\x20with\x20cessation\x20attempts.\x20It\x20prevents\x20nicotine\x20stimulation\x20of\x20the\x20mesolimbic\x20dopamine\x20system\x20associated\x20with\x20nicotine\x20addiction,\x20thus\x20helping\x20to\x20occlude\x20the\x20rewarding\x20effect\x20of\x20smoking.</p>\x0a<p>Varenicline\x20is\x20prescribed\x20only\x20to\x20patients\x20<strong>18\x20years</strong>\x20or\x20older.\x20It\x20is\x20taken\x20<strong>orally</strong>\x20and\x20the\x20dose\x20taken\x20is\x200.5\x20mg\x20once\x20daily\x20on\x20days\x201\x20to\x203,\x20increased\x20to\x200.5\x20mg\x20twice\x20daily\x20on\x20days\x204\x20through\x207,\x20and\x201\x20mg\x20twice\x20daily\x20after\x20day\x208\x20for\x2011\x20weeks.\x20Therapy\x20should\x20start\x20one\x20week\x20before\x20the\x20target\x20quit\x20date.\x20It\x20can\x20be\x20continued\x20for\x20another\x2012\x20weeks\x20(1\x20mg\x20BD)\x20to\x20maintain\x20abstinence.</p>\x0a<p>The\x20adverse\x20effects\x20include\x20nausea,\x20disturbed\x20sleep,\x20sleepwalking,\x20agitation,\x20drowsiness,\x20and\x20constipation,\x20and&nbsp;may\x20also\x20increase\x20the\x20risk\x20of\x20pancreatitis.\x20Varenicline\x20has\x20also\x20been\x20implicated\x20in\x20specific\x20skin\x20syndromes\x20such\x20as\x20<strong>Stevens-Johnson&nbsp;syndrome</strong>,\x20erythema\x20multiforme,\x20and\x20photosensitivity.\x20Varenicline\x20can\x20cause\x20renal\x20failure\x20and\x20kidney\x20stones,\x20thus\x20renal\x20function\x20must\x20be\x20monitored.</p>\x0a<p>The\x20FDA\x20has\x20issued\x20a\x20warning\x20about\x20<strong>mood</strong>\x20and\x20<strong>behavioural\x20changes</strong>\x20associated\x20with\x20its\x20use,\x20and\x20there\x20is\x20some\x20evidence\x20of\x20<strong>increased\x20cardiovascular\x20risk.</strong></p>\x0a<p><strong>Cevimeline</strong><span\x20data-preserver-spaces=\x22true\x22>&nbsp;is\x20a&nbsp;</span><strong><span\x20data-preserver-spaces=\x22true\x22>muscarinic\x20agonist</span></strong><span\x20data-preserver-spaces=\x22true\x22>&nbsp;with\x20an\x20affinity\x20for\x20both&nbsp;</span><strong><span\x20data-preserver-spaces=\x22true\x22>M1</span></strong><span\x20data-preserver-spaces=\x22true\x22>&nbsp;and</span><strong><span\x20data-preserver-spaces=\x22true\x22>&nbsp;M3&nbsp;</span></strong><span\x20data-preserver-spaces=\x22true\x22>receptors\x20on\x20the\x20lacrimal\x20and\x20salivary\x20glands.&nbsp;</span><span\x20data-preserver-spaces=\x22true\x22>While&nbsp;</span><strong><span\x20data-preserver-spaces=\x22true\x22>M1\x20activation&nbsp;</span></strong>results\x20in&nbsp;<strong><span\x20data-preserver-spaces=\x22true\x22>increased\x20secretion</span></strong><span\x20data-preserver-spaces=\x22true\x22>,&nbsp;</span><strong><span\x20data-preserver-spaces=\x22true\x22>M3\x20activation&nbsp;</span></strong>results\x20in<strong><span\x20data-preserver-spaces=\x22true\x22>&nbsp;smooth\x20muscle\x20contraction</span></strong><span\x20data-preserver-spaces=\x22true\x22>,\x20and\x20expulsion\x20of\x20the\x20secretions.&nbsp;</span><span\x20data-preserver-spaces=\x22true\x22>Cevimeline\x20enhances\x20lacrimal\x20secretions\x20in&nbsp;</span><strong><span\x20data-preserver-spaces=\x22true\x22>Sjogren&rsquo;s\x20syndrome.</span></strong></p>\x0a<p>&nbsp;</p>','Prostaglandins\x20have\x205\x20carbon\x20ring','JbgWj','Isomj','MWAAf','Atorvastatin\x2080\x20mg','jLNce','A\x20patient\x20who\x20is\x20a\x20known\x20case\x20of\x20HIV\x20is\x20started\x20on\x20combined\x20active\x20antiretroviral\x20therapy\x20(cART).\x20After\x205\x20months\x20of\x20treatment,\x20he\x20develops\x20hyperpigmentation\x20in\x20the\x20palms\x20and\x20soles.\x20What\x20is\x20the\x20most\x20likely\x20drug\x20causing\x20this?','3,\x204','totalTimeResult','9jHTAkt','Tolerance\x20develops\x20due\x20to\x20long-term\x20use.','TwdMC','</div>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<div\x20class=\x22option-text\x22>','kNnHz','return\x20(function()\x20','scoreCircle','OOfXR','aFIMJ','GmfMh','PPxwm','<div\x20class=\x22mt-2\x22><p\x20class=\x22text-sm\x20text-white\x20text-opacity-70\x20mb-1\x22>Hinglish\x20Explanation:</p><audio\x20src=\x22','cAMP','oKDeM','qKXtk','<p>The<strong>\x20antilipidemic\x20drugs</strong>\x20likely\x20to\x20cause<strong>\x20gallstones\x20</strong>are\x20the\x20peroxisome\x20proliferator-activated\x20receptors\x20(<strong>PPARs</strong>)\x20that\x20act\x20by\x20activating\x20<strong>PPAR\x20alpha.</strong></p>\x0a<p><strong>PPARs</strong>\x20are\x20a\x20superfamily\x20of\x20nuclear\x20receptors\x20involved&nbsp;in\x20the\x20regulation\x20of\x20energy\x20homeostasis\x20and\x20metabolic\x20function.&nbsp;It\x20has\x20three\x20subtypes:</p>\x0a<ul>\x0a<li>PPAR&alpha;\x20-\x20reduces\x20triglyceride\x20level&nbsp;</li>\x0a<li>PPAR&gamma;\x20-\x20causes\x20insulin\x20sensitization&nbsp;</li>\x0a<li>PPAR&delta;\x20-\x20enhances\x20fatty\x20acids\x20metabolism</li>\x0a</ul>\x0a<p>Lipoprotein\x20lipase\x20(LPL)\x20is\x20a\x20key\x20enzyme\x20in\x20the\x20degradation\x20of\x20VLDL.\x20Fibrates\x20bind\x20to\x20PPAR\x20alpha\x20and\x20cause\x20<strong>stimulation</strong>\x20of\x20<strong>lipoprotein\x20lipase</strong>\x20enzyme.\x20Increased\x20LPL\x20synthesis\x20enhances\x20the\x20clearance\x20of\x20triglyceride-rich\x20lipoproteins.\x20Additionally,\x20fibrates\x20also\x20<strong>stimulate\x20fatty\x20acid\x20oxidation</strong>\x20and\x20<strong>reduce</strong>\x20the\x20expression\x20of\x20<strong>apo\x20C-III</strong>\x20(inhibitor\x20of\x20lipolysis).\x20All\x20fibrates\x20increase\x20the\x20lithogenicity\x20of\x20bile,\x20thereby\x20increasing\x20the\x20risk\x20of\x20gall\x20stones</p>\x0a<p>Other\x20options:&nbsp;</p>\x0a<table\x20style=\x22height:\x20531px;\x20width:\x20498px;\x22>\x0a<tbody>\x0a<tr>\x0a<td\x20style=\x22width:\x2016.0156px;\x22><span\x20style=\x22text-decoration:\x20underline;\x22><strong>Class</strong></span></td>\x0a<td\x20style=\x22width:\x2010px;\x22><strong>HMG-\x20CoA\x20reductase\x20inhibitors\x20(statins)</strong></td>\x0a<td\x20style=\x22width:\x2070px;\x22><strong>Niacin</strong></td>\x0a<td\x20style=\x22width:\x2010px;\x22><strong>Bile\x20acid-binding\x20resins</strong></td>\x0a</tr>\x0a<tr>\x0a<td\x20style=\x22width:\x2016.0156px;\x22><span\x20style=\x22text-decoration:\x20underline;\x22><strong>Examples</strong></span></td>\x0a<td\x20style=\x22width:\x2010px;\x22>\x0a<p\x20class=\x22p1\x22>Lovastatin,\x20atorvastatin</p>\x0a</td>\x0a<td\x20style=\x22width:\x2070px;\x22>Niacin</td>\x0a<td\x20style=\x22width:\x2010px;\x22>\x0a<p>Colestipol,\x20<br\x20/>colesevelam</p>\x0a</td>\x0a</tr>\x0a<tr>\x0a<td\x20style=\x22width:\x2016.0156px;\x22><span\x20style=\x22text-decoration:\x20underline;\x22><strong>Mechanism\x20of\x20action</strong></span></td>\x0a<td\x20style=\x22width:\x2010px;\x22>\x0a<p\x20class=\x22p1\x22>Inhibits\x20HMG-CoA\x20reductase</p>\x0a</td>\x0a<td\x20style=\x22width:\x2070px;\x22>Decreases\x20the\x20production\x20of\x20VLDLs\x20and\x20the\x20catabolism\x20of\x20HDLs</td>\x0a<td\x20style=\x22width:\x2010px;\x22>Binds\x20to\x20bile\x20acids\x20in\x20the\x20intestinal\x20lumen\x20and\x20increases\x20excretion.&nbsp;</td>\x0a</tr>\x0a<tr>\x0a<td\x20style=\x22width:\x2016.0156px;\x22><span\x20style=\x22text-decoration:\x20underline;\x22><strong>Major\x20effects\x20on\x20lipoprotein\x20levels</strong></span></td>\x0a<td\x20style=\x22width:\x2010px;\x22>\x0a<p>Reduces\x20LDL\x20levels</p>\x0a</td>\x0a<td\x20style=\x22width:\x2070px;\x22>\x0a<ul>\x0a<li>Reduces\x20triglycerides,&nbsp;\x20LDL,\x20and\x20lipoprotein\x20a\x20levels</li>\x0a<li>Significant\x20<strong>increase\x20HDL</strong>\x20levels</li>\x0a</ul>\x0a</td>\x0a<td\x20style=\x22width:\x2010px;\x22>Reduces\x20LDL\x20levels&nbsp;</td>\x0a</tr>\x0a<tr>\x0a<td\x20style=\x22width:\x2016.0156px;\x22><span\x20style=\x22text-decoration:\x20underline;\x22><strong>Important\x20side\x20effects</strong></span></td>\x0a<td\x20style=\x22width:\x2010px;\x22>\x0a<ul>\x0a<li><strong>Myopathy</strong></li>\x0a<li\x20class=\x22p1\x22>Elevations\x20of\x20serum\x20amino-transferase\x20activity</li>\x0a<li\x20class=\x22p1\x22>Elevation\x20of\x20creatine\x20kinase\x20activity</li>\x0a</ul>\x0a</td>\x0a<td\x20style=\x22width:\x2070px;\x22>\x0a<ul>\x0a<li>Cutaneous\x20vasodilation</li>\x0a<li>Elevations\x20in\x20amino-transferases\x20levels&nbsp;</li>\x0a</ul>\x0a</td>\x0a<td\x20style=\x22width:\x2010px;\x22>\x0a<ul>\x0a<li>Constipation</li>\x0a<li>Bloating&nbsp;</li>\x0a</ul>\x0a</td>\x0a</tr>\x0a</tbody>\x0a</table>\x0a<p>&nbsp;</p>','EEEiT','tqhpz','True\x20statement\x20regarding\x20the\x20administration\x20of\x205\x20alpha-reductase\x20inhibitors\x20is/are:','src','KrdJF','\x22\x20controls\x20class=\x22w-full\x22></audio></div>','mUwVe','gWHEx','1,2,4','Muscarine','4,\x203,\x202,\x201','PUrLa','Correct','RfWlj','pQlJB','Marrow','</div>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20','Drug\x202\x20represents\x20partial\x20agonist\x20and\x20drug\x203\x20represents\x20inverse\x20agonist','getAttribute','hidden','solutionContainer','Calcium','quizPerformanceData','OlMcU','<div\x20class=\x22page\x22\x20title=\x22Page\x20942\x22>\x0a<div\x20class=\x22section\x22>\x0a<div\x20class=\x22layoutArea\x22>\x0a<div\x20class=\x22column\x22>\x0a<p><strong>Rituximab</strong>\x20is\x20a&nbsp;<strong>monoclonal\x20antibody</strong>\x20that\x20acts\x20against<strong>\x20CD20\x20B&shy;-cell\x20antigen</strong>\x20expressed\x20on\x20the\x20surface\x20of\x20B&shy;-lymphocytes,\x20plasma\x20cells,\x20and\x20B&shy;-cell\x20lymphomas.</p>\x0a<div\x20class=\x22page\x22\x20title=\x22Page\x20943\x22>\x0a<div\x20class=\x22section\x22>\x0a<div\x20class=\x22layoutArea\x22>\x0a<div\x20class=\x22column\x22>\x0a<div\x20class=\x22page\x22\x20title=\x22Page\x20943\x22>\x0a<div\x20class=\x22section\x22>\x0a<div\x20class=\x22layoutArea\x22>\x0a<div\x20class=\x22column\x22>\x0a<p>It\x20promotes\x20<strong>apoptosis</strong>\x20through\x20transmembrane\x20signal&shy;ling\x20as\x20well\x20as\x20by\x20<strong>antibody\x20&shy;dependent</strong>\x20and\x20<strong>complement</strong>&shy;\x20dependent\x20cytotoxicity.\x20It\x20is\x20used\x20in\x20the\x20treatment\x20of\x20<strong>B&shy;-cell\x20lymphoma</strong>,\x20<strong>non-&shy;Hodgkin\x20lymphoma,</strong>\x20and\x20<strong>chronic\x20lymphocytic\x20leukemia</strong>.\x20It\x20can\x20be\x20used\x20both\x20as\x20a\x20single\x20agent\x20as\x20well\x20as\x20in\x20combination\x20with\x20cyto&shy;toxic\x20chemotherapy.</p>\x0a<div\x20class=\x22page\x22\x20title=\x22Page\x20943\x22>\x0a<div\x20class=\x22section\x22>\x0a<div\x20class=\x22layoutArea\x22>\x0a<div\x20class=\x22column\x22>\x0a<div\x20class=\x22page\x22\x20title=\x22Page\x20943\x22>\x0a<div\x20class=\x22section\x22>\x0a<div\x20class=\x22layoutArea\x22>\x0a<div\x20class=\x22column\x22>\x0a<p>Adverse\x20effects\x20are\x20infusion\x20reactions\x20like\x20chills,\x20fever,\x20urticarial\x20rashes,\x20pruritus,\x20dyspnea,\x20and\x20hypotension.\x20Pretreatment\x20with\x20antihistaminics\x20and\x20corticosteroids\x20prevents\x20the\x20reactions.</p>\x0a</div>\x0a</div>\x0a</div>\x0a</div>\x0a</div>\x0a</div>\x0a</div>\x0a</div>\x0a</div>\x0a</div>\x0a</div>\x0a</div>\x0a</div>\x0a</div>\x0a</div>\x0a</div>\x0a</div>\x0a</div>\x0a</div>\x0a</div>','correct','study','Aliskiren\x20-\x20hypokalemia','solutionText','QpZjZ','hjvMd','\x22\x20data-src=\x22','https://cdn1.dailyrounds.org/uploads/1cdc3b043f0b47cbac9a11aee230237c.JPEG','prototype','jbGaM','video[data-src]','voIHe','iXBwt','zLRsH','MGBPL','ArrowLeft','title','aahzq','oYLER','questionNav','CtMyV','quizFile','LKUoC','DOMContentLoaded','totalAttempted','New\x20drug\x20application\x20is\x20done\x20after\x20phase\x204','nav-btn-incorrect','NNleC','answered','124716pieGfU','incorrectCount','Potency\x20of\x20drug\x20B\x20is\x20more\x20than\x20that\x20of\x20drug\x20A.','<p>The\x20correct\x20option\x20regarding\x20the\x20drugs\x20used\x20to\x20treat\x20schizophrenia\x20symptoms\x20is\x20<strong>option\x20C</strong>.</p>\x0a<p>Drugs\x20used\x20to\x20treat\x20schizophrenia\x20can\x20be\x20classified:</p>\x0a<ul>\x0a<li>Typical\x20or\x201st\x20generation\x20antipsychotics.</li>\x0a<li>Atypical\x20or\x202nd\x20generation\x20antipsychotics.</li>\x0a</ul>\x0a<p>All\x20typical\x20antipsychotics\x20markedly\x20<strong>improve\x20positive\x20symptoms</strong>\x20of\x20schizophrenia,\x20which\x20is\x20attributed\x20to\x20their\x20<strong>antagonism</strong>\x20at&nbsp;the<strong>\x20D<sub>2</sub>\x20receptor</strong>.\x20Some\x20of\x20the\x20drugs\x20included\x20in\x20this\x20class\x20are\x20<strong>chlorpromazine</strong>\x20and\x20<strong>haloperidol.</strong></p>\x0a<p>Atypical\x20antipsychotics\x20are\x20antagonists\x20or\x20inverse\x20agonists\x20at\x20the\x205HT<sub>2A</sub>\x20receptor.\x20<strong>5HT<sub>2A</sub>\x20antagonism</strong>\x20is\x20responsible\x20for\x20<strong>reducing\x20negative\x20symptoms</strong>\x20in\x20schizophrenia.\x20Some\x20of\x20the\x20drugs\x20that\x20belong\x20to\x20this\x20class\x20are\x20clozapine,\x20aripiprazole,\x20and\x20brexpiprazole.</p>\x0a<p>Atypical\x20antipsychotics\x20have\x20lower\x20extrapyramidal\x20symptoms\x20as\x20compared\x20to\x20typical\x20antipsychotics\x20as\x20the\x20former\x20has\x20a\x20lesser\x20affinity\x20to\x20the\x20D2\x20receptor.\x20<strong>Muscarinic\x20antagonists</strong>&nbsp;can\x20be\x20given\x20to\x20decrease\x20the\x20extrapyramidal\x20symptoms.\x20For\x20example,\x20<strong>promethazine</strong>\x20or\x20<strong>hydroxyzine</strong>\x20is\x20given\x20for\x20acute\x20muscular\x20dystonia,\x20which\x20is\x20a\x20form\x20of\x20extrapyramidal\x20symptoms.</p>\x0a<p><strong>5HT<sub>1A</sub>\x20receptor\x20antagonism</strong>,&nbsp;not\x20agonism,\x20has\x20been\x20found\x20to\x20reduce\x20food\x20intake\x20and\x20hence\x20reduce\x20body\x20weight.</p>\x0a<div\x20class=\x22page\x22\x20title=\x22Page\x20256\x22>\x0a<div\x20class=\x22section\x22>\x0a<div\x20class=\x22layoutArea\x22>\x0a<div\x20class=\x22column\x22>\x0a<p>Aripiprazole\x20and\x20brexpiprazole\x20are\x20atypical\x20antipsychotics\x20that\x20have\x20partial\x20agonist\x20effects\x20at\x20the\x205HT<sub>1A</sub>\x20receptor.\x20They\x20have\x20been\x20approved\x20for\x20the\x20treatment\x20of\x20schizophrenia\x20and\x20as\x20an\x20adjunctive\x20treatment\x20for\x20depression.</p>\x0a</div>\x0a</div>\x0a</div>\x0a</div>','A\x20hypertensive\x20patient\x20on\x20medication\x20presents\x20with\x20the\x20lab\x20values\x20as\x20shown\x20below.\x20Which\x20of\x20the\x20following\x20drugs\x20should\x20be\x20stopped?','preventDefault','markReviewBtn','add','yfqnF','push','XteJB','These\x20drugs\x20should\x20not\x20be\x20stopped\x20even\x20in\x20severe\x20conditions\x20like\x20injury,\x20surgery,\x20etc.','Penicillin','aGfyM','RamHi','A\x20lady\x20who\x20had\x20undergone\x20mastectomy\x20for\x20breast\x20cancer\x20is\x20being\x20treated\x20with\x20tamoxifen.\x20How\x20long\x20should\x20it\x20be\x20stopped\x20for\x20before\x20she\x20can\x20conceive?','N\x20-\x20acetyl\x20cyclophosphamide','Not\x20Attempted','cEpEr','10TbAQuL','Furosemide','Frusemide','Lithium','PbArp','Quinidine','<div\x20class=\x22p-3\x20rounded-lg\x20border\x20','Tmax','lYUpX','sZWGY','doekT','FHBEB','getItem','smgPb','quizSidebar','Trastuzumab','Inj.\x20Fluconazole,\x20followed\x20by\x20oral\x20fluconazole','TuRqX','No\x20questions\x20available\x20for\x20this\x20quiz.','WbwVJ','1-c,\x202-d,\x203-a,\x204-b','A-2,\x20B-4,\x20C-1,\x20D-3','10QMtJYK','selectedAnswer','Bradycardia','QvInC','RcTKH','ZaDMl','nKpuV','none','A\x20new\x20drug\x20application\x20is\x20filed\x20after\x20which\x20phase\x20of\x20clinical\x20trials?','qodOn','text','Inhibition\x20of\x20phosphodiesterase-5','removeItem','solutionVideo','dOfUB','prevBtn','mYKpf','Phase\x203','Nelfinavir','HrgDn','stringify','Ofxfj','arwpo','accuracy','cbecS','\x20-\x20Brain\x20And\x20Scalpel','3386104FNPIWE','button','tAvwn','NAPQI\x20is\x20the\x20metabolite\x20of\x20which\x20of\x20the\x20following\x20drug\x20toxicity?','\x20>\x20','Calcium\x20channel\x20blockers','1-a,\x202-c,\x203-d,\x204-b','Weakly\x20basic\x20drugs','Match\x20the\x20following\x20teratogenic\x20drugs\x20with\x20their\x20teratogenic\x20effects.','isSupported','Release\x20of\x20nitrous\x20oxide\x20radicals','div','OFgdr','<div\x20class=\x22mt-2\x22><p\x20class=\x22text-sm\x20text-white\x20text-opacity-70\x20mb-1\x22>English\x20Explanation:</p><audio\x20src=\x22','yxRKR','axiMd','error','search','kZvQJ','KLDcC','reload','Bebtelovimab','ggWHb','Tocainide','yRVlc','<p><strong>Sildenafil\x20</strong>is\x20a<strong>\x20phosphodiesterase\x205\x20inhibitor\x20</strong>and<strong>&nbsp;</strong>the<strong>&nbsp;</strong>action\x20of\x20the\x20drug\x20is\x20mediated\x20through<strong>\x20cGMP</strong>.\x20Erectile\x20dysfunction&nbsp;is\x20treated\x20by\x20phosphodiesterase-5&nbsp;(PDE-5)\x20inhibitors\x20like\x20sildenafil,\x20vardenafil,\x20and\x20tadalafil<strong>.&nbsp;</strong></p>\x0a<p>The\x20corpus\x20cavernosum\x20produces\x20nitric\x20oxide\x20during\x20arousal\x20that\x20stimulates\x20the\x20formation\x20of\x20cGMP.\x20cGMP\x20causes\x20relaxation\x20of\x20the\x20smooth\x20muscle\x20of\x20the\x20corpus\x20cavernosum\x20and\x20penile\x20arteries,\x20engorgement\x20of\x20the\x20corpus\x20cavernosum,\x20and\x20erection.&nbsp;</p>\x0a<p>The\x20above-mentioned\x20drugs<strong>\x20compete</strong>\x20for\x20<strong>cyclic\x20GMP</strong>,\x20binding\x20at\x20the\x20site\x20of\x20cyclic\x20GMP\x20hydrolysis\x20on\x20PDE5,\x20enhancing\x20the\x20<strong>accumulation\x20</strong>of<strong>\x20cGMP&nbsp;</strong>and\x20hence\x20used\x20in\x20the\x20management\x20of\x20erectile\x20dysfunction.\x20They\x20are\x20useful\x20in\x20treating\x20pulmonary\x20arterial\x20hypertension.</p>\x0a<p><strong>Adverse\x20effects</strong>\x20of\x20the\x20drug\x20are&nbsp;headache,\x20flushing,\x20nasal\x20congestion,\x20nasopharyngitis,\x20and\x20dyspepsia.&nbsp;Sildenafil\x20and\x20Vardenafil&nbsp;also\x20cause\x20<strong>retinal</strong>\x20<strong>PDE-6\x20inhibition</strong>\x20and\x20can\x20result\x20in\x20blurring\x20of\x20vision\x20and\x20<strong>blue-green\x20tinting\x20of\x20the\x20vision</strong>.</p>\x0a<p>&nbsp;</p>','Diclofenac','Phase\x204\x20is\x20also\x20called\x20post-marketing\x20surveillance','A\x20and\x20C','ookrk','XrCFr','<p>The\x20given\x20clinical\x20scenario\x20and\x20the\x20image\x20showing\x20a\x20pin-point\x20pupil\x20(miosis)\x20suggest&nbsp;<strong>opioid\x20overdose</strong>.\x20The\x20true\x20statement\x20among\x20those\x20given\x20is\x20that\x20it\x20is\x20caused\x20by\x20activation\x20of\x20the<strong>\x20Edinger-Westphal\x20nucleus.</strong></p>\x0a<p><strong>Edinger-Westphal\x20nucleus</strong>\x20is\x20a\x20part\x20of\x20the\x20<strong>light\x20reflex\x20pathway\x20</strong>and\x20is&nbsp;located\x20in\x20the\x20midbrain.\x20This\x20nucleus\x20is\x20responsible\x20for\x20causing\x20<strong>pupillary\x20constriction</strong>\x20when\x20the\x20retina\x20is\x20exposed\x20to\x20light.&nbsp;</p>\x0a<p>Opioid\x20overdose\x20symptoms\x20are\x20a\x20triad\x20of\x20coma,\x20respiratory\x20depression,\x20and\x20pinpoint\x20pupils\x20(miosis).\x20Other\x20features\x20are\x20hypotension,\x20bradycardia,\x20shallow\x20breathing,\x20and\x20hypothermia.</p>\x0a<p><strong>Tolerance</strong>&nbsp;to\x20miosis\x20does\x20not\x20develop\x20even\x20in\x20addicts\x20who\x20develop\x20a\x20high\x20tolerance\x20to\x20opioids.\x20Miosis\x20is\x20induced\x20by\x20all\x20opioid\x20agonists.</p>\x0a<p><strong>Naloxone&nbsp;</strong>is\x20the\x20drug\x20of\x20choice\x20for\x20opioid\x20overdose.&nbsp;It<strong>&nbsp;</strong>is\x20administered<strong>&nbsp;</strong>after\x20adequate\x20ventilation\x20is\x20established.\x20<strong>Airway\x20protection&nbsp;</strong>and&nbsp;<strong>ventilatory\x20maintenance</strong>&nbsp;are\x20the\x20most\x20important\x20steps\x20in\x20the\x20treatment\x20of\x20opioid\x20overdose;\x20this\x20is\x20because&nbsp;<strong>respiratory\x20depression</strong>&nbsp;is\x20the\x20major\x20cause\x20of\x20mortality\x20in\x20such\x20cases.&nbsp;<strong>Single-dose</strong>&nbsp;<strong>activated\x20charcoal</strong>&nbsp;can\x20be\x20administered\x20if\x20the\x20opioid\x20ingestion\x20occurred\x20within&nbsp;<strong>one\x20hour</strong>.</p>\x0a<p><strong>Levallorphan</strong>\x20is\x20an\x20<strong>opioid\x20antagonist</strong>,\x20with\x20properties\x20similar\x20to\x20those\x20of\x20<strong>naloxone</strong>.\x20It\x20can\x20be\x20used\x20for\x20<strong>opioid\x20overdose</strong>.\x20It\x20reverses\x20severe\x20opioid-induced\x20respiratory\x20depression.</p>\x0a<p><strong>Phenylephrine</strong>\x20is\x20an\x20<strong>&alpha;1-selective\x20agonist</strong>\x20that\x20causes\x20mydriasis,<strong>&nbsp;</strong>but\x20it\x20is\x20not\x20useful\x20in\x20the\x20reversal\x20of\x20opioid-induced\x20miosis.</p>','45\x20hours','not-attempted','rrwqI','bxdyZ','XpEaD','Topically\x20applied\x20sulfonamide\x20antibacterial','questionText','Phase\x202\x20is\x20done\x20on\x20healthy\x20individuals','<p><strong>N-acetyl-p-benzoquinone\x20imine</strong>&nbsp;(NAPQI)\x20is\x20a\x20metabolite\x20of\x20<strong>paracetamol</strong>\x20drug\x20toxicity.&nbsp;</p>\x0a<p>Paracetamol\x20is\x20an\x20analgesic\x20and\x20antipyretic\x20with\x20<strong>weak\x20anti-inflammatory\x20action</strong>.\x20It\x20is\x20mainly\x20metabolized&nbsp;in\x20the\x20<strong>liver</strong>\x20by\x20conjugation\x20with\x20<strong>glucuronic\x20acid</strong>\x20and\x20sulfate\x20and\x20is\x20excreted\x20in\x20the\x20urine.</p>\x0a<p>At\x20toxic\x20doses,\x20the\x20glucuronide\x20and\x20sulfate\x20conjugation\x20pathway\x20becomes\x20<strong>saturated</strong>.\x20The\x20metabolites\x20of\x20paracetamol\x20get\x20converted\x20into\x20NAPQI.\x20NAPQI\x20is&nbsp;<strong>highly\x20reactive</strong>\x20and\x20causes\x20enzymatic\x20dysfunction\x20in\x20the\x20liver.\x20Normally,\x20minor\x20amounts\x20of\x20NAPQI\x20produced\x20in\x20our\x20body\x20are\x20rapidly\x20eliminated\x20by\x20conjugation\x20with\x20<strong>reduced\x20glutathione(GSH)</strong>\x20and\x20then\x20excreted\x20into\x20the\x20urine.</p>\x0a<p>Therefore,\x20paracetamol\x20toxicity\x20is\x20treated\x20with\x20<strong>N-acetyl\x20cysteine(NAC)</strong>,\x20which\x20<strong>replenishes\x20GSH.&nbsp;</strong>NAC\x20thereby\x20helps\x20in\x20the\x20excretion\x20of\x20NAPQI\x20from\x20the\x20body.\x20N-acetyl\x20cysteine\x20is\x20an\x20<strong>anti-oxidant</strong>\x20and\x20functions\x20by\x20detoxifying\x20NAPQI.</p>\x0a<p>Paracetamol\x20poisoning\x20is\x20the\x20<strong>most\x20common</strong>\x20cause\x20of\x20liver\x20failure\x20necessitating\x20transplantation.</p>\x0a<p>The\x20<strong>maximum\x20dose</strong>\x20of\x20acetaminophen\x20that\x20can\x20be\x20given\x20is\x20<strong>4\x20g/day</strong>.&nbsp;</p>','querySelectorAll','L-glutamine','hNCGs','oJDRA','Isoniazid','filter','yOXzL','No\x20question\x20text\x20available','A\x2029-year-old\x20lady\x20came\x20to\x20psychiatry\x20OPD\x20with\x20symptoms\x20of\x20hypomania.\x20There\x20is\x20a\x20past\x20history\x20of\x20maniac\x20episode.\x20Now,\x20she\x20is\x20planning\x20to\x20conceive.\x20\x20Which\x20drug\x20should\x20be\x20avoided\x20for\x20being\x20highly\x20teratogenic\x20to\x20the\x20fetus?','https://cdn1.dailyrounds.org/uploads/9a743f063aa049a4abcbf92fcafe7d5e.PNG','yHTWF','iVPUC','<div\x20class=\x22glass-light\x20p-4\x20mb-4\x22><video\x20src=\x22','FfXtR','RvlZY','ySWBx','WzThz','Acetaminophen','Canagliflozin','HLQpX','qFAiJ','Rosuvastatin\x20+\x20Fenofibrate','055\x20Pharmacology\x20Ini-Cet\x202022','IClqz','shuYw','A\x20patient\x20was\x20diagnosed\x20with\x20pulmonary\x20tuberculosis\x20and\x20was\x20started\x20on\x20first-line\x20antitubercular\x20drugs.\x20Which\x20of\x20the\x20following\x20drug\x20acts\x20by\x20inhibiting\x20the\x20synthesis\x20of\x20the\x20marked\x20layer\x20shown\x20in\x20the\x20image?','padStart','PYQs','toString','5-alpha\x20reductase','ospvj','uvdkR','<p>The\x20wrong\x20statement/s\x20regarding\x20disulfiram\x20is\x20only\x203.</p>\x0a<p>Disulfiram\x20is\x20an\x20<strong>irreversible\x20inhibitor</strong>\x20of\x20both\x20cytosolic\x20and\x20mitochondrial\x20forms\x20of\x20<strong>aldehyde\x20dehydrogenase.</strong>&nbsp;It\x20is\x20used\x20in\x20behavioral\x20modification\x20for\x20alcohol\x20de-addiction.&nbsp;The\x20principle\x20of\x20action\x20is\x20<strong>aversive\x20conditioning</strong>\x20(not\x20anti-craving).</p>\x0a<p>Disulfiram\x20can\x20be\x20given\x20only\x20to\x20<strong>highly\x20motivated</strong>\x20individuals.\x20It\x20should\x20not\x20be\x20administered\x20until\x20the\x20person\x20has\x20<strong>abstained</strong>\x20from\x20alcohol\x20for\x20<strong>at\x20least\x2012\x20hours</strong>.&nbsp;The\x20disulfiram-alcohol\x20reaction\x20may\x20persist\x20as\x20long\x20as\x2014\x20days\x20after\x20the\x20last\x20dose\x20of\x20disulfiram.</p>\x0a<p>Alcohol\x20consumption\x20during\x20disulfiram\x20therapy\x20can\x20lead\x20to\x20<strong>increased</strong>\x20concentrations\x20of\x20<strong>acetaldehyde</strong>.\x20This\x20can\x20cause\x20aversive\x20reactions,\x20resulting\x20in\x20flushing,\x20pulsating\x20headache,\x20throbbing\x20pain\x20in\x20the\x20head\x20and\x20neck,\x20nausea,\x20vomiting,\x20rashes,\x20<strong>respiratory\x20difficulties</strong>,\x20chest\x20pain,\x20and\x20autonomic\x20manifestations.</p>\x0a<p>Disulfiram\x20is\x20usually\x20given\x20in\x20the\x20dose\x20of\x20<strong>250\x20mg/day</strong>\x20(range\x20of\x20125&ndash;500\x20mg/day).</p>','VcypI','LkUcL','rTAvp','1,4','4\x20-\x20acetyl\x20cyclophosphamide','<p>\u00a0</p>\x0a<p>Bioavailability\x20of\x20drug\u00a0injected\x20intravenously\x20is\x20100%,\x20but\x20it\x20is\x20lower\u00a0after\x20oral\x20ingestion\x20because\x20of\u00a0incomplete\x20absorption\x20and\x20first-pass\x20metabolism\x20in\x20the\x20intestinal\x20wall/liver.</p>\x0a<p>The\x20image\x20below\x20shows\x20the\x20difference\x20between\x20the\x20bioavailability\x20of\x20drugs\x20injected\x20intravenously(iv)\x20and\x20orally(PO).\x20Note\x20the\x20area\x20under\x20the\x20respective\x20curves\x20is\x20shaded\x20in\x20red\x20and\x20blue\x20colours\x20which\x20represent\x20the\x20absorption\x20of\x20the\x20drug.</p>','<p>In\x20the\x20given\x20image,\x20<strong>drug\x20A\x20&amp;\x20drug\x20B\x20are\x20agonists.</strong>&nbsp;</p>\x0a<div\x20class=\x22page\x22\x20title=\x22Page\x2053\x22>\x0a<div\x20class=\x22section\x22>\x0a<div\x20class=\x22layoutArea\x22>\x0a<div\x20class=\x22column\x22>\x0a<div\x20class=\x22page\x22\x20title=\x22Page\x2050\x22>\x0a<div\x20class=\x22section\x22>\x0a<div\x20class=\x22layoutArea\x22>\x0a<div\x20class=\x22column\x22>\x0a<p>Drugs\x20that\x20bind\x20to\x20physiological\x20receptors\x20and\x20mimic\x20the\x20regulatory\x20effects\x20of\x20endogenous\x20signaling\x20compounds\x27\x20are\x20<strong>agonists</strong>.\x20Drugs\x20that\x20are\x20only\x20partially\x20as\x20effective\x20as\x20agonists\x20are\x20<strong>partial\x20agonists</strong>.</p>\x0a<div\x20class=\x22page\x22\x20title=\x22Page\x2053\x22>\x0a<div\x20class=\x22section\x22>\x0a<div\x20class=\x22layoutArea\x22>\x0a<div\x20class=\x22column\x22>\x0a<p>The<strong>\x20efficacy</strong>\x20of\x20a\x20drug\x20indicates\x20the\x20capacity\x20of\x20a\x20drug\x20to\x20activate\x20a\x20receptor\x20and\x20<strong>generate\x20a\x20cellular\x20response</strong>.\x20A\x20drug\x20with\x20high\x20efficacy\x20is\x20a\x20full\x20agonist,\x20eliciting\x20a\x20full\x20response\x20at\x20some\x20concentration.\x20A\x20drug\x20with\x20a\x20low\x20intrinsic\x20efficacy\x20will\x20be\x20a\x20partial\x20agonist.\x20<strong>D</strong><strong>rug\x20A\x20&amp;\x20drug\x20B&nbsp;</strong>are\x20<strong>agonists&nbsp;</strong>(Option\x20C)\x20that\x20have\x20the\x20<strong>same\x20efficacy&nbsp;</strong>(Option\x20A),\x20although,\x20at\x20different\x20concentrations.</p>\x0a<p><strong>Drug\x20C</strong>\x20<strong>does\x20not\x20produce\x20a\x20full\x20response</strong>\x20at\x20any\x20concentration,\x20making\x20it\x20a\x20<strong>partial\x20agonist</strong>.\x20In\x20the\x20<strong>presence\x20of\x20a\x20full\x20agonist</strong>,\x20a\x20partial\x20agonist\x20behaves\x20like\x20a\x20<strong>competitive\x20antagonist</strong>&nbsp;(Option\x20D).</p>\x0a<p>When\x20two\x20drugs\x20produce\x20equivalent\x20responses,\x20the\x20drug\x20whose\x20dose-response\x20curve\x20lies\x20to\x20the\x20left\x20is\x20said\x20to\x20be\x20the\x20more\x20potent\x20since\x20it\x20requires\x20a\x20lower\x20dose\x20to\x20produce\x20the\x20same\x20effect.&nbsp;<strong>Drug\x20A</strong>\x20&amp;\x20<strong>drug</strong>&nbsp;<strong>B</strong>\x20produce\x20the\x20same\x20action\x20and\x20level\x20of\x20response\x20in\x20the\x20tissue.\x20The\x20curve\x20of\x20drug\x20A\x20on\x20the\x20left\x20indicates\x20that\x20it\x20produces\x20the<strong>\x20same\x20response</strong>\x20at\x20a\x20<strong>lower\x20concentration</strong>,\x20making\x20it\x20<strong>more\x20potent</strong>\x20than\x20drug\x20B\x20(Option\x20B).</p>\x0a</div>\x0a</div>\x0a</div>\x0a</div>\x0a</div>\x0a</div>\x0a</div>\x0a</div>\x0a</div>\x0a</div>\x0a</div>\x0a</div>','classList','custom_quiz.html','hUBzN','bgUYM','No\x20solution\x20provided','dArjv','Timolol','XSCPB','Spurious\x20drug','Only\x203','https://cdn1.dailyrounds.org/uploads/58ca7aff3ff64887b8cf57ae267880a1.JPEG','glass-light\x20px-6\x20py-3\x20text-white\x20hover:bg-yellow-500\x20hover:bg-opacity-20\x20transition-all\x20duration-300\x20flex\x20items-center','customQuizData','bookmarkText','LZzuk','Are\x20you\x20sure\x20you\x20want\x20to\x20leave\x20the\x20quiz?\x20Your\x20progress\x20will\x20be\x20lost.','OdcoT','GdxPQ','mxFjr','createElement','UTvYC','FpcxU','YiRsF','1\x20month','<p>The\x20correct\x20match\x20is\x20<strong>verapamil</strong>\x20causes\x20<strong>constipation</strong>.</p>\x0a<p>Verapamil\x20is\x20a\x20calcium\x20channel\x20blocker\x20used\x20for\x20the\x20treatment\x20of\x20paroxysmal\x20supraventricular\x20tachycardia,\x20atrial\x20fibrillation,\x20and\x20atrial\x20flutter.\x20Bradycardia\x20and\x20<strong>constipation</strong>\x20are\x20the\x20important\x20side\x20effects\x20of\x20verapamil.</p>\x0a<p>Other\x20options:</p>\x0a<p>Option\x20A:\x20<strong>Hydralazine</strong>\x20is\x20a\x20<strong>vasodilator</strong>\x20used\x20in\x20the\x20treatment\x20of&nbsp;heart\x20failure,\x20and\x20<strong>hypertensive\x20emergencies</strong>,\x20especially\x20preeclampsia.&nbsp;The\x20drug\x20is\x20used&nbsp;as\x20a\x20combination\x20pill\x20containing\x20isosorbide\x20dinitrate\x20(<strong>BiDil</strong>)\x20in\x20the\x20treatment\x20of\x20heart\x20failure.\x20The\x20important\x20side\x20effect\x20of\x20hydralazine\x20is\x20<strong>drug-induced\x20lupus</strong>.</p>\x0a<p>Option\x20B:\x20<strong>Atenolol</strong>\x20is\x20a\x20<strong>cardioselective\x20beta-1\x20blocker</strong>\x20used\x20in\x20the\x20treatment\x20of\x20angina\x20and\x20hypertension.\x20Atenolol\x20doesn\x27t\x20cause\x20<strong>hemolytic\x20anemia</strong>.</p>\x0a<p>Option\x20C:\x20<strong>Aliskiren</strong>\x20is\x20a\x20<strong>direct\x20renin\x20inhibitor</strong>\x20used\x20as\x20an\x20alternative&nbsp;<strong>antihypertensive</strong>\x20drug\x20for\x20those\x20who\x20do\x20not\x20respond\x20or\x20do\x20not\x20tolerate\x201st\x20line\x20drugs.\x20The\x20side\x20effect\x20of\x20aliskiren\x20is\x20<strong>hyperkalemia</strong>\x20and\x20not\x20hypokalemia.</p>','modeModal','Match\x20the\x20following\x20antiarrhythmic\x20drugs\x20with\x20their\x20mechanism\x20of\x20action:','Nivolumab','EpemS','addEventListener','Phospholipase\x20C\x20acts\x20via\x20which\x20of\x20the\x20following\x20G\x20protein-coupled\x20receptors?','yUiCZ','Aspirin','2,\x203,\x20and\x204','correct_choice_id','Hydroxyurea','Which\x20of\x20the\x20following\x20is\x20false\x20regarding\x20disulfiram?','VaGJV','2732543AqGTeK','wbPXh','JzwQP','display','bookmarkBtn','A\x20patient\x20is\x20brought\x20with\x20altered\x20sensorium\x20and\x20seizures.\x20Attender\x20shows\x20the\x20laboratory\x20report\x20which\x20reveals\x20elevated\x20transaminases.\x20Which\x20of\x20the\x20following\x20can\x20be\x20used\x20in\x20this\x20condition?','jrHja','vhZRJ','solutionAudio','bXMJu','Emtricitabine','Strong\x20electrolytes','aGvnl','Midazolam','YzOrq','submitSection','https://dhmbxeygs57ff.cloudfront.net/uploads/672ca9540c3b4fe7b9d71a5ec95b1f1dx1280x1585.JPEG','nav-btn-correct','\x22\x20data-option-index=\x22','MgUPo','InMlU','<p>The\x20correct\x20statement\x20is\x20<strong>Drug\x201\x20represents\x20agonist\x20and\x20drug\x204\x20represents\x20inverse\x20agonist.</strong></p>\x0a<p><strong>Graph\x201\x20</strong>represents\x20the\x20<strong>agonist:\x20</strong>An\x20agonist\x20is\x20an\x20agent\x20which\x20initiates\x20the\x20<strong>normal</strong>\x20<strong>physiological\x20response</strong>\x20when\x20combined\x20with\x20a\x20receptor.</p>\x0a<p>Example:\x20Salbutamol\x20is\x20a\x20beta-2\x20receptor\x20agonist.</p>\x0a<p><strong>Graph\x202</strong>\x20represents\x20a\x20<strong>partial\x20agonist</strong>:\x20An\x20agent\x20which\x20produces\x20a\x20<strong>submaximal\x20or\x20partial\x20effect</strong>\x20when\x20combined\x20with\x20a\x20receptor.</p>\x0a<p>Example:\x20B<span\x20class=\x22ILfuVd\x22\x20lang=\x22en\x22><span\x20class=\x22hgKElc\x22>uprenorphine\x20and\x20butorphanol\x20are\x20partial\x20agonists\x20at\x20opioid\x20receptors.\x20</span></span></p>\x0a<p><strong>Graph\x203\x20</strong>represents\x20the\x20<strong>antagonist</strong>:\x20An\x20agent\x20which\x20blocks\x20or\x20reduces\x20the\x20action\x20of\x20an\x20agonist\x20on\x20a\x20receptor,\x20but\x20does\x20not\x20have\x20any\x20effect\x20of\x20its\x20own.</p>\x0a<p>Example:\x20N<span\x20class=\x22ILfuVd\x22\x20lang=\x22en\x22><span\x20class=\x22hgKElc\x22>altrexone\x20and\x20naloxone\x20are\x20antagonists\x20at\x20opioid\x20receptors\x20</span></span></p>\x0a<p><strong>Graph\x204</strong>\x20represents\x20an<strong>\x20inverse\x20agonist</strong>:\x20An\x20agent\x20which\x20activates\x20a\x20receptor\x20to\x20produce\x20an\x20effect\x20in\x20the\x20opposite\x20direction\x20to\x20that\x20of\x20the\x20agonist.</p>\x0a<p>Example:\x20&beta;-Carboline\x20is\x20an\x20inverse\x20agonist\x20at\x20benzodiazepine\x20site\x20of\x20GABA-A\x20receptor.</p>\x0a<p>The\x20image\x20given\x20below\x20shows\x20action\x20of\x20various\x20types\x20of\x20selective\x20receptor\x20modulators.</p>','iCcRC','kQQsF','A\x20patient\x20who\x20is\x20on\x20treatment\x20for\x20hyperlipidemia\x20develops\x20gallstones.\x20What\x20is\x20the\x20mechanism\x20of\x20action\x20of\x20the\x20causative\x20drug\x20that\x20was\x20given\x20to\x20this\x20patient?','.m3u8','<p>The\x20correct\x20option\x20is\x20Option\x20C:&nbsp;<strong>1-a,\x202-d,\x203-b,\x204-c</strong></p>\x0a<p><strong>Quinidine\x20</strong>is\x20a<strong>&nbsp;class\x20IA</strong>\x20anti-arrhythmic\x20agent.\x20Class\x201a\x20agents\x20are\x20<strong>sodium\x20channel\x20blockers</strong>\x20with\x20significant\x20potassium\x20channel\x20blocking\x20properties.\x20This\x20slows\x20conduction\x20and\x20<strong>prolongs\x20the\x20QRS\x20duration\x20</strong>and\x20<strong>action\x20potential\x20duration</strong>.&nbsp;</p>\x0a<p><strong>Digoxin</strong>\x20is\x20a&nbsp;<strong>Na+\x20K+\x20ATPase\x20inhibitor</strong>\x20that\x20works\x20by\x20increasing\x20AV\x20node\x20refractoriness.</p>\x0a<p><strong>Esmolol</strong>&nbsp;is\x20a&nbsp;<strong>&beta;-receptor-blocker\x20</strong>and&nbsp;a<strong>&nbsp;class\x20II\x20antiarrhythmic.</strong></p>\x0a<p><strong>Ibutilide</strong>\x20is\x20a\x20<strong>class\x20III&nbsp;</strong>anti-arrhythmic\x20agent.\x20It\x20works\x20by\x20<strong>blocking\x20K+</strong>\x20channels.</p>','\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<div\x20class=\x22mb-4\x22>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<div\x20class=\x22flex\x20justify-between\x20items-center\x20mb-3\x22>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<h4\x20class=\x22text-lg\x20font-bold\x20text-white\x22>Question\x20','Hyponatremia','gradient-yellow\x20px-6\x20py-3\x20text-white\x20transition-all\x20duration-300\x20flex\x20items-center','appendChild','gAexi','pWoPI','HdOEE','</div>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20</div>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<div\x20class=\x22space-y-2\x20mb-4\x22>','markedForReview','gray','The\x20dose-response\x20curve\x20for\x20three\x20drugs\x20in\x20the\x20same\x20tissue\x20is\x20shown\x20in\x20the\x20image\x20below.\x20Which\x20of\x20the\x20following\x20statements\x20is\x20true?','status','testModeLegend','<p><strong>Sildenafil\x20</strong>acts\x20by\x20inhibiting\x20<strong>phosphodiesterase-5&nbsp;</strong>(PDE-5)&nbsp;and\x20is\x20used\x20in\x20the\x20treatment\x20of\x20<strong>erectile\x20dysfunction.</strong></p>\x0a<p>PDE-5\x20inhibitors\x20cause\x20the\x20accumulation\x20of\x20<strong>cGMP</strong>\x20in\x20the\x20corpus\x20cavernosum,\x20which\x20leads\x20to\x20the\x20<strong>relaxation\x20of\x20smooth\x20muscles\x20of\x20penile\x20arteries</strong>\x20that\x20fill\x20the\x20corpus\x20cavernosum,\x20thereby\x20improving\x20erectile\x20function\x20in\x20patients\x20with\x20erectile\x20dysfunction.</p>\x0a<p>In\x20addition\x20to\x20erectile\x20dysfunction,\x20sildenafil\x20can\x20be\x20used\x20in\x20the\x20treatment\x20of\x20<strong>pulmonary\x20arterial\x20hypertension</strong>.</p>\x0a<p>Adverse\x20effects\x20include\x20<strong>headache,\x20flushing,</strong>\x20nasal\x20congestion,&nbsp;<strong>blue-green\x20tinting\x20of\x20vision</strong>,<strong>&nbsp;</strong>and\x20erections\x20lasting\x20more\x20than\x204\x20hours.</p>\x0a<p>Sildenafil\x20is\x20<strong>contraindicated</strong>\x20in\x20patients\x20using\x20<strong>nitrate\x20vasodilators,</strong>&nbsp;which\x20could\x20result\x20in\x20dangerously\x20low\x20blood\x20pressure.</p>','HSYxQ','pkIQE','EOIZf','dataset','w-8\x20h-8\x20text-sm\x20font-medium\x20rounded\x20transition-all\x20duration-200','optionsContainer','<p>The\x20drug\x20used\x20to\x20manage\x20this\x20condition\x20is\x20<strong>prazosin</strong>\x20as\x20it\x20can\x20counteract\x20the\x20effects\x20of\x20breathlessness\x20most\x20probably\x20caused\x20by\x20pulmonary\x20edema.</p>\x0a<p>The\x20venom\x20is\x20a\x20potent\x20<strong>autonomic\x20stimulator</strong>\x20that\x20causes\x20the\x20release\x20of\x20massive\x20amounts\x20of\x20<strong>catecholamines</strong>\x20from\x20the\x20adrenals.\x20It\x20also\x20has\x20a\x20direct\x20effect\x20on\x20the\x20myocardium.</p>\x0a<p>It\x20can\x20present\x20as\x20<strong>neurotoxicity</strong>\x20with\x20restlessness\x20or\x20seizure-like\x20activity,\x20abnormal\x20oculomotor\x20function,\x20and\x20loss\x20of\x20pharyngeal\x20muscle\x20control\x20that\x20leads\x20to\x20respiratory\x20compromise.\x20Tongue\x20fasciculations\x20and\x20hypersalivation\x20are\x20also\x20common.\x20<strong>Cardiovascular\x20toxicity</strong>\x20from\x20systemic\x20envenomation\x20includes\x20tachycardia,\x20hypertension,\x20pulmonary\x20edema,\x20and\x20cardiogenic\x20shock.</p>\x0a<p>If\x20the\x20scorpion\x20has<strong>\x20hemolytic</strong>\x20venom,\x20the\x20reaction\x20is\x20mainly\x20<strong>local</strong>,\x20with\x20edema,\x20pain,\x20and\x20reddening.\x20This\x20usually\x20lasts\x20for\x20one\x20to\x20two\x20hours.&nbsp;</p>\x0a<p>Treatment:</p>\x0a<ul>\x0a<li>Pain\x20-\x20Paracetamol,\x20NSAIDs,\x20or\x20opioids&nbsp;</li>\x0a<li>Sedation\x20for\x20agitation,\x20oculomotor\x20abnormalities,\x20uncoordinated\x20neuromuscular\x20activity,\x20and\x20muscle\x20spasms\x20-\x20<strong>Benzodiazepines</strong>&nbsp;</li>\x0a<li>Hypertension\x20and<strong>\x20pulmonary\x20edema&nbsp;</strong>-&nbsp;<strong>Prazosin</strong>\x20counteracts\x20the\x20adrenergic\x20surge\x20that\x20can\x20lead\x20to\x20these\x20effects</li>\x0a<li>Cardiogenic\x20shock\x20-\x20Antivenom,\x20prazosin,\x20nitroglycerin,\x20dobutamine</li>\x0a<li>Cholinergic\x20effects\x20-\x20Atropine</li>\x0a<li>Supportive\x20care,\x20wound\x20care</li>\x0a</ul>','Fenofibrate\x20160\x20mg','Hiaps','<p>Alkalinization\x20of\x20urine\x20will\x20be\x20helpful\x20in\x20the\x20removal\x20of\x20<strong>weakly\x20acidic\x20drugs</strong>\x20as\x20they\x20are\x20susceptible\x20to<strong>&nbsp;ion\x20trapping</strong>\x20in\x20the&nbsp;urine.</p>\x0a<p>Drugs\x20that\x20are\x20subjected\x20to\x20renal\x20clearance\x20are\x20excreted\x20into\x20the\x20urine\x20by\x20glomerular\x20filtration\x20and\x20active\x20tubular\x20secretion.\x20Nonionized\x20compounds\x20are\x20reabsorbed\x20more\x20rapidly\x20than\x20ionized\x20polar\x20molecules.\x20When\x20the\x20<strong>pH</strong>\x20of\x20the\x20<strong>urine&nbsp;increases</strong>,\x20more\x20salicylate\x20is\x20in\x20its\x20ionized\x20form\x20at\x20equilibrium.\x20Hence,\x20salicylic\x20acid\x20<strong>diffuses</strong>\x20into\x20the\x20<strong>tubular\x20lumen</strong>\x20of\x20the\x20kidney.\x20Urine\x20alkalinization\x20is\x20recommended\x20as\x20a\x20first-line\x20treatment\x20only\x20for\x20moderately\x20severe\x20salicylate\x20poisoning\x20that&nbsp;does\x20not\x20meet\x20the\x20criteria\x20for\x20hemodialysis.</p>\x0a<p>Alkalinization\x20of\x20the\x20urine\x20is\x20achieved\x20by\x20administration\x20of\x20<strong>100&ndash;150\x20mEq</strong>\x20of\x20<strong>sodium\x20bicarbonate</strong>\x20in\x201\x20L\x20of\x205%\x20dextrose\x20in\x20water\x20(D5W).\x20It\x20is\x20infused\x20intravenously&nbsp;at\x20twice\x20the\x20maintenance\x20fluid\x20requirements.</p>\x0a<p>Alkalinization\x20of\x20urine\x20is\x20<strong>contraindicated</strong>\x20in\x20<strong>renal\x20failure</strong>\x20or\x20if\x20fluid\x20administration\x20may\x20worsen&nbsp;<strong>pulmonary\x20edema</strong>\x20or\x20congestive\x20heart\x20failure.</p>','Nhkwe','startAt','ncFXc','innerHTML','Second-generation\x20sulfonylurea','fromCharCode','Area\x20under\x20the\x20curve'];_0x5b7e=function(){return _0x1ad39f;};return _0x5b7e();}function toggleMarkForReview(){const _0x47378a=_0x2c7093,_0x5dc8a6={'OcIUa':function(_0x403c0c){return _0x403c0c();}};questionStates[currentQuestionIndex][_0x47378a(0x206)]=!questionStates[currentQuestionIndex]['markedForReview'],_0x5dc8a6['OcIUa'](updateMarkReviewButton),_0x5dc8a6['OcIUa'](updateQuestionNav);}function updateMarkReviewButton(){const _0x5dcc79=_0x2c7093,_0xb350d9={'sOubT':_0x5dcc79(0x3c9),'VaGJV':_0x5dcc79(0x38b),'wCHBY':'glass-light\x20px-6\x20py-3\x20text-white\x20hover:bg-purple-500\x20hover:bg-opacity-20\x20transition-all\x20duration-300\x20flex\x20items-center','oJDRA':'Mark\x20for\x20Review'},_0x713ea8=document[_0x5dcc79(0x2a6)](_0x5dcc79(0x12f)),_0x1ecabb=document['getElementById'](_0xb350d9['sOubT']),_0x185766=questionStates[currentQuestionIndex]['markedForReview'];_0x713ea8[_0x5dcc79(0x3d8)]=_0x185766?_0xb350d9[_0x5dcc79(0x1e2)]:_0xb350d9[_0x5dcc79(0x255)],_0x1ecabb[_0x5dcc79(0x3c5)]=_0x185766?'Marked':_0xb350d9[_0x5dcc79(0x198)];}function previousQuestion(){const _0x13b500=_0x2c7093,_0x3e7f65={'fHvcr':function(_0x4fe14d,_0x464469){return _0x4fe14d>_0x464469;},'rRSOM':function(_0x460fe2,_0x5d5d00){return _0x460fe2-_0x5d5d00;},'RVKQG':function(_0xe0670d){return _0xe0670d();}};_0x3e7f65[_0x13b500(0xcf)](currentQuestionIndex,0x0)&&(questionStartTime&&(questionStates[currentQuestionIndex][_0x13b500(0xc7)]+=_0x3e7f65['rRSOM'](Date[_0x13b500(0x362)](),questionStartTime)),currentQuestionIndex--,_0x3e7f65[_0x13b500(0xad)](displayQuestion));}function nextQuestion(){const _0x270595=_0x2c7093,_0xa8fa89={'UjWfN':function(_0x2b784f){return _0x2b784f();},'IEmMb':function(_0x20f960,_0x7f50df){return _0x20f960===_0x7f50df;},'VJaiQ':'PWsgT','MZDfY':function(_0x4d53f5,_0xbd5dcb){return _0x4d53f5-_0xbd5dcb;},'UfPgp':_0x270595(0xf0),'wOjQj':_0x270595(0x9c),'HhcZM':_0x270595(0xd7),'ikPpx':function(_0x3132cb,_0x4667f5){return _0x3132cb===_0x4667f5;},'SHyXr':_0x270595(0x30a),'AKYiA':function(_0x55f117){return _0x55f117();},'pkgsx':function(_0x28ad1f,_0x3147aa){return _0x28ad1f===_0x3147aa;},'EEEiT':_0x270595(0x26b),'XxDxU':function(_0x5497b4,_0x4e310b){return _0x5497b4(_0x4e310b);},'vUWYt':_0x270595(0x3a7)};questionStartTime&&(_0xa8fa89[_0x270595(0x7f)](_0xa8fa89[_0x270595(0x317)],_0xa8fa89[_0x270595(0x317)])?questionStates[currentQuestionIndex]['timeSpent']+=Date[_0x270595(0x362)]()-questionStartTime:_0x50ae81=_0x158afd['filter'](_0x4e0a6a=>!(_0x4e0a6a[_0x270595(0x121)][_0x270595(0x360)](_0x366bc6[_0x270595(0x24c)]()[_0x270595(0x38a)](/ /g,'-'))&&_0x4e0a6a[_0x270595(0x2ae)]===_0x36b957)));if(currentQuestionIndex<_0xa8fa89[_0x270595(0x340)](questionsData[_0x270595(0x22c)],0x1))currentQuestionIndex++,displayQuestion();else{if(_0xa8fa89[_0x270595(0x2d7)]!==_0xa8fa89['wOjQj']){if(_0xa8fa89[_0x270595(0x7f)](currentMode,_0xa8fa89[_0x270595(0x264)])||_0xa8fa89[_0x270595(0x338)](currentMode,'timed_exam'))confirm(_0xa8fa89['SHyXr'])&&_0xa8fa89[_0x270595(0x347)](submitQuiz);else{if(_0xa8fa89[_0x270595(0x397)](_0xa8fa89[_0x270595(0xf3)],_0xa8fa89[_0x270595(0xf3)]))_0xa8fa89[_0x270595(0x2d2)](confirm,_0xa8fa89[_0x270595(0x3a9)])&&(currentQuestionIndex=0x0,displayQuestion());else{const _0x1d7924=_0x329c99?function(){const _0x519056=_0x270595;if(_0x39cf9a){const _0x3c8d28=_0x3f4aa4[_0x519056(0x282)](_0x273ab7,arguments);return _0x12f84=null,_0x3c8d28;}}:function(){};return _0xe63297=![],_0x1d7924;}}}else _0x3486de++,_0xa8fa89[_0x270595(0x257)](_0x446cff);}}function startTimer(){const _0x507d83=_0x2c7093,_0x5afe7c={'mYKpf':function(_0x43d849,_0x36a5d8){return _0x43d849-_0x36a5d8;},'QvInC':function(_0x5d9fea){return _0x5d9fea();},'InMlU':function(_0x2112c1,_0x1230ac){return _0x2112c1<=_0x1230ac;},'oyHaI':function(_0x2e6076,_0x5c3fe3){return _0x2e6076===_0x5c3fe3;},'jLNce':_0x507d83(0x245),'vPiHl':function(_0x3cdb90,_0x23834e){return _0x3cdb90(_0x23834e);},'lYUpX':_0x507d83(0x3a2),'GXYaH':function(_0x45e1f3,_0x4a6394){return _0x45e1f3===_0x4a6394;},'kWVrS':_0x507d83(0x25b),'iZYhh':function(_0x70d14d){return _0x70d14d();},'GItAJ':function(_0x264eb1,_0x379bff){return _0x264eb1(_0x379bff);},'Yzfyl':function(_0x1a8d61,_0x2ca5d8,_0x42a023){return _0x1a8d61(_0x2ca5d8,_0x42a023);}};if(timer)_0x5afe7c[_0x507d83(0x2a1)](clearInterval,timer);timeRemaining=0x78,_0x5afe7c[_0x507d83(0x28a)](updateTimerDisplay),timer=_0x5afe7c['Yzfyl'](setInterval,()=>{const _0x1eba72=_0x507d83,_0x420fbb={'OPNVX':function(_0xaa00da,_0x5a9e2b){const _0x39d39d=_0x2f70;return _0x5afe7c[_0x39d39d(0x162)](_0xaa00da,_0x5a9e2b);},'RvlZY':function(_0x123045){const _0x3178da=_0x2f70;return _0x5afe7c[_0x3178da(0x155)](_0x123045);}};timeRemaining--,updateTimerDisplay(),_0x5afe7c[_0x1eba72(0x1f7)](timeRemaining,0x0)&&(_0x5afe7c['oyHaI'](_0x5afe7c['jLNce'],_0x5afe7c[_0x1eba72(0xdf)])?(_0x5afe7c[_0x1eba72(0x27b)](clearInterval,timer),_0x5afe7c[_0x1eba72(0x277)](currentMode,_0x5afe7c[_0x1eba72(0x144)])?_0x5afe7c[_0x1eba72(0x2ef)](_0x5afe7c[_0x1eba72(0x249)],_0x5afe7c[_0x1eba72(0x249)])?_0x5afe7c['iZYhh'](submitQuiz):_0x107ab7[_0x4d73fa][_0x1eba72(0xc7)]+=_0x420fbb['OPNVX'](_0x484de5[_0x1eba72(0x362)](),_0x1110e5):nextQuestion()):_0x420fbb[_0x1eba72(0x1a3)](_0x52833a));},0x3e8);}function updateTimerDisplay(){const _0x16cd29=_0x2c7093,_0x36cdca={'mFloS':function(_0x2a538a,_0x37db58){return _0x2a538a/_0x37db58;},'cNnKC':function(_0x5d9dcf,_0x59ae03){return _0x5d9dcf%_0x59ae03;},'iXanl':'timeDisplay','yHTWF':function(_0x54767f,_0x3e4fda){return _0x54767f+_0x3e4fda;}},_0x1eb4aa=Math[_0x16cd29(0x2b3)](_0x36cdca[_0x16cd29(0x35f)](timeRemaining,0x3c)),_0x29a417=_0x36cdca['cNnKC'](timeRemaining,0x3c);document[_0x16cd29(0x2a6)](_0x36cdca[_0x16cd29(0x2b4)])[_0x16cd29(0x3c5)]=_0x36cdca[_0x16cd29(0x19f)](_0x1eb4aa,':')+_0x29a417[_0x16cd29(0x1b1)]()[_0x16cd29(0x1af)](0x2,'0');}function toggleSidebar(){const _0x33a741=_0x2c7093,_0x3127cb={'OixIE':'quizSidebar','MGBPL':_0x33a741(0x359)};document['getElementById'](_0x3127cb[_0x33a741(0x21f)])[_0x33a741(0x1bd)][_0x33a741(0x3d7)](_0x3127cb[_0x33a741(0x11a)]);}document[_0x2c7093(0x1da)](_0x2c7093(0x123),()=>{const _0x424a58=_0x2c7093,_0x15c7ec={'GwluP':'selected','doekT':function(_0x5d6d78,_0x8f273e){return _0x5d6d78===_0x8f273e;},'TLacG':_0x424a58(0x10c),'bZsnn':_0x424a58(0x233),'XRwcY':_0x424a58(0xbf),'ubwUF':_0x424a58(0x3ac),'mxFjr':function(_0x2bb4d1,_0x11101b){return _0x2bb4d1===_0x11101b;},'cuVCJ':_0x424a58(0x17b),'jBqvU':'iQGOZ','fGgOp':function(_0x8baa3e){return _0x8baa3e();}};if(!window[_0x424a58(0xd4)][_0x424a58(0x319)][_0x424a58(0x389)]('custom_quiz.html')){if(_0x424a58(0x39f)===_0x424a58(0x18f)){_0x3cb87a[_0x424a58(0x1bd)][_0x424a58(0x3d2)](_0x15c7ec['GwluP']);if(_0x15c7ec[_0x424a58(0x146)](_0x48c863,_0x4abd5a))_0x1dfbd9['classList'][_0x424a58(0x130)](_0x15c7ec['TLacG']);else{if(_0x186537===_0x46a24a&&!_0x7dee77)_0x4dba88['classList'][_0x424a58(0x130)](_0x15c7ec[_0x424a58(0x2cd)]);}}else document['getElementById']('modeModal')['style'][_0x424a58(0x1e6)]=_0x15c7ec['ubwUF'];}else _0x15c7ec[_0x424a58(0x1cf)](_0x15c7ec[_0x424a58(0x276)],_0x15c7ec[_0x424a58(0x349)])?_0x30710c=_0x15c7ec[_0x424a58(0x2e4)]:_0x15c7ec['fGgOp'](initializeQuiz);}),document[_0x2c7093(0x1da)](_0x2c7093(0x323),function(_0x43fda4){const _0x3cf2a6=_0x2c7093,_0x15ef14={'KNqyZ':function(_0x171b70,_0x59521d){return _0x171b70<_0x59521d;},'Zbhti':_0x3cf2a6(0x220),'NBmWj':function(_0x175322,_0x1b1bf9){return _0x175322>_0x1b1bf9;},'rDSgO':function(_0x57f820,_0x45fccb){return _0x57f820+_0x45fccb;},'sZWGY':function(_0x141d20,_0x7296ce){return _0x141d20*_0x7296ce;},'pePnf':function(_0x40da4d,_0x1a5235){return _0x40da4d/_0x1a5235;},'NNleC':_0x3cf2a6(0xe9),'GHBSt':function(_0x17c5d9,_0x4b4fff){return _0x17c5d9-_0x4b4fff;},'kZvQJ':function(_0x5c31ad,_0x243b5c){return _0x5c31ad/_0x243b5c;},'OwRuH':_0x3cf2a6(0x2aa),'pkOca':_0x3cf2a6(0x372),'Isomj':_0x3cf2a6(0x353),'LzPbM':_0x3cf2a6(0x32b),'JzwQP':function(_0xa378b9,_0x5f33fd){return _0xa378b9/_0x5f33fd;},'SiDNz':function(_0x348300,_0x35c1f7){return _0x348300%_0x35c1f7;},'jrHja':_0x3cf2a6(0xe2),'ABVoY':function(_0x27253f,_0x29dd61){return _0x27253f%_0x29dd61;},'rOmBD':_0x3cf2a6(0x236),'hNCGs':_0x3cf2a6(0x106),'Looaj':function(_0x56925c,_0x57e6c3){return _0x56925c!==_0x57e6c3;},'TuRBE':_0x3cf2a6(0x1d6),'LamhE':_0x3cf2a6(0x159),'FpcxU':function(_0x3bf87e,_0x22d7b4){return _0x3bf87e===_0x22d7b4;},'SgMIB':function(_0x49d470,_0x5956b6){return _0x49d470>=_0x5956b6;},'XWjZi':function(_0x376b63,_0x1d27d6){return _0x376b63<=_0x1d27d6;},'DgNYe':function(_0x5926ef,_0x22b810){return _0x5926ef===_0x22b810;},'Tgorx':'LZzuk','CrBit':function(_0x8b76e8,_0x28c989){return _0x8b76e8(_0x28c989);},'tOuXF':'.option-button','smgPb':function(_0x2630bd,_0x982106){return _0x2630bd<_0x982106;},'UnQht':function(_0x8306c3,_0x343335){return _0x8306c3===_0x343335;},'mWxSu':_0x3cf2a6(0xea),'OHGVI':_0x3cf2a6(0x16e),'SQZZv':function(_0xa2b5f4,_0x75f760){return _0xa2b5f4===_0x75f760;},'HdOEE':_0x3cf2a6(0xa9),'XrCFr':function(_0x34fb0d){return _0x34fb0d();},'BQmve':function(_0x40e508,_0x790389){return _0x40e508===_0x790389;},'gWHEx':function(_0x487921,_0x5c229d){return _0x487921===_0x5c229d;},'LkUcL':_0x3cf2a6(0x10d),'NBFNd':_0x3cf2a6(0x23e),'YtZwy':'test','tckEa':function(_0x5723f9,_0x4ee708){return _0x5723f9===_0x4ee708;},'KBoZd':'timed_exam'};if(_0x15ef14['Looaj'](document[_0x3cf2a6(0x2a6)](_0x15ef14[_0x3cf2a6(0x35e)])[_0x3cf2a6(0x22d)][_0x3cf2a6(0x1e6)],_0x15ef14[_0x3cf2a6(0x3bb)]))return;if(_0x15ef14['FpcxU'](document[_0x3cf2a6(0x2a6)](_0x15ef14['Zbhti'])[_0x3cf2a6(0x1bd)][_0x3cf2a6(0x356)](_0x15ef14[_0x3cf2a6(0x197)]),![]))return;if(_0x15ef14['SgMIB'](_0x43fda4[_0x3cf2a6(0x3c4)],'1')&&_0x15ef14[_0x3cf2a6(0xd1)](_0x43fda4[_0x3cf2a6(0x3c4)],'4')){if(_0x15ef14[_0x3cf2a6(0xb8)](_0x15ef14[_0x3cf2a6(0x2a4)],_0x3cf2a6(0x1cb))){const _0x8326cf=_0x15ef14[_0x3cf2a6(0x2c7)](parseInt,_0x43fda4['key'])-0x1,_0x45ed72=document['querySelectorAll'](_0x15ef14[_0x3cf2a6(0xbc)]);if(_0x15ef14[_0x3cf2a6(0x149)](_0x8326cf,_0x45ed72[_0x3cf2a6(0x22c)]))selectOption(_0x8326cf);}else _0x104e5e[_0x3cf2a6(0x121)][_0x3cf2a6(0x360)](_0x2e316a[_0x3cf2a6(0x24c)]()['replace'](/ /g,'-'))&&(_0x15ef14[_0x3cf2a6(0x31b)](_0x1c5dfc['questionIndex'],_0x5eda7d['length'])&&(_0x51ce8d[_0x16890a[_0x3cf2a6(0x2ae)]][_0x3cf2a6(0xa1)]=!![]));}else{if(_0x15ef14['UnQht'](_0x43fda4[_0x3cf2a6(0x3c4)],_0x3cf2a6(0x11b))){if(_0x15ef14[_0x3cf2a6(0x1d2)](_0x15ef14[_0x3cf2a6(0x2ce)],_0x15ef14[_0x3cf2a6(0x81)])){const _0x59dca6=_0x2baa92[_0x3cf2a6(0x2a6)](_0x15ef14[_0x3cf2a6(0x300)]),_0x561b51=_0x15ef14[_0x3cf2a6(0x315)](_0x15ef14[_0x3cf2a6(0x3c7)](_0x2d0894,_0x5193ec),0x0)?_0x4fb326[_0x3cf2a6(0x26d)](_0x15ef14[_0x3cf2a6(0x145)](_0x15ef14[_0x3cf2a6(0xd3)](_0x378c87,_0x15ef14[_0x3cf2a6(0x3c7)](_0x523710,_0x81dd68)),0x64)):0x0,_0x596ae8=_0x15ef14[_0x3cf2a6(0x145)](_0x15ef14[_0x3cf2a6(0x145)](0x2,_0x161a2c['PI']),0x41),_0x3a0fa0=_0xab809a[_0x3cf2a6(0x2a6)](_0x15ef14[_0x3cf2a6(0x127)]);_0x3a0fa0[_0x3cf2a6(0x22d)][_0x3cf2a6(0x258)]=_0x596ae8+'\x20'+_0x596ae8,_0x3a0fa0['style'][_0x3cf2a6(0x263)]=_0x15ef14['GHBSt'](_0x596ae8,_0x15ef14[_0x3cf2a6(0x17e)](_0x561b51,0x64)*_0x596ae8),_0x52b844[_0x3cf2a6(0x2a6)](_0x15ef14['OwRuH'])[_0x3cf2a6(0x3c5)]=_0x561b51+'%',_0x24558f[_0x3cf2a6(0x2a6)](_0x15ef14['pkOca'])['textContent']=_0x16baf3[_0x3cf2a6(0x22c)],_0x171a11['getElementById'](_0x15ef14[_0x3cf2a6(0xdc)])[_0x3cf2a6(0x3c5)]=_0x16c93d,_0x5c1f60['getElementById'](_0x3cf2a6(0xce))[_0x3cf2a6(0x3c5)]=_0x3670e1,_0x368922[_0x3cf2a6(0x2a6)](_0x15ef14['LzPbM'])[_0x3cf2a6(0x3c5)]=_0x23685f;const _0x551116=_0x5b230e['floor'](_0x15ef14['JzwQP'](_0xffeaf8,0xea60)),_0x488740=_0x27c7d0[_0x3cf2a6(0x2b3)](_0x15ef14[_0x3cf2a6(0x1e5)](_0x15ef14[_0x3cf2a6(0x34c)](_0x4cb817,0xea60),0x3e8));_0xe26fb0[_0x3cf2a6(0x2a6)](_0x15ef14[_0x3cf2a6(0x1e9)])['textContent']=_0x551116+':'+_0x488740[_0x3cf2a6(0x1b1)]()[_0x3cf2a6(0x1af)](0x2,'0');const _0x23ca64=_0x15ef14['kZvQJ'](_0x5843d3,_0x4c5c55[_0x3cf2a6(0x22c)]),_0x248f35=_0xa77f0d[_0x3cf2a6(0x2b3)](_0x23ca64/0xea60),_0x4d730c=_0x4051ae[_0x3cf2a6(0x2b3)](_0x15ef14[_0x3cf2a6(0xa6)](_0x23ca64,0xea60)/0x3e8);_0x5e4cc8[_0x3cf2a6(0x2a6)](_0x15ef14[_0x3cf2a6(0x399)])['textContent']=_0x248f35+':'+_0x4d730c[_0x3cf2a6(0x1b1)]()[_0x3cf2a6(0x1af)](0x2,'0'),_0x59dca6[_0x3cf2a6(0x1bd)][_0x3cf2a6(0x3d2)](_0x15ef14['hNCGs']);}else previousQuestion();}else{if(_0x15ef14[_0x3cf2a6(0x2c5)](_0x43fda4['key'],_0x15ef14[_0x3cf2a6(0x204)])||_0x15ef14[_0x3cf2a6(0x29d)](_0x43fda4[_0x3cf2a6(0x3c4)],'\x20'))_0x43fda4['preventDefault'](),_0x15ef14['XrCFr'](nextQuestion);else{if(_0x15ef14['BQmve'](_0x43fda4[_0x3cf2a6(0x3c4)][_0x3cf2a6(0x24c)](),'b')&&(_0x15ef14[_0x3cf2a6(0xfa)](currentMode,_0x15ef14[_0x3cf2a6(0x1b7)])||_0x15ef14['gWHEx'](currentMode,_0x15ef14[_0x3cf2a6(0x7c)])))_0x15ef14[_0x3cf2a6(0x18a)](toggleBookmark);else{if(_0x15ef14[_0x3cf2a6(0x2c5)](_0x43fda4[_0x3cf2a6(0x3c4)]['toLowerCase'](),'m')&&(_0x15ef14[_0x3cf2a6(0xfa)](currentMode,_0x15ef14[_0x3cf2a6(0x239)])||_0x15ef14[_0x3cf2a6(0x384)](currentMode,_0x15ef14[_0x3cf2a6(0x2ab)])))toggleMarkForReview();else _0x43fda4[_0x3cf2a6(0x3c4)][_0x3cf2a6(0x24c)]()==='s'&&(_0x15ef14[_0x3cf2a6(0xfa)](currentMode,_0x3cf2a6(0xd7))||currentMode===_0x15ef14[_0x3cf2a6(0x2ab)])&&_0x15ef14['XrCFr'](submitQuiz);}}}}});</script>

</body></html>